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Coloproctology has made tremendous progress, asserting itself as a specialty, it has 
been taught in all medical schools and chosen by many as an option in their careers. 
There are numerous textbooks that discuss in detail the various issues of 
Coloproctology. In this age of computers and virtual reality, when the knowledge they 
accumulate and recycle increases each day dramatically, one would be able to question 
the decision to make another book on this subject. 
When I was invited to edit this publication, I felt as a challenge to review and compile 
the chapters presented in this work and make it appropriate and useful to those who 
will consult it. 
The chapters of screening and surveillance, preparation, monitoring and 
considerations about intestinal inflammation through colonoscopy, lead us to current 
knowledge and accurate guidance in the improvement of those who already performs 
colonoscopies and those who wish to develop research or improve clinical 
performance. 
The studies of virtual colonoscopy, intraoperative enteroscopy, transanal endoscopic 
operations and the treatment of rectal varices show the quality of the experts in 
diagnosing and treating ailments with accuracy, the lessons that challenge the 
knowledge and the technical skills possessed by the endoscopists and surgeons of 
today. 
It is a different book, nice and easy to read. Its nine chapters were written by authors 
from many different countries, are well designed and they exhaust the subject within 
their themes. I am extremely honored to preface and edit this book and I congratulate 
all the authors on their work. 
 
José Joaquim Ribeiro da Rocha 
Division of Coloproctology of the Department of Surgery and Anatomy, 
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1. Introduction 
Colorectal cancer (CRC) is the second most frequent malignant disease in Europe. Every year,
412,000 people are diagnosed with this condition, and 207,000 patients die of it. Secondary 
prevention of CRC consists of early diagnosis of the disease in asymptomatic individuals
(screening) and long term follow up of high risk patients (surveillance). Three groups of 
screening methods are currently available: stool testing (guaiac or immunochemical fecal
occult blood tests – gFOBT and FIT respectively and DNA tests), endoscopic examinations
(flexible sigmoidoscopy and colonoscopy) and radiologic examinations (computed 
tomographic colonography and double contrast barium enema). Colonoscopy is therefore
used as the only screening method or as a second step in case of positive results of primary 
screening examination (two steps screening programs). From 27 countries in the European 
Union, the most frequently used test is FOBT (in 11 states). There is a choice between FOBT
and colonoscopy in 6 countries. FOBT and flexible sigmoidoscopy is available in Italy.
Currently, the only country using colonoscopy as the only screening method is Poland. At the
end of 2010, the European guidelines for quality assurance in colorectal cancer screening and
diagnosis were published, summarizing the evidence based medicine data for the efficacy, the
interval, the age range, the risk-benefit and cost-effectiveness of colonoscopy screening.
Unfortunately, prospective randomized trial on the effect of screening colonoscopy in the 
reduction of CRC incidence and mortality has not been published yet. Promising should be the
NordICC study, which was introduced in 2009, however the results will be available in a
fifteen year period. Series of recently published studies (Canada, Germany, Poland) focusing 
on the interval (post-colonoscopic) cancers confirmed the inadequate protection of proximal
colon by colonoscopy. Another important issue would be the quality and safety of 
colonoscopy and the bowel cleansing. Concerning the surveillance colonoscopy, it plays a 
major role in specific follow up strategies in CRC high risk groups. It can be concluded that
with some limitations, colonoscopy still remains the fundamental diagnostic and prophylactic
examination in colorectal cancer screening and surveillance.
2. Colorectal cancer epidemiology in Europe
Colorectal cancer is the second most frequent malignant disease in developed countries.
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2. Colorectal cancer epidemiology in Europe 
Colorectal cancer is the second most frequent malignant disease in developed countries. 
CRC incidence is generally higher in male population, and the risk of the disease increases 
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with age, as the majority of cases are diagnosed in patients over 50 years of age (Spann et 
al., 2002). Burden of European countries is ranked as the highest in the global statistics, 
both in incidence and mortality. Compared to the US, in 1998 – 2002 the European 
population showed a similar incidence for men, while that for women was slightly lower; 
the incidence in the USA for men and women was 38.6 and 28.3 respectively: in Europe it 
was 38.5 and 24.6 (ASR-W), as calculated per 100,000 inhabitants (Curado et al., 2007) . 
However, mortality over the same period of time was significantly higher  in Europe than 
in the US, both for men and women: in the USA the figures were 13.5 and 9.2 respectively, 
while in Europe they were 18.5 and 10.7 (ASR-W), as calculated per 100,000 inhabitants 
(World Health Organization [WHO], 2006). To document the situation in Europe, we used 
figures available from the international studies summarizing global and European 
epidemiologic data (Curado et al., 2007; Ferlay et al., 2004, 2007; Parkin et al., 2005). A 
detailed comparison of countries within Europe using the global age standardization 
(ASR-W) of incidence is presented in figure 1.  
 
 
Fig. 1. International comparison of CRC incidence in European countries 
Colorectal cancer comprises 12.9% of all newly-diagnosed carcinomas in the European 
population (men 12.8%, women 13.1%) and account for 12.2% of deaths caused by 
malignancy. Colorectal cancer is the second most common malignancy, after breast 
carcinoma (13.5% of all malignities), followed by bronchogenic carcinoma (12.1% of all 
malignancies). Every year 412,900 people are diagnosed with CRC in Europe, and 207,400 of 
them die of the disease (Ferlay et al., 2007). The average incidence has shown a tendency to 
rise in recent years, with an annual increment 0.5%. Data available regarding time trends of 
CRC mortality are displayed in figure 2. The CRC-related mortality has stabilized or shown 
a slight decrease over recent years.  
 




Fig. 2. Colorectal cancer mortality trends in Europe (men left, women right) 
3. Colorectal cancer prevention   
Colorectal cancer belongs to preventable cancers. Primary prevention focuses on dietary and 
lifestyle recommendations. Secondary prevention of CRC consists of early diagnosis of the 
disease in asymptomatic individuals (screening) in patients older than 50 years of age and a 
long term follow up of high risk patients (surveillance).  
4. Colorectal cancer screening 
Three groups of screening methods are currently available (see in the table below): stool 
testing (guaiac or immunochemical fecal occult blood tests – gFOBT and FIT respectively 
and DNA tests), endoscopic examinations (flexible sigmoidoscopy and colonoscopy) and 
radiologic examinations (computed tomographic colonography and double contrast barium 
enema). Colonoscopy is therefore used as the only screening method or as a second step in 
case of positive results of primary screening examination (Zavoral et al, 2009). 
 
Type of method Method 
Stool tests  
 
for presence of occult blood  
       guaiac-based (gFOBT) 
       immunochemical (FIT) 





flexible sigmoideoscopy (FS) 
colonoscopy  
computed tomographic colonography (CTC)  
double contrast barium enema (DCBE) 
Table 1. Overview of CRC screening methods 
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In 2008, the Report on the Implementation of the Council Recommendation on Cancer 
Screening, which provides the most comprehensive data available, was published (Karsa et 
al., 2008). According to this report, CRC screening is running or being established in 19 of 27 
EU countries. The target group contains approximately 136 million individuals suitable for 
CRC screening (aged 50 to 74 years). Of this number, 43% individuals come from 12 
countries where CRC population screening is performed or being prepared on either 
national or regional levels; 34% come from 5 countries where national population screening 
has been implemented (Finland, France, Italy, Poland, and United Kingdom). In 7 EU 
countries, national non-population based screening is carried out, which covers 27% of the 
target population. In 2007, gFOBT (which was the only test recommended by the Council of 
the European Union in 2003) was used as the only screening method in twelve countries 
(Bulgaria, Czech Republic, Finland, France, Hungary, Latvia, Portugal, Romania, Slovenia, 
Spain, Sweden, and United Kingdom). Colonoscopy was the only screening method used in 
Poland. In six countries, two types of tests were used: iFOBT and FS in Italy, and gFOBT and 
colonoscopy in Austria, Cyprus, Germany, Greece, and Slovak Republic. In the remaining 
eight states (Belgium, Denmark, Estonia, Ireland, Lithuania, Luxembourg, Malta, and the 
Netherlands), CRC screening has not been implemented yet. The age limit for the target 
population varies across the EU countries. In 2007, it was estimated that a total of 12 million 
individuals participated in CRC screening. 
4.1 Selected colonoscopy CRC screening programs  
Poland is currently the only state using colonoscopy as the only screening method, without 
the alternative of FOBT. An opportunistic screening programme was initiated in 2000, and 
by now, this had grown to 80 centers across the whole of Poland. The programme is 
financed by the Ministry of Health, independentantly from the overall healthcare system. 
The target population (asymptomatic individuals aged 55–66 years) is recruited through 
general practitioners. High emphasis is placed on the quality control of colonoscopies, with 
complications reported for 0.1% procedures, and no patient dying. The advantage of the 
programme consists in thorough monitoring and evaluation, including monitoring of 
interval cancers (Regula et al., 2006). 
Germany was the first country to introduce a population screening programme (in 1976) 
based on an annual gFOBT for individuals older than 44 years of age. Starting in 2002, the 
participants were offered a choice between colonoscopy at 55 years of age (in a ten-year 
interval) and FOBT in annual intervals between 50 and 54 years of age and in a two-year 
interval after 55 years of age. In case of FOBT positivity, screening colonoscopy followed. 
Between 2003 – 2008, there were 2 821 392 colonoscopies performed in over 2 100 practices 
all over Germany. The cumulative participation rate was 17.2% for women and 15.5% for 
men. Adenomas were diagnosed in a total of 19.4%, advanced adenomas in 6.4% and 
carcinomas in 0.9% of the examined patients. The majority of cancers were in early stage 
(UICC 47.3%, UICC II 22.3%, UICC III 20.7%, and UICC IV 9.6%). The overall and serious 
complication rate was 2.8 and 0.58 respectively per 1 000 colonoscopies. The cost analyses 
have proven the cost effectiveness of such screening (Pox et al., 2007). 
In the Czech Republic, CRC screening has many years of tradition. It was the second 
country in the world to start a nation-wide screening programme (in 2000), based on 
biennial gFOBT offered to asymptomatic individuals older than 50 years of age. In order to 
achieve higher compliance rate, screening colonoscopy was added to current FOBT 
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screening as an alternative method in 2009, in the same intervals as in the German 
programme. Both, gFOBT and various types of FIT are offered as well. During years 2006 – 
2010, there were 47 760 screening colonoscopies (FOBT+) and 5 574 primary screening 
colonoscopies performed. Adenomas and carcinomas were diagnosed in 16 454 (30.9%) and 
2 539 (4.8%) respectively. The proportion of advanced adenomas and generalized cancer 
(UICC stage III and IV) was 48% and 20.7% respectively (Zavoral et al., 2009). 
4.2 Screening colonoscopy studies 
The multinational NordICC (The Nordic-European Initiative on Colorectal Cancer) study 
was introduced in June 2009, however the results will be available in a fifteen year period. 
This study focuses on monitoring the effect of colonoscopy screening on reducing CRC 
incidence and mortality. The northern states of Europe (Norway, Sweden, and Iceland), 
Poland, and the Netherlands all participate. The Czech Republic, Hungary and Latvia are 
currently observers and may join the study later. According to the study protocol, a 
minimum of 66,000 individuals aged 55 to 64 years will be drawn directly from population 
registers in the participating countries and randomly assigned to either once-only 
colonoscopy screening or no screening (2:1 randomization, men and women). The primary 
objective is to compare the incidence and mortality against the control group after 15 years. 
At this time, more than 5 500 individuals have been examined so far and the recruitment 
will continue until the end of 2012 (NordiCC Study Protocol, 2011). 
CONFIRM (Colonoscopy vs. Fecal Immunochemical Test Reducing Mortality from 
Colorectal Cancer), the VA Cooperative study, is a multicenter, randomized, parallel group 
trial directly comparing screening colonoscopy with annual FIT screening in average risk 
individuals. The quantitative FIT (OC Sensor Diana) cut-off will be set at 100 ng/ml. The 
primary endpoint expected is CRC mortality reduction by 40% within a 10 year enrolment. 
The planned study duration is 12.5 years with 2.5 years of recruitment of 50 000 participants 
(1:1 randomization, 95% men, aged 50 – 75) and 2.5 years of follow-up for enrolled 
participants (Dominitz et al., 2011).  
COLONPREV (Colorectal Cancer Screening in Average-Risk Population: a Multicenter, 
Randomized Controlled Trial Comparing Immunochemical Fecal Occult Blood Testing 
versus Colonoscopy) study is being carried out since November 2008 in eight Spanish 
regions under the coordination of the public health system, primary care physicians and 
tertiary academic medical centers. Asymptomatic individuals aged 50 – 69 years have been 
randomized into two groups (1:1). Biennial quantitative FIT (OC Sensor, cut-off level 75 
ng/ml), followed by colonoscopy in case of its positivity has been offered to one group and 
colonoscopy to the second group. First preliminary results are expected in June 2011 
(Castellas et al., 2011) 
The Japan Polyp Study (JPS) is a multicenter randomized control trial focusing on 
postpolypectomy surveillance and conducted in eleven centers since February 2003. Two 
complete colonoscopies with the removal of all neoplastic lesions (to reach “clean colon”) 
have been performed to the enrolled patients who have been randomized into two groups 
(1:1) afterwards, according to the colonoscopy follow-up interval. One group underwent a 
colonoscopy after 48 months, the second group at 24 and 48 months. From a total of 4 752 
individuals, 3 926 (83%) agreed with the initial colonoscopy and 2 757 (58%) patients were 
randomized. There has been a great impact on polyp distribution and macroscopic type in 
the first two initial colonoscopies. Very high adenoma detection (63%) was reached 
(Matsuda, 2011). 
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screening as an alternative method in 2009, in the same intervals as in the German 
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(Matsuda, 2011). 
 
Endoscopic Procedures in Colon and Rectum 
 
6 
4.3 Screening colonoscopy characteristics 
At the end of 2010, the European guidelines for quality assurance in colorectal cancer 
screening and diagnosis were published, summarizing the evidence based medicine data for 
the efficacy, the interval, the age range, the risk-benefit and cost-effectiveness of colorectal 
cancer screening, including sigmoidoscopy (FS) and colonoscopy screening analysis.   
4.3.1 Evidence for effectiveness of sigmoidoscopy screening 
Flexible sigmoidoscopy screening reduces colorectal cancer (CRC) incidence and mortality if 
performed in an organised screening programme with careful monitoring of the quality and 
systematic evaluation of the outcomes, adverse effects and costs (Atkin et al., 2010). The 
evidence on the efficacy is avaible from randomised controlled trials (RCTs). The most 
important one is the large UK study in which 57 237 individuals were randomised into the 
screening group for a once-only sigmoidoscopy alone. This study found a significant 31% 
reduction in CRC mortality and also a significant reduction in CRC incidence from 
sigmoidoscopy in an intention-to-treat analysis (Atkin et al., 2010).  
The optimal interval for sigmoidoscopy screening was only assessed in two indirect studies 
that only considered intervals of three and five years (Platell et al., 2002, Schoen et al., 2003). 
The UK flexible sigmoidoscopy screening study showed that there was little attenuation of 
the protective effect of sigmoidoscopy after 11 years of follow-up. This is in line with the 
evidence for colonoscopy screening. In conclusion, the optimal interval for endoscopy 
screening should not be less than 10 years and may even be extended to 20 years (Atkin et 
al., 2010). 
There is limited evidence suggesting that the best age range for flexible sigmoidoscopy 
screening should be between 55 and 64 years (Segnan et al., 2007). One study 
demonstrated that elderly subjects (75 years old) have an increased rate of endoscopist-
reported difficulties and a higher rate of incomplete examinations compared to subjects 
aged 50–74 years (Pabby et al, 2005). Average-risk sigmoidoscopy screening should be 
discontinued after 74 years of age, given the increasing co-morbidity in this age range 
(Atkin et al., 2010). 
4.3.2 Evidence for effectiveness of colonoscopy screening 
Limited evidence exists on the efficacy of colonoscopy screening on CRC incidence and 
mortality (Atkin et al, 2010). However, two recent case–control studies found a significant 
reduction of 31% in CRC mortality (Baxter et al., 2009) and 48% in advanced neoplasia 
detection rates (Brenner et al., 2010). The reduction in these studies was limited to the 
rectum and left side of the colon. No significant reduction was found in right-sided disease. 
Cross-sectional surveys have shown that colonoscopy is more sensitive than sigmoidoscopy 
in detecting adenomas and cancers and that this increased sensitivity could translate into 
increased effectiveness (Walsh et al., 2003). The efficacy of colonoscopy as a primary 
screening test has not been proven by prospective randomized control trial.  
The optimal interval for colonoscopy screening has been assessed in a cohort study and a 
case-control study. The cohort study found that CRC incidence in a population with 
negative colonoscopy was 31% lower than general population rates and remained reduced 
beyond 10 years after the negative colonoscopy (Singh et al., 2006). Similar results were 
obtained in the case–control study (Brenner et al., 2006) where the reduction of risk of CRC 
was 74 % and persisted up to 20 years.  
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Screening colonoscopies do not need to be performed at intervals shorter than 10 years and  
this time interval may even be extended to 20 years (Atkin et al., 2010).  
There is no direct evidence confirming the optimal age range for colonoscopy screening. 
Indirect evidence suggests that the prevalence of neoplastic lesions in the younger 
population (less than 50 years) is too low to justify colonoscopic screening, while in the 
elderly population (more than 75 years) the lack of benefit could be a major issue (Pabby et 
al., 2005). The optimal age for a single colonoscopy appears to be around 55 years. Average 
risk colonoscopy screening should not be performed before age 50 and should be 
discontinued after 74 years of age (Atkin et al., 2010). 
5. Colonoscopic surveillance following adenoma removal 
The adenomatous polyp is the precursor of most colorectal cancers and is the most 
frequently detected lesion during a colonoscopy examination (Lieberman et al., 2000). 
Hyperplastic polyps, on the other hand, usually have no clinical significance. Based on the 
statistics, in 33 % – 50 % of patients consecutive adenomas develop within three years after 
the removal of first adenoma. In addition, in 0,3-0,9 % of cases colorectal carcinoma is 
detected within five years (Alberts et al., 2000; Arber et al., 2006; Baron et al., 2006; Martinez 
et al., 2009; Robertson et al., 2005). Most of these adenomas and malignancies are, however, 
represented by lesions missed during the first colonoscopy. The quality of a colonoscopic 
examination must therefore be emphasized. Medical centers involved in screening 
programmes thus often undergo quality controls. One of the key aims of a surveillance 
colonoscopy is to detect all new lesions or lesions that have been missed at baseline 
colonoscopy before they progress to malignancy. The other aim of a follow-up colonoscopy 
is the detection of colorectal carcinoma at an early, prognostically more favorable stage 
(Robertson et al., 2005).  
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Picture 4. Postpolypectomy site 
Colonoscopy is an invasive method with a small, however not insignificant risk of possible 
complications, amongst which are perforation (0,06 % diagnostic and 2 % therapeutical 
colonoscopies) and hemorrhage after polypectomy (02,-2,7 % according to size of lesion) 
(Rosen et al., 1993). Surveillance colonoscopies represent a burden for endoscopic centers 
prolonging the waiting lists. For these reasons, surveillance colonoscopies should be carried 
out in recommended intervals in order to prevent the development of colorectal carcinoma. 
The malignant potential of an adenoma depends on its size, histological verification and the 
grade of dysplasia. It is higher in advanced adenomas (larger than 10 mm or more, with a 
villous component or a high grade dysplasia). Recent studies show, that the villous 
component is a less significant predictor for the development of malignancy than the 
remaining two factors.   
5.1 Risk factors for advanced adenomas and colorectal cancer after baseline 
polypectomy 
The risk of detection of advanced adenoma or carcinoma during a surveillance colonoscopy 
depends on the quality of the first (baseline) colonoscopy and the characteristics of the 
removed polyp.   
It is generally agreed that high quality colonoscopies carried out less frequently are more 
efficient in the prevention of colorectal cancer than more frequent colonoscopies of a lower 
quality. Colonoscopy examination should only be carried out after adequate bowel 
preparation in order to properly visualize bowel mucosa. Patients with poor bowel 
preparation have to be invited for a repeated colonoscopy, considering the colonoscopy was 
well indicated in the first place. The examination must also be complete (reaching the 
caecum) and the withdrawal of an endoscope should be slow and careful. All detected 
lesions have to be removed carefully, ideally as hoc during their detection since they can 
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easily be overlooked during the next examination. Polyp removal must be done during the 
withdrawal of a scope due to the possible risk of bleeding and perforation.  
Based on the following meta-analysis (Saini et al., 2006) it is obvious that a personal history 
of 3 adenomatous polyps increases the risk for the presence of advanced adenoma 2x, 
whereas the history of five polyps increases the risk at a surveillance colonoscopy 4x, as 
opposed to the detection of a single polyp during a baseline colonoscopy. The polyp size 
also plays a significant role. The real size is considered to be the size of the histological 
specimen measured by a pathologist. In case a piece-meal polypectomy is performed, the 
size is based upon the judgment of the endoscopist (comparing the lesion with a known size 
of biopsy forceps). Adenomas measuring between 10 to 20 mm have twice the increased 
risk, adenomas measuring 20 mm or more have 3x the increased risk of turning to 
malignancy as opposed to small adenomas (up to 10mm) (Cafferty et al., 2007).   
Adenoma histology does not play as significant role as believed earlier. However, a villous 
structure polyp increases the chance of villous adenoma detection during a surveillance 
colonoscopy (Cafferty et al., 2007). On the other hand, the presence of high grade dysplasia 
significantly increases the risk of malignant changes in adenomas of varying size (Saini et 
al., 2006). 
Based on the studies listed below, the localization of polyp in the right colon increases the 
risk of advanced colorectal neoplasia 1,5-2,5 times as opposed to its localization in the left 
colon (Laiyemo et al., 2009; Martinez et al., 2009; Saini et al., 2006)  
5.2 Risk factors in patients    
One of the risk factors is older age, which correlates with the higher  incidence of 
advanced colorectal neoplasia, at the same time it is related to an increased difficulty of a 
colonoscopy examination and its performance, worse bowel preparation and a higher risk 
of complications related to the examination itself. It is always necessary to proceed 
individually recognizing all comorbidities of a patient, the benefit of the examination 
itself, whilst considering whether the lead time for progression of adenoma to colorectal 
cancer does not exceed the life-expectancy of an individual, particularly in patients aged 
75 years or older. The upper age boundary for surveillance cessation is usually 75 years of 
age. A positive family history for an adenoma, unless a dominant genetic disease is 
suspected, does not require any special precautions during surveillance colonoscopies 
(Atkin et al., 2010).   
5.3 Stratification of risk factors in patients  
According to European guidelines for the quality assurance in colorectal cancer screening 
and diagnosis (2010), the degree of risk should be determined based on the findings at 
baseline colonoscopy. It is recommended to divide patients into groups with low, 
intermediate and high risk of colorectal neoplasia development, thus more easily 
determining the interval of colonoscopy examinations. Based on these results, further 
surveillance can be modified (Atkin et al., 2010).  
Low risk group: Patients with one or two polyps measuring up to 10 mm, with tubular 
structure and low grade dysplasia are considered to be in low risk of developing colorectal 
carcinoma and may further continue in the population screening programme. However, it is 
necessary to also consider their age, family history, degree of bowel preparation and the 
quality of colonoscopy examinations. 
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Intermediate risk group: Patients with three or four small polyps, or one adenomatous 
polyp measuring ≥ 10 mm and  20 mm, or a polyp with villous structure or high grade 
dysplasia, are considered to be in an intermediate risk group and should have a follow up 
colonoscopy in a three year interval. If there is a negative finding during the first 
surveillance colonoscopy another examination is indicated 5 years after the previous one. 
After two surveillance colonoscopies with a physiological finding, the patient can transfer to 
the common population colorectal cancer screening programme. If low or intermediate risk 
adenomas are detected, the patient should further be placed in an intermediate risk group 
(next surveillance colonoscopy being in a 3 year interval), in high risk polyps the next 
colonoscopy is recommended within 1 year. 
High risk group: Patients with five small polyps or one polyp measuring at least 20mm or 
more are indicated to have a surveillance colonoscopy within one year from their baseline 
colonoscopy. If there is a negative finding or an adenoma with intermediate risk is detected, 
the next examination is recommended after three years. Two negative controls shift the 
interval for another colonoscopy by further 5 years. When a high risk adenoma is detected 
during a surveillance colonoscopy, an early examination is necessary – within 1 year. The 
aim of an early surveillance examination is to detect concurrent lesions that were not picked 
up during a baseline colonoscopy. 
5.4 Recommendations for surveillance in chosen colonoscopy findings 
Endoscopically removed pT1 carcinoma is considered a high risk lesion based on its 
biological characteristics, the first surveillance colonoscopy interval thus being within 12 
months from the first one (Chu et al., 2003; Di Gregorio et al., 2005; Rex et al., 2006).   
For surveillance purposes, serrated adenomas (i.e., traditional serrated adenomas and mixed 
polyps with at least one adenomatous component) should be dealt with using standard 
recommendations like any other adenoma. Currently, there is no data available that would 
explicitly certify the need for any other surveillance programme.  
There has been no proof that a small hyperplastic polyp has an increased risk of colorectal 
carcinoma, patients with this finding are therefore placed in standard population screening 
programme. Individuals with one or more hyperplastic polyps measuring more than 10mm, 
or with non-neoplastic serrated lesions of the colon, or with multiple small lesions in the 
right colon, are considered to have a higher risk of developing colorectal neoplasia. 
However, accurate recommendations cannot be reliably determined for the current lack of 
data (Atkin et al., 2010).   
Large sessile lesion removed by a piece-meal resection should be checked within 2-3 
months, so that small areas of residual tissue can be treated endoscopically early enough. 
Within the next 3 months they can easily be identified using India ink tattooing and ideally 
completely eradicated. When a large residual finding is detected during a follow up 
examination, further endoscopic or surgical treatment should be considered.   
5.5 Stopping surveillance 
Stopping surveillance depends on several factors, not only on the characteristics of detected 
polyps, but also on age, comorbidities and personal wishes. The upper age boundary for 
surveillance colonoscopy is considered to be 75 years or older (Atkin et al., 2010). At this 
stage, patients can discontinue the surveillance programme and return to the population 
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months, so that small areas of residual tissue can be treated endoscopically early enough. 
Within the next 3 months they can easily be identified using India ink tattooing and ideally 
completely eradicated. When a large residual finding is detected during a follow up 
examination, further endoscopic or surgical treatment should be considered.   
5.5 Stopping surveillance 
Stopping surveillance depends on several factors, not only on the characteristics of detected 
polyps, but also on age, comorbidities and personal wishes. The upper age boundary for 
surveillance colonoscopy is considered to be 75 years or older (Atkin et al., 2010). At this 
stage, patients can discontinue the surveillance programme and return to the population 
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screening programme. On the other hand, patients undergoing the surveillance programme 
being followed up endoscopically are not indicated to continue with the FOBT.  
6. Conclusion  
Colonoscopy plays a major role in colorectal cancer screening. Recently published 
Europeans guidelines showed that although no randomized control study on the efficacy of 
colonoscopy has been completed yet, the recent case-control studies found a significant 
reduction of 31% CRC mortality. Very promising is the NordICC trial which could confirm 
these results. To reduce the appearance of interval cancer, colonoscopy quality control and 
adequate bowel preparation is necessary. Colonoscopy can be considered an effective and 
safe procedure.  
A well organized surveillance programme for patients with adenoma, advanced adenoma 
or carcinoma is just as important as a baseline colonoscopy examination with its quality and 
precision being the determining factors of the follow up intervals. Patients should be 
divided into three categories using simple criteria, depending on the presumed risk of 
developing colorectal cancer, while being endoscopically followed up at given intervals. It is 
always necessary to take into consideration age, comorbidities, personal and family history, 
and the personal wish of each individual. 
7. Acknowledgment 
Authors would like to thank Dr. Gabriela Veprekova for important contribution and 
literature research together with the preparation of the manuscript, and also to assoc. prof. 
Ladislav Dusek, MSc., PhD, dr. Jan Muzik, MSc., PhD and dr. Jakub Gregor, PhD for 
providing the epidemiology figures. 
8. References 
Alberts, D.S.; Martinez, M.E.; Roe, D.J.; Guillen-Rodriguez, J.M.; Marshall, J.R.; van 
Leeuwen, J.B.; Reid, M.E.; Ritenbaugh, C.; Vargas, P.A.; Bhattacharyya, A.B.; 
Earnest, D.L. & Sampliner, R.E. (2000). Lack of effect of a high-fiber cereal 
supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer 
Prevention Physicians' Network. N.Engl.J.Med., vol. 342, no. 16, pp. 1156-1162 
Arber, N.; Eagle, C.J.; Spicak, J.; Racz, I;, Dite, P.; Hajer, J.; Zavoral, M.; Lechuga, M.J.; 
Gerletti, P.; Tang, J.; Rosenstein, R.B.; Macdonald, K.; Bhadra, P.; Fowler, R.; Wittes, 
J.; Zauber, A.G.; Solomon, S.D. & Levin, B. (2006). Celecoxib for the prevention of 
colorectal adenomatous polyps. N.Engl.J.Med., vol. 355, no. 9, pp. 885-895 
Atkin, W.; Valori, R.; Kuipers, E.J.; Hoff, G.; Senore, C.; Segnan N.; Jover, R.; Schmiegel, W.; 
Lambert, R. & Pox, C. (2010). Colonoscopic surveillance following adenoma 
removal. In: Segnan N, Patnick J, von Karsa L. European guidelines for quality 
assurance in colorectal cancer screening and diagnosis, 1st ed., European Union, 
2010:274-297, ISBN 978-92-79-16435-4, doi: 10.2772/1458 
Atkin, W.S.; Edwards, R.; Kralj-Hans, I.; Wooldrage, K.; Hart, A.R.; Northover, J.M.; Parkin, 
D.M.; Wardle, J.; Duffy, S.W. & Cuzick, J. (2010). Once-only flexible sigmoidoscopy 
 
Screening and Surveillance Colonoscopy 
 
13 
screening in prevention of colorectal cancer: a multicentre randomised controlled 
trial. Lancet, vol. 375, no. 9726, pp. 1624-1633 
Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Quan, H.; Riddell, R.; Lanas, A.; Bolognese, J.A.; 
Oxenius, B.; Horgan, K.; Loftus, S. & Morton, D.G. (2006). A randomized trial of 
rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, vol. 
131, no. 6, pp. 1674-1682 
Baxter, N.N.; Goldwasser, M.A.; Paszat, L.F.; Saskin, R.; Urbach, D.R. & Rabeneck, L. (2009). 
Association of colonoscopy and death from colorectal cancer. Ann.Intern.Med., vol. 
150, no. 1, pp. 1-8 
Brenner, H.; Hoffmeister, M; Arndt, V.; Stegmaier, C.; Altenhofen, L. & Haug, U. (2010). 
Protection from right- and leftsided colorectal neoplasms after colonoscopy: 
population-based study. J.Natl.Cancer Inst., vol. 102, no. 2, pp. 89-95 
Brenner, H.; Chang-Claude, J.; Seiler, C.M.; Sturmer, T. & Hoffmeister, M. (2006). Does a 
negative screening colonoscopy ever need to be repeated? Gut, vol. 55, no. 8, pp. 
1145-1150 
Cafferty, F.H.; Wong, J.M.; Yen, A.M.; Duffy, S.W.; Atkin, W.S. & Chen, T.H. (2007). 
Findings at follow-up endoscopies in subjects with suspected colorectal 
abnormalities: effects of baseline findings and time to follow-up. Cancer J, vol. 13, 
no. 4, pp. 263-270 
Castells, A. & Quintero, E. (2011). Colorectal Cancer Screening in Average-Risk Population: 
A Multicenter, Randomized Controlled Trial Comparing Immunochemical Fecal 
Occult Blood Testing versus Colonoscopy. WEO/OMED Colorectal Cancer 
Screening Committee Meeting. Available at 
 http://www.worldendo.org/assets/downloads/pdf/resources/ccsc/2011/weo_c
rc11_3_2_5_castells.pdf. Last accessed June, 4, 2011 
Chu, D.Z.; Chansky, K.; Alberts, D.S.; Meyskens, F.L. Jr.; Fenoglio-Preiser, C.M.; Rivkin, S.E.; 
Mills, G.M.; Giguere, J.K.; Goodman, G.E.; Abbruzzese, J.L. & Lippman, S.M. 
(2003). Adenoma recurrences after resection of colorectal carcinoma: results from 
the Southwest Oncology Group 9041 calcium chemoprevention pilot study. 
Ann.Surg.Oncol, vol. 10, no. 8, pp. 870-875 
Curado, M.P.; Edwards, B.; Shin, H.R.; Storm,.H.; Ferlay, J.; Heanue, M. & Boyle, P. (2007). 
Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160, 
Lyon, IARC. Available at http://www-dep.iarc.fr/, section CI5 IX. Last accessed 
June, 4, 2011 
Di Gregorio, C.; Benatti, P.; Losi, L.; Roncucci, L.; Rossi, G.; Ponti, G.; Marino, M.; Pedroni, 
M.; Scarselli, A.; Roncari, B. & Ponz, L.M. (2005). Incidence and survival of patients 
with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based 
study. Int J Colorectal Dis, vol. 20, no. 2, pp. 147-154 
Dominitz, J.A. & Robertson, D.J. (2011). Colonoscopy Versus Fecal Immunochemical Testing 
in Reducing Mortality From Colorectal Cancer (CONFIRM). Available at 
http://clinicaltrials.gov/ct2/show/NCT01239082.  Last accessed June, 4, 2011 
Ferlay, J.; Bray, F. & Pisani, P. GLOBOCAN 2002. Cancer incidence, mortality and 
prevalence worldwide. IARC Cancer Base No. 5 version 2.0. IARC press, Lyon 
 
Endoscopic Procedures in Colon and Rectum 
 
12
screening programme. On the other hand, patients undergoing the surveillance programme 
being followed up endoscopically are not indicated to continue with the FOBT.  
6. Conclusion  
Colonoscopy plays a major role in colorectal cancer screening. Recently published 
Europeans guidelines showed that although no randomized control study on the efficacy of 
colonoscopy has been completed yet, the recent case-control studies found a significant 
reduction of 31% CRC mortality. Very promising is the NordICC trial which could confirm 
these results. To reduce the appearance of interval cancer, colonoscopy quality control and 
adequate bowel preparation is necessary. Colonoscopy can be considered an effective and 
safe procedure.  
A well organized surveillance programme for patients with adenoma, advanced adenoma 
or carcinoma is just as important as a baseline colonoscopy examination with its quality and 
precision being the determining factors of the follow up intervals. Patients should be 
divided into three categories using simple criteria, depending on the presumed risk of 
developing colorectal cancer, while being endoscopically followed up at given intervals. It is 
always necessary to take into consideration age, comorbidities, personal and family history, 
and the personal wish of each individual. 
7. Acknowledgment 
Authors would like to thank Dr. Gabriela Veprekova for important contribution and 
literature research together with the preparation of the manuscript, and also to assoc. prof. 
Ladislav Dusek, MSc., PhD, dr. Jan Muzik, MSc., PhD and dr. Jakub Gregor, PhD for 
providing the epidemiology figures. 
8. References 
Alberts, D.S.; Martinez, M.E.; Roe, D.J.; Guillen-Rodriguez, J.M.; Marshall, J.R.; van 
Leeuwen, J.B.; Reid, M.E.; Ritenbaugh, C.; Vargas, P.A.; Bhattacharyya, A.B.; 
Earnest, D.L. & Sampliner, R.E. (2000). Lack of effect of a high-fiber cereal 
supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer 
Prevention Physicians' Network. N.Engl.J.Med., vol. 342, no. 16, pp. 1156-1162 
Arber, N.; Eagle, C.J.; Spicak, J.; Racz, I;, Dite, P.; Hajer, J.; Zavoral, M.; Lechuga, M.J.; 
Gerletti, P.; Tang, J.; Rosenstein, R.B.; Macdonald, K.; Bhadra, P.; Fowler, R.; Wittes, 
J.; Zauber, A.G.; Solomon, S.D. & Levin, B. (2006). Celecoxib for the prevention of 
colorectal adenomatous polyps. N.Engl.J.Med., vol. 355, no. 9, pp. 885-895 
Atkin, W.; Valori, R.; Kuipers, E.J.; Hoff, G.; Senore, C.; Segnan N.; Jover, R.; Schmiegel, W.; 
Lambert, R. & Pox, C. (2010). Colonoscopic surveillance following adenoma 
removal. In: Segnan N, Patnick J, von Karsa L. European guidelines for quality 
assurance in colorectal cancer screening and diagnosis, 1st ed., European Union, 
2010:274-297, ISBN 978-92-79-16435-4, doi: 10.2772/1458 
Atkin, W.S.; Edwards, R.; Kralj-Hans, I.; Wooldrage, K.; Hart, A.R.; Northover, J.M.; Parkin, 
D.M.; Wardle, J.; Duffy, S.W. & Cuzick, J. (2010). Once-only flexible sigmoidoscopy 
 
Screening and Surveillance Colonoscopy 
 
13 
screening in prevention of colorectal cancer: a multicentre randomised controlled 
trial. Lancet, vol. 375, no. 9726, pp. 1624-1633 
Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Quan, H.; Riddell, R.; Lanas, A.; Bolognese, J.A.; 
Oxenius, B.; Horgan, K.; Loftus, S. & Morton, D.G. (2006). A randomized trial of 
rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, vol. 
131, no. 6, pp. 1674-1682 
Baxter, N.N.; Goldwasser, M.A.; Paszat, L.F.; Saskin, R.; Urbach, D.R. & Rabeneck, L. (2009). 
Association of colonoscopy and death from colorectal cancer. Ann.Intern.Med., vol. 
150, no. 1, pp. 1-8 
Brenner, H.; Hoffmeister, M; Arndt, V.; Stegmaier, C.; Altenhofen, L. & Haug, U. (2010). 
Protection from right- and leftsided colorectal neoplasms after colonoscopy: 
population-based study. J.Natl.Cancer Inst., vol. 102, no. 2, pp. 89-95 
Brenner, H.; Chang-Claude, J.; Seiler, C.M.; Sturmer, T. & Hoffmeister, M. (2006). Does a 
negative screening colonoscopy ever need to be repeated? Gut, vol. 55, no. 8, pp. 
1145-1150 
Cafferty, F.H.; Wong, J.M.; Yen, A.M.; Duffy, S.W.; Atkin, W.S. & Chen, T.H. (2007). 
Findings at follow-up endoscopies in subjects with suspected colorectal 
abnormalities: effects of baseline findings and time to follow-up. Cancer J, vol. 13, 
no. 4, pp. 263-270 
Castells, A. & Quintero, E. (2011). Colorectal Cancer Screening in Average-Risk Population: 
A Multicenter, Randomized Controlled Trial Comparing Immunochemical Fecal 
Occult Blood Testing versus Colonoscopy. WEO/OMED Colorectal Cancer 
Screening Committee Meeting. Available at 
 http://www.worldendo.org/assets/downloads/pdf/resources/ccsc/2011/weo_c
rc11_3_2_5_castells.pdf. Last accessed June, 4, 2011 
Chu, D.Z.; Chansky, K.; Alberts, D.S.; Meyskens, F.L. Jr.; Fenoglio-Preiser, C.M.; Rivkin, S.E.; 
Mills, G.M.; Giguere, J.K.; Goodman, G.E.; Abbruzzese, J.L. & Lippman, S.M. 
(2003). Adenoma recurrences after resection of colorectal carcinoma: results from 
the Southwest Oncology Group 9041 calcium chemoprevention pilot study. 
Ann.Surg.Oncol, vol. 10, no. 8, pp. 870-875 
Curado, M.P.; Edwards, B.; Shin, H.R.; Storm,.H.; Ferlay, J.; Heanue, M. & Boyle, P. (2007). 
Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160, 
Lyon, IARC. Available at http://www-dep.iarc.fr/, section CI5 IX. Last accessed 
June, 4, 2011 
Di Gregorio, C.; Benatti, P.; Losi, L.; Roncucci, L.; Rossi, G.; Ponti, G.; Marino, M.; Pedroni, 
M.; Scarselli, A.; Roncari, B. & Ponz, L.M. (2005). Incidence and survival of patients 
with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based 
study. Int J Colorectal Dis, vol. 20, no. 2, pp. 147-154 
Dominitz, J.A. & Robertson, D.J. (2011). Colonoscopy Versus Fecal Immunochemical Testing 
in Reducing Mortality From Colorectal Cancer (CONFIRM). Available at 
http://clinicaltrials.gov/ct2/show/NCT01239082.  Last accessed June, 4, 2011 
Ferlay, J.; Bray, F. & Pisani, P. GLOBOCAN 2002. Cancer incidence, mortality and 
prevalence worldwide. IARC Cancer Base No. 5 version 2.0. IARC press, Lyon 
 
Endoscopic Procedures in Colon and Rectum 
 
14
2004. Available at http://www-dep.iarc.fr/, section GLOBOCAN 2002 Last 
accessed June, 4, 2011 
Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M. & Boyle, P. (2007) Estimates of 
the cancer incidence and mortality in Europe in 2006. Ann Oncol. Mar;18(3):581-92. 
Epub 2007 Feb 7. PMID: 17287242 
Karsa, L. v.; Anttila, A.; Ronco, G.; Ponti, A.; Malila, N.; Arbyn, M.; Segnan, N.; Castillo-
Beltran; M., Boniol; M., Ferlay, J.; Hery, C.; Sauvaget, C.; Voti, L. & Autier, P. (2008). 
Cancer screening in the European Union. Report on the implementation of the 
Council Recommendation on cancer screening - First Report. ISBN 978-92-79-08934-
3. European Communities (publ.) Printed in Luxembourg by the services of the 
European Commission, 2008. Available at 
 http://ec.europa.eu/health/ph_determinants/genetics/documents/cancer_screen
ing.pdf. Last accessed June, 4, 2011 
Laiyemo, A.O.; Pinsky, P.F.; Marcus, P.M.; Lanza, E.; Cross, A.J.; Schatzkin, A. & Schoen R.E. 
(2009). Utilization and yield of surveillance colonoscopy in the continued follow-up 
study of the polyp prevention trial. Clin.Gastroenterol.Hepatol., vol. 7, no. 5, pp. 562-
567 
Lieberman, D.A.; Weiss, D.G.; Bond, J.H.; Ahnen, D.J.; Garewal, H. & Chejfec, G. (2000). Use 
of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans 
Affairs Cooperative Study Group 380. N.Engl.J.Med., vol. 343, no. 3, pp. 162-168 
Matsuda, T. Japan Polyp Study: Post-polypectomy RCT- Update. (2011). WEO/OMED 
Colorectal Cancer Screening Committee Meeting. Available at  
 http://www.worldendo.org/assets/downloads/pdf/resources/ccsc/2011/weo_c
rc11_3_1_1_matsuda.pdf. Last accessed June, 4, 2011 
Martinez, M.E.; Baron, J.A.; Lieberman, D.A.; Schatzkin, A.; Lanza, E.; Winawer, S.J.; Zauber, 
A.G.; Jiang, R.; Ahnen, D.J.; Bond, J.H.; Church, T.R.; Robertson, D.J.; Smith-
Warner, S.A.; Jacobs, E.T.; Alberts, D.S. & Greenberg, E.R. (2009). A pooled analysis 
of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. 
Gastroenterology, vol. 136, no. 3, pp.832-841 
NordiCC Study Protocol. Version MB 260409. Available at  
 http://www.kreftregisteret.no/en/Research/Projects/NordICC. Last accessed 
June, 4, 2011 
Parkin, D.M.; Whelan, S.L.; Ferlay, J. & Storm, H. (2005). Cancer Incidence in Five 
Continents, Vol. I to VIII. IARC CancerBase No. 7, Lyon. Available at http://www-
dep.iarc.fr/, section CI5 I-VIII. Last accessed June, 4, 2011 
Platell, C.F.; Philpott, G. & Olynyk JK (2002). Flexible sigmoidoscopy screening for colorectal 
neoplasia in average-risk people: evaluation of a five-year rescreening interval. 
Med.J.Aust., vol. 176, no. 8, pp. 371-373 
Pabby, A.; Suneja, A.; Heeren, T. & Farraye, F.A. (2005). Flexible sigmoidoscopy for 
colorectal cancer screening in the elderly. Dig.Dis Sci., vol. 50, no. 11, pp. 2147-2152 
Pox, C.; Schmiegel, W. & Classen M. (2007). Current status of screening colonoscopy in 
Europe and in the United States. Endoscopy 2007 Feb;39(2):168-73. PMID: 17327977. 
doi:10.1055/s-2007-966182 
 
Screening and Surveillance Colonoscopy 
 
15 
Regula, J.; Rupinski, M.; Kraszewska, E.; Polkowski, M.; Pachlewski, J.; Orlowska, J.; 
Nowacki, M.P. & Butruk, E. (2006). Colonoscopy in colorectal-cancer screening for 
detection of advanced neoplasia.  N. Engl J Med 2006 Nov 2;355(18):1863-72. 
PMID: 17079760  
Rex, D.K.; Kahi, C.J.; Levin, B.; Smith, R.A.; Bond, J.H.; Brooks, D.; Burt, R.W.; Byers, T.; 
Fletcher, R.H.; Hyman, N.; Johnson, D.; Kirk, L.; Lieberman, D.A.; Levin, T.R.; 
O'Brien, M.J.; Simmang, C.; Thorson, A.G. & Winawer, S.J. (2006). Guidelines for 
colonoscopy surveillance after cancer resection: a consensus update by the 
American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. 
CA Cancer J Clin, vol. 56, no. 3, pp. 160-167 
Robertson, D.J.; Greenberg, E.R.; Beach, M.; Sandler, R.S.; Ahnen, D.; Haile, R.W.; Burke, 
C.A.; Snover, D.C.; Bresalier, R.S.; Keown-Eyssen, G.; Mandel, J.S.; Bond, J.H.; Van 
Stolk, R.U.; Summers, R.W.; Rothstein, R.; Church, T.R.; Cole, B.F.; Byers, T.; Mott, 
L. & Baron, J.A. (2005). Colorectal cancer in patients under close colonoscopic 
surveillance. Gastroenterology, vol. 129, no. 1, pp. 34-41 
Rosen, L.; Bub, D.S.; Reed, J.F., III. & Nastasee, S.A. (1993). Hemorrhage following 
colonoscopic polypectomy. Dis.Colon Rectum, vol. 36, no. 12, pp. 1126-1131 
Schoen, R.E.; Pinsky, P.F.; Weissfeld, J.L.; Bresalier, R.S.; Church, T.; Prorok, P. & Gohagan, 
J.K. (2003). Results of repeat sigmoidoscopy 3 years after a negative examination. 
JAMA, vol. 290, no. 1, pp. 41-48 
Schoenfeld, P.; Cash, B.; Flood, A.; Dobhan, R.; Eastone, J.; Coyle, W.; Kikendall, J.W.; Kim, 
H.M.; Weiss, D.G.; Emory, T.; Schatzkin, A. & Lieberman, D. (2005). Colonoscopic 
screening of average-risk women for colorectal neoplasia. N.Engl.J.Med., vol. 352, 
no. 20, pp. 2061-2068 
Segnan, N.; Senore, C.; Andreoni, B.; Azzoni, A.; Bisanti, L.; Cardelli; A., Castiglione, G.; 
Crosta, C.; Ederle, A.; Fantin, A.; Ferrari, A.; Fracchia, M.; Ferrero, F.; Gasperoni, S.; 
Recchia, S.; Risio, M.; Rubeca, T.; Saracco, G. & Zappa, M. (2007). Comparing 
attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for 
colorectal cancer screening. Gastroenterology, vol. 132, no. 7, pp. 2304-2312 
Saini, S.D.; Kim, H.M. & Schoenfeld, P. (2006). Incidence of advanced adenomas at 
surveillance colonoscopy in patients with a personal history of colon adenomas: a 
meta-analysis and systematic review. Gastrointest.Endosc., vol. 64, no. 4, pp. 614-626 
Singh, H.; Turner, D.; Xue, L.; Targownik, L.E. & Bernstein, C.N. (2006). Risk of developing 
colorectal cancer following a negative colonoscopy examination: evidence for a 10-
year interval between colonoscopies. JAMA, vol. 295, no. 20, pp. 2366-2373 
Spann, S.J.; Rozen, P.; Young, G.P. & Levin, B. (2002). Colorectal cancer: how big is the 
problem, why prevent it, and how might it present? In: Rozen P, Young GP, Levin 
B, Spann SJ. Colorectal Cancer in Clinical Practice. London, England: Martin Dunitz 
Ltd; pp: 1-18  
Walsh, J.M. & Terdiman, J.P. (2003). Colorectal cancer screening: scientific review. JAMA, 
vol. 289, no. 10, pp. 1288-1296 
World Health Organization (2006), mortality database, United Nations, World Population 
Prospects. Available at   
 http://www.un.org/esa/population/unpop.htm. Last accessed June, 4, 2011 
 
Endoscopic Procedures in Colon and Rectum 
 
14
2004. Available at http://www-dep.iarc.fr/, section GLOBOCAN 2002 Last 
accessed June, 4, 2011 
Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M. & Boyle, P. (2007) Estimates of 
the cancer incidence and mortality in Europe in 2006. Ann Oncol. Mar;18(3):581-92. 
Epub 2007 Feb 7. PMID: 17287242 
Karsa, L. v.; Anttila, A.; Ronco, G.; Ponti, A.; Malila, N.; Arbyn, M.; Segnan, N.; Castillo-
Beltran; M., Boniol; M., Ferlay, J.; Hery, C.; Sauvaget, C.; Voti, L. & Autier, P. (2008). 
Cancer screening in the European Union. Report on the implementation of the 
Council Recommendation on cancer screening - First Report. ISBN 978-92-79-08934-
3. European Communities (publ.) Printed in Luxembourg by the services of the 
European Commission, 2008. Available at 
 http://ec.europa.eu/health/ph_determinants/genetics/documents/cancer_screen
ing.pdf. Last accessed June, 4, 2011 
Laiyemo, A.O.; Pinsky, P.F.; Marcus, P.M.; Lanza, E.; Cross, A.J.; Schatzkin, A. & Schoen R.E. 
(2009). Utilization and yield of surveillance colonoscopy in the continued follow-up 
study of the polyp prevention trial. Clin.Gastroenterol.Hepatol., vol. 7, no. 5, pp. 562-
567 
Lieberman, D.A.; Weiss, D.G.; Bond, J.H.; Ahnen, D.J.; Garewal, H. & Chejfec, G. (2000). Use 
of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans 
Affairs Cooperative Study Group 380. N.Engl.J.Med., vol. 343, no. 3, pp. 162-168 
Matsuda, T. Japan Polyp Study: Post-polypectomy RCT- Update. (2011). WEO/OMED 
Colorectal Cancer Screening Committee Meeting. Available at  
 http://www.worldendo.org/assets/downloads/pdf/resources/ccsc/2011/weo_c
rc11_3_1_1_matsuda.pdf. Last accessed June, 4, 2011 
Martinez, M.E.; Baron, J.A.; Lieberman, D.A.; Schatzkin, A.; Lanza, E.; Winawer, S.J.; Zauber, 
A.G.; Jiang, R.; Ahnen, D.J.; Bond, J.H.; Church, T.R.; Robertson, D.J.; Smith-
Warner, S.A.; Jacobs, E.T.; Alberts, D.S. & Greenberg, E.R. (2009). A pooled analysis 
of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. 
Gastroenterology, vol. 136, no. 3, pp.832-841 
NordiCC Study Protocol. Version MB 260409. Available at  
 http://www.kreftregisteret.no/en/Research/Projects/NordICC. Last accessed 
June, 4, 2011 
Parkin, D.M.; Whelan, S.L.; Ferlay, J. & Storm, H. (2005). Cancer Incidence in Five 
Continents, Vol. I to VIII. IARC CancerBase No. 7, Lyon. Available at http://www-
dep.iarc.fr/, section CI5 I-VIII. Last accessed June, 4, 2011 
Platell, C.F.; Philpott, G. & Olynyk JK (2002). Flexible sigmoidoscopy screening for colorectal 
neoplasia in average-risk people: evaluation of a five-year rescreening interval. 
Med.J.Aust., vol. 176, no. 8, pp. 371-373 
Pabby, A.; Suneja, A.; Heeren, T. & Farraye, F.A. (2005). Flexible sigmoidoscopy for 
colorectal cancer screening in the elderly. Dig.Dis Sci., vol. 50, no. 11, pp. 2147-2152 
Pox, C.; Schmiegel, W. & Classen M. (2007). Current status of screening colonoscopy in 
Europe and in the United States. Endoscopy 2007 Feb;39(2):168-73. PMID: 17327977. 
doi:10.1055/s-2007-966182 
 
Screening and Surveillance Colonoscopy 
 
15 
Regula, J.; Rupinski, M.; Kraszewska, E.; Polkowski, M.; Pachlewski, J.; Orlowska, J.; 
Nowacki, M.P. & Butruk, E. (2006). Colonoscopy in colorectal-cancer screening for 
detection of advanced neoplasia.  N. Engl J Med 2006 Nov 2;355(18):1863-72. 
PMID: 17079760  
Rex, D.K.; Kahi, C.J.; Levin, B.; Smith, R.A.; Bond, J.H.; Brooks, D.; Burt, R.W.; Byers, T.; 
Fletcher, R.H.; Hyman, N.; Johnson, D.; Kirk, L.; Lieberman, D.A.; Levin, T.R.; 
O'Brien, M.J.; Simmang, C.; Thorson, A.G. & Winawer, S.J. (2006). Guidelines for 
colonoscopy surveillance after cancer resection: a consensus update by the 
American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. 
CA Cancer J Clin, vol. 56, no. 3, pp. 160-167 
Robertson, D.J.; Greenberg, E.R.; Beach, M.; Sandler, R.S.; Ahnen, D.; Haile, R.W.; Burke, 
C.A.; Snover, D.C.; Bresalier, R.S.; Keown-Eyssen, G.; Mandel, J.S.; Bond, J.H.; Van 
Stolk, R.U.; Summers, R.W.; Rothstein, R.; Church, T.R.; Cole, B.F.; Byers, T.; Mott, 
L. & Baron, J.A. (2005). Colorectal cancer in patients under close colonoscopic 
surveillance. Gastroenterology, vol. 129, no. 1, pp. 34-41 
Rosen, L.; Bub, D.S.; Reed, J.F., III. & Nastasee, S.A. (1993). Hemorrhage following 
colonoscopic polypectomy. Dis.Colon Rectum, vol. 36, no. 12, pp. 1126-1131 
Schoen, R.E.; Pinsky, P.F.; Weissfeld, J.L.; Bresalier, R.S.; Church, T.; Prorok, P. & Gohagan, 
J.K. (2003). Results of repeat sigmoidoscopy 3 years after a negative examination. 
JAMA, vol. 290, no. 1, pp. 41-48 
Schoenfeld, P.; Cash, B.; Flood, A.; Dobhan, R.; Eastone, J.; Coyle, W.; Kikendall, J.W.; Kim, 
H.M.; Weiss, D.G.; Emory, T.; Schatzkin, A. & Lieberman, D. (2005). Colonoscopic 
screening of average-risk women for colorectal neoplasia. N.Engl.J.Med., vol. 352, 
no. 20, pp. 2061-2068 
Segnan, N.; Senore, C.; Andreoni, B.; Azzoni, A.; Bisanti, L.; Cardelli; A., Castiglione, G.; 
Crosta, C.; Ederle, A.; Fantin, A.; Ferrari, A.; Fracchia, M.; Ferrero, F.; Gasperoni, S.; 
Recchia, S.; Risio, M.; Rubeca, T.; Saracco, G. & Zappa, M. (2007). Comparing 
attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for 
colorectal cancer screening. Gastroenterology, vol. 132, no. 7, pp. 2304-2312 
Saini, S.D.; Kim, H.M. & Schoenfeld, P. (2006). Incidence of advanced adenomas at 
surveillance colonoscopy in patients with a personal history of colon adenomas: a 
meta-analysis and systematic review. Gastrointest.Endosc., vol. 64, no. 4, pp. 614-626 
Singh, H.; Turner, D.; Xue, L.; Targownik, L.E. & Bernstein, C.N. (2006). Risk of developing 
colorectal cancer following a negative colonoscopy examination: evidence for a 10-
year interval between colonoscopies. JAMA, vol. 295, no. 20, pp. 2366-2373 
Spann, S.J.; Rozen, P.; Young, G.P. & Levin, B. (2002). Colorectal cancer: how big is the 
problem, why prevent it, and how might it present? In: Rozen P, Young GP, Levin 
B, Spann SJ. Colorectal Cancer in Clinical Practice. London, England: Martin Dunitz 
Ltd; pp: 1-18  
Walsh, J.M. & Terdiman, J.P. (2003). Colorectal cancer screening: scientific review. JAMA, 
vol. 289, no. 10, pp. 1288-1296 
World Health Organization (2006), mortality database, United Nations, World Population 
Prospects. Available at   
 http://www.un.org/esa/population/unpop.htm. Last accessed June, 4, 2011 
 
Endoscopic Procedures in Colon and Rectum 
 
16
Zavoral, M.; Suchanek, S.; Zavada, F.; Dusek, L.; Muzik, J.; Seifert & B.; Fric, P. (2009). 
Colorectal cancer screening in Europe. World Journal Of Gastroenterology, 
Vol.15,No.47, (December 2009), pp. 5907-5915, ISSN 1007-9327 
2 
Preparing for Colonoscopy 
Parakkal Deepak, Humberto Sifuentes,  
Muhammed Sherid and Eli D.Ehrenpreis 




Colorectal cancer screening for average risk individuals beginning at the age of fifty has 
been recommended by the American Cancer Society, the American College of 
Gastroenterology, the American Society for Gastrointestinal Endoscopy, the American 
Gastroenterological Association and the American College of Radiology (Levin et al., 2008). 
Colorectal cancer screening has been shown to reduce the incidence and mortality of cancer 
of the colon and rectum due to early detection and removal of precancerous lesions and 
adenomas. Colonoscopy is generally considered to be the preferred method of screening 
despite the emergence of computed tomographic (CT) colonography and the use of other 
recommended screening modalities (Rex et al., 2009). Other indications for colonoscopy 
(ASGE, 2000) include evaluation and treatment of gastrointestinal bleeding, unexplained 
iron deficiency anemia, clinically significant chronic diarrhea of unexplained origin, foreign 
body removal, decompression of acute nontoxic megacolon or sigmoid volvulus, balloon 
dilation of stenotic lesions and in palliative procedures for colonic obstructive or bleeding 
neoplasms. 
Colonoscopy requires thorough cleansing of the large intestine for full visualization as well 
as the safe and effective completion of the procedure. This chapter describes the rationale for 
bowel preparation, the types of preparations currently available, complications associated 
with bowel preparations and special considerations for bowel preparation in specific 
segments of the population. The consequences of inadequate bowel preparation, use of 
antibiotic prophylaxis for the procedure and management of anticoagulants and antiplatelet 
agents before and after colonoscopy will also be reviewed. Literature was accessed using 
MEDLINE (through March, 2011) for all relevant articles published in the English language. 
2. Preparing for colonoscopy 
2.1 Why prepare? 
Inadequate bowel preparation is responsible for up to one third of all incomplete 
colonoscopy procedures (Belsey et al., 2007). Poor preparation precludes up to 10% of 
examinations (Kazarian et al., 2008), negatively impacts the rate of overall polyp (Froehlich 
et al., 2005; Harewood et al., 2003) and adenomatous polyp detection (Thomas-Gibson et al., 
2006). In additional, poor bowel preparation raises costs due to aborted examinations 
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followed by repeated procedures.  In a study of 200 consecutive outpatient colonoscopies, 
imperfect bowel preparation resulted in a 12% increase in costs at a university hospital and 
22% increase in costs at a public hospital (Rex et al., 2002). 
2.2 Types of bowel preparations 
The ideal colon preparation should rapidly and reliably cleanse the colon of fecal material 
while having no effect on the gross or microscopic appearance of the colon (Wexner et al., 
2006). It should require a short period for ingestion and evacuation, cause no discomfort, 
and produce no significant fluid or electrolyte shifts while also being palatable, simple, and 
inexpensive. 
Agents used for bowel preparation can be divided into three main categories according to 
their mechanism of action, these being isosmotic, hyperosmotic, and adjunctive 
preparations. Polyethylene glycol-electrolyte lavage solutions (PEG-ELSs) and sodium 
phosphate (NaP) formulations are among the most commonly used. 
2.2.1 Isosmotic bowel preparations 
Isosmotic preparations that contain polyethylene glycol (PEG) are osmotically balanced, 
high-volume, nonfermentable electrolyte solutions (Table 1). These preparations cleanse the 
bowel with minimal water and electrolyte absorption or secretion in the bowel lumen and 
provide evacuation, primarily by the mechanical effects of a large-volume lavage. Standard 
dosing of the 4 liter PEG-ELS is 240 ml(8 oz.) every 10 minutes or a rate of 20 to 30 mL/min 
if administered by nasogastric tube. This intake rate is generally continued until the rectal 
output is clear or the entire volume of the preparation is ingested (Wexner et al., 2006). 
Because of the salty taste of PEG-ELS, sulfate-free PEG preparations were developed; 
patients by a 3:1 ratio preferred the sulfate free 4 liter PEG-ELS compared to the original 
formulation (76% versus 24%, p≤0.0001) with no difference in the efficacy of colonic 
cleansing (Di Palma and Marshall, 1990). To improve taste, flavored preparations have also 
been introduced. Unfortunately, flavorings may increase the osmotic load, and some contain 
carbohydrates that, with bacterial fermentation, could lead to production of combustible 
gases (Wexner, 1996). 
A further development for the advancement PEG-ELSs came with reduced volume 
preparations. Good or excellent cleansing was reported in 87% of the patients receiving 2-
liter PEG-ELSs combined with bisacodyl (irritant laxative tablets) (n=93) compared to 92% of 
patients receiving a 4-liter sulfate free PEG-ELSs (p=0.16). The lower volume preparation 
was associated with decreased abdominal fullness (p < 0.01), nausea (p < 0.01), vomiting (p 
= 0.01), and overall discomfort (p < 0.01) (Di Palma et al., 2003). For this regimen, dosing on 
the evening prior to the procedure consists of two 5 mg bisacodyl delayed release tablets 
followed after the first bowel movement by 240 mL of PEG-ELS preparation every 10 
minutes until the excreted effluent is clear or until a total of 2 L is ingested.  Only clear 
liquids are permitted on the day of the preparation. Another low volume PEG-ELS consists 
of the addition of ascorbic acid in the 2-L PEG solution, that is also dosed  240 mL every 10 
minutes split into two one 1 liter doses, each accompanied by 16 oz. of clear fluid for 
hydration.. This regimen permits a normal breakfast and lunch followed by a light dinner 
(clear soup or yogurt or both) on the day prior to the procedure, followed by bowel prep 
starting 1 hour after the evening meal. The second liter dose can be consumed 1.5 hours after 
the initial 1 liter or on the morning of the colonoscopy (Wexner et al., 2006).The 2 liter PEG 
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with ascorbic acid was compared to 4-liter PEG-ELS in a trial where successful gut cleansing 
was achieved in 136 of 153 (88.9%) cases of the 2 liter PEG with ascorbic acid group and 147 
of 155 (94.8%) cases of the 4 L PEG-ELS group. The 2 liter regimen was also associated with 
lower frequency of nausea (14% versus 23%; 95% confidence interval [CI], -17 to -1) and 
abdominal pain (3% versus 8%; 95% CI, -10 to -0.2).Patient ratings of acceptability and taste 
were better for the 2-liter PEG with ascorbic acid group than for the PEG-ELS group (P < 
0.025) with a higher completion rate of entire preparation (p=0.035) (Ell et al, 2008). 
Collectively, these studies suggest that the 2 liter preparations of PEG-ELS are as effective as 
and better tolerated than the 4 liter PEG-ELS preparations.  
Efficacy of the standard 4-L PEG-ELS preparation can be improved by administration of 
split doses, even with minimal dietary restriction before the first dose (El Sayed et al., 2003). 
Ingestion of the entire preparation on the day of the procedure about 5 hours before the 
colonoscopy has also been shown to improve the clean-out quality when compared with 
patients who received PEG-ELS the previous day (approximately19 hours before the 
procedure) (Church, 1998).  
2.2.2 Hyperosmotic bowel preparations 
Hyperosmotic bowel preparations have a mechanism of action of drawing water and 
electrolytes into the bowel lumen, stimulating fluid loss, peristalsis and evacuation. These 
small-volume preparations cause fluid shifts, accompanied by electrolyte alterations 
(Ehrenpreis et al., 1998; Lichtenstein, 2009). Of these, the most commonly used include oral 
NaP available in as tablets and an aqueous solution (now withdrawn from the US market). 
The aqueous NaP preparation contains monobasic and dibasic NaP. The solution form of 
NaP contains 90 ml of solution with each 45-mL dose containing contains 29.7 g NaP. Two 
doses of 45 mL aqueous solution are given at least 10 to 12 hours apart, with the second dose 
given within 5 hours of the procedure. Each of these solutions should be diluted in 8 oz of 
clear liquid with a minimum of l 16 oz of clear liquids to be consumed after each dose 
(Wexner et al., 2006). The first study(Vanner et al., 1990)  compared the 4 L PEG-ELS with 
the 90 ml NaP solution included 102 patients randomized to receive either oral NaP 
solution(n=54) or standard PEG-ELSs (n=48) prior to colonoscopy. Overall, good to excellent 
bowel cleansing was reported in a significantly higher number of patients who received 
sodium phosphate(80%) compared to the patients who received PEG-ELS(33%), (p<0.001). 
Completion of bowel preparation was also significantly higher in the NaP group (85%) 
compared to the PEG-ELS group (31%), (p<0.001). A recent meta-analysis reviewed 
randomized controlled clinical trials from 1990 to 2005 and compared the tolerability, 
efficacy, and safety of various preparations. Pooled data from 15 trials with 3293 patients 
that compared PEG and NaP preparations showed that 94.4% of patients completed taking 
NaP compared with 70.9% of patients taking PEG solution Using a random effects model, 
the odds ratio of completion of preparation was 0.16 (95% CI: 0.09–0.29; P < 0.00001) in favor 
of NaP (Tan and Tjandra, 2006). 
Two NaP tablet preparations are FDA approved for cleansing prior to colonoscopy. The 
original formulation (Visicol™) contained microcrystalline cellulose (MCC), an excipient 
and was thought to reduce mucosal visibility during colonoscopy, with a new MCC-free 
preparation now available (Osmoprep™). The dose is 40 tablets (60 g) for the MCC 
containing preparation and 32 tablets (48 g) for the MCC-free preparation, both divided into 
2 doses separated by 10 to 12 hours. 20 tablets are taken the night before the colonoscopy, 4 
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tablets every 15 minutes followed by 8 oz clear liquids and the remaining 12-20 tablets on 
the morning of the colonoscopy within 3-5 hours of the procedure. A split-dose NaP 
schedule, with one dose taken the day before and one on the day of the procedure separated 
by 12 hours, was also found to be superior relative to a single dose (Frommer, 1997). All 
NaP regimens should be taken with a minimum of 2 L of clear liquids. In the event that the 
bowel preparation is inadequate after the full dose of the NaP formulation, the reparation 
should be completed using a non-NaP formulation such as PEG-ELS (Wexner et al., 2006) 
Clinical studies have shown the original MCC containing NaP tablet formulation to be as 
efficacious and better tolerated than 4 liter PEG-ELS formulation and be equally as effective 
as an aqueous NaP solution. (Aronchick et al., 2000). The 32 tablet MCC free NaP tablet 
formulation has been shown to be at least as efficacious and better tolerated than the MCC 
containing formulation (Wruble et al., 2007) and also with better colon cleansing and 
tolerability compared to the 2 liter PEG-ELS formulation (Johanson JF et al.,2007). A 
prospective trial (Rex et al., 2006(B)) reported that patients receiving the 32 tablet NaP 
formulation (n=239) compared with the 40 tablet formulation (n=236) had significantly 
smaller increase in serum phosphate levels from baseline (3.5 mg/dl versus 4.4 mg/dl, 
p≤0.0002). This improvement must be tempered by the common occurrence of electrolyte 
and fluid imbalances as well as serious side effects from NaP containing preparations (see 
below). 
Recently a new sulfate based osmotic laxative(SUPREP) was approved by the FDA in 
August, 2010 for bowel preparation before colonoscopy containing sodium sulfate 17.5 g, 
potassium sulfate 3.13 g, magnesium sulfate 1.6 g in each 6 oz bottle. Sodium absorption in 
the small intestine with sodium sulfate preparations is largely reduced because of the 
absence of chloride, the accompanying anion necessary for active absorption against 
electrochemical gradient. Unlike oral sodium phosphate, sulfate salts do not produce renal 
tubular injury in animal models (Pelham, et al, 2009). 
A split dose (2-Day) regimen is advocated.  The efficacy of the oral sulfate solution (OSS) 
was compared with 4 liter sulfate free PEG-ELS in a multicenter, single-blind, randomized, 
non-inferiority study involving one hundred thirty-six outpatients undergoing colonoscopy. 
Successful or excellent bowel preparation was more frequent with OSS than with sulfate free 
PEG-ELS (98.4% versus 89.6%; P = .04 and 71.4% versus 34.3%; P < .001 respectively). 
Gastrointestinal side effects and adverse events were not significantly different between the 
2 groups (Rex et al., 2010). 
Other hyperosmolar bowel preparations include sodium picosulfate, a salt that has 
similar action as NaP, producing a cathartic effect by osmotic effect in the bowel. This 
preparation is commonly used alone and in combination with magnesium citrate outside 
of the United States, especially in the United Kingdom for bowel preparation for 
colonoscopy. A pooled analysis of 381 patients receiving sodium picosulfate and 369 
patients receiving sodium phosphate demonstrated a significantly higher efficacy in 
bowel cleansing (described as good or excellent cleansing), with the NaP formulation 
(90%) compared with sodium picosulfate (82%) (p =0.004). A similar adverse event profile 
was seen with the two preparations (Tan and Tjandra, 2006). The pooled analysis also 
demonstrated a similar efficacy of sodium picosulfate when compared to 4 liter PEG-ELSs 
with an additional reduction in the number of adverse events (48% versus 71% 
respectively, p=0.003). 
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electrochemical gradient. Unlike oral sodium phosphate, sulfate salts do not produce renal 
tubular injury in animal models (Pelham, et al, 2009). 
A split dose (2-Day) regimen is advocated.  The efficacy of the oral sulfate solution (OSS) 
was compared with 4 liter sulfate free PEG-ELS in a multicenter, single-blind, randomized, 
non-inferiority study involving one hundred thirty-six outpatients undergoing colonoscopy. 
Successful or excellent bowel preparation was more frequent with OSS than with sulfate free 
PEG-ELS (98.4% versus 89.6%; P = .04 and 71.4% versus 34.3%; P < .001 respectively). 
Gastrointestinal side effects and adverse events were not significantly different between the 
2 groups (Rex et al., 2010). 
Other hyperosmolar bowel preparations include sodium picosulfate, a salt that has 
similar action as NaP, producing a cathartic effect by osmotic effect in the bowel. This 
preparation is commonly used alone and in combination with magnesium citrate outside 
of the United States, especially in the United Kingdom for bowel preparation for 
colonoscopy. A pooled analysis of 381 patients receiving sodium picosulfate and 369 
patients receiving sodium phosphate demonstrated a significantly higher efficacy in 
bowel cleansing (described as good or excellent cleansing), with the NaP formulation 
(90%) compared with sodium picosulfate (82%) (p =0.004). A similar adverse event profile 
was seen with the two preparations (Tan and Tjandra, 2006). The pooled analysis also 
demonstrated a similar efficacy of sodium picosulfate when compared to 4 liter PEG-ELSs 
with an additional reduction in the number of adverse events (48% versus 71% 
respectively, p=0.003). 
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Isosmotic    
Full volume    
Colyte (Scwarz Pharm, Mequon, Wis) PEG-3350 Yes  
Flavored   4000 ml 
Nonflavored   4000 ml 
GoLYTELY (Braintree, Braintree, Mass) PEG-3350 Yes  
Flavored   4000 ml 






Flavored   4000 ml 
Nonflavored   4000 ml 





Flavored   4000 ml 
Low volume    
Halflytely (Braintree) PEG-3350 and bisacodyl Yes 2000 ml 
MoviPrep (Salix , Morrisville, NC) PEG-3350 and ascorbic acid Yes 2000 ml 
Hyperosmotic    
Fleet Phospho-Soda EZ-Prep(oral) NaP 29.7 grams/45 ml ‡ 75 ml§ 




Yes 40 tablets 




Yes 32 tablets 







Yes 118 ml 
SUPREP kit(Braintree, Braintree, Mass) 
In 6 oz-Na 
sulfate-17.5g, K 
sulfate-3.13 g, 
Mg sulfate 1.6 g 
Yes 360 ml 
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LoSoPrep kit (E-Z-EM Inc, Lake Success, NY) 
Mg citrate -18 g 
plus 20 mg 
bisacodyl oral 
and 10 mg 
suppository 
Yes 38.5 ml 
Magnesium citrate Mg citrate-17.45 g Yes 300 ml 
Adjunctive medications    
Senna (AmerisourceBergen, Chesterbrook,PA) Sennosides 8.6 mg Yes Tablets 
Bisacodyl (Amkas) Bisacodyl 5 mg Yes Tablets 
‡ FDA recommends against use of over-the-counter oral NaP for bowel preparation.  
§ C.B. Fleet ceased distribution and initiated a recall on December 11, 2008. 
Table 1. Agents used for bowel preparation 
Magnesium citrate is another hyperosmotic agent that also promotes release of 
cholecystokinin, resulting in fluid and electrolyte secretion as well as stimulation of 
peristalsis. It is typically not effective as a sole agent for colonic cleansing; hence it is used 
mainly in combination with other agents. Magnesium is renally excreted and should be used 
in extreme caution in patients with renal insufficiency or renal failure.. Sodium picosulfate 
in combination with magnesium citrate has been compared to 2 liter PEG-ELS with ascorbic 
acid with similar efficacy (73 % versus 84% respectively, p=0.367) and adverse event profile. 
Improved preparation was seen in the ascending colon (p=0.024) and cecum (p=0.003) 
(Worthington et al., 2008). Magnesium citrate in combination with 2 liter PEG-ELS solution 
has also been shown to improve preparation quality and improve patient satisfaction 
compared to 4 liter PEG-ELSs (Sharma et al., 1998). Combination preparations containing 
magnesium citrate also include a 240-mL dose of balanced magnesium solution and 20 mg 
bisacodyl(oral) the evening before the procedure and a 10-mg bisacodyl suppository the 
morning of the procedure (Delegge and Kaplan, 2005).A pulsed rectal irrigation with 
magnesium citrate as also been suggested to enhance preparation for colonoscopy; however, 
this requires skilled nursing for administration and is associated with a high cost (Chang et 
al, 1991). 
2.3 Additional medications/methods used in bowel cleansing 
2.3.1 Bisacodyl 
Bisacodyl is a poorly absorbed diphenylmethane which acts locally on the colon as a 
peristaltic stimulant. Its active metabolites stimulate colonic motility with an onset of action 
between 6 and 10 hours. It is often used as an adjunct with PEG-ELS although this 
combination has not demonstrated a significant difference in the quality of the preparation 
or amount of residual colonic fluid during colonoscopy (Ziegenhagen et al., 1992).Use of 
bisacodyl as an adjunct to PEG-ELS may allow patients to consume a smaller volume of 
PEG necessary for colonic cleansing (Sharma et al., 1998). 
2.3.2 Senna 
Senna is an anthraquinone derivative that is activated by colonic bacteria. These activated 
derivates have a direct effect on intestinal mucosa increasing the rate of colonic motility, 
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enhancing colonic transit and inhibiting water and electrolyte secretion. Like bisacodyl, 
senna can also be used as an adjunct to PEG-ELS. It has also been shown to reduce the 
amount of PEG-ELS required for effective bowel preparation (Iida et al., 1992). 
2.3.3 Flavoring 
Several methods to improve the palatability of both PEG-ELS and NaP solutions have been 
attempted. PEG-ELSs are now available in multiple flavors including cherry, citrus-berry, 
lemon-lime, orange and pineapple. Carbohydrate-electrolyte solutions such as Gatorade® 
and Crystal Light® have also been recommended to improve the taste in PEG and NaP 
solutions(Wexner et al.,2006).Other methods to improve taste that are often used in clinical 
practice include slowing the rate of consumption, chilling the solution and consuming 
lemon slices with preparations. 
2.4 Assessment of bowel preparation quality 
The American Society for Gastrointestinal Endoscopy (ASGE) and American College of 
Gastroenterology (ACG) Taskforce on Quality in Endoscopy have suggested that every 
colonoscopy report should include an assessment of the quality of bowel preparation. They 
proposed the use of terms such as “excellent,” “good,” “fair,” and “poor,” but admitted that 
these terms lack standardized definitions (Rex et al., 2006(A)). 
 One validated measurement of preparation quality is the Boston Bowel Preparation Scale 
(BBPS), which was developed to limit inter-observer variability in the rating of bowel 
preparation quality, while preserving the ability to distinguish various degrees of bowel 
cleanliness (Lai et al., 2009). The subjective terms previously described were replaced by a 3 
point scoring system applied to each of the 3 regions of the colon: the right colon (including 
the cecum and ascending colon), the transverse colon (including the hepatic and splenic 
flexures), and the left colon (including the descending colon, sigmoid colon, and rectum). 
The points are defined as follows: 0 = unprepared colon segment with mucosa not seen 
because of solid stool that cannot be cleared; 1 = portion of mucosa of the colon segment 
seen, but other areas of the colon segment not well seen because of staining, residual stool, 
and/or opaque liquid; 2 = minor amount of residual staining, small fragments of stool 
and/or opaque liquid, but mucosa of colon segment seen well; 3 = entire mucosa of colon 
segment seen well with no residual staining, small fragments of stool or opaque liquid. Each 
of the 3 segment scores is then summed for a total score of 0 to 9, in which 0 is unprepared 
and 9 is entirely clean. If an endoscopist aborts a procedure due to an inadequate 
preparation, then any nonvisualized proximal segments are assigned a score of 0.  An 
instructional video demonstrating the BPPS is available and can be accessed online at 
http://bmc.org/gastroenterology/research.htm (Lai et al., 2009). In a comprehensive 
validation study, the BBPS was found to be a reliable instrument for assessing bowel 
cleanliness during colonoscopy (Calderwood & Jacobson, 2010). 
2.5 Complications of bowel preparation 
2.5.1 Inadequate bowel preparation 
An inadequate preparation for colonoscopy can result in many complications including 
missed lesions, cancelled procedures, increased procedure time, and an increased potential 
in complication rates. Currently, there are no specific guidelines for the management of 
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LoSoPrep kit (E-Z-EM Inc, Lake Success, NY) 
Mg citrate -18 g 
plus 20 mg 
bisacodyl oral 
and 10 mg 
suppository 
Yes 38.5 ml 
Magnesium citrate Mg citrate-17.45 g Yes 300 ml 
Adjunctive medications    
Senna (AmerisourceBergen, Chesterbrook,PA) Sennosides 8.6 mg Yes Tablets 
Bisacodyl (Amkas) Bisacodyl 5 mg Yes Tablets 
‡ FDA recommends against use of over-the-counter oral NaP for bowel preparation.  
§ C.B. Fleet ceased distribution and initiated a recall on December 11, 2008. 
Table 1. Agents used for bowel preparation 
Magnesium citrate is another hyperosmotic agent that also promotes release of 
cholecystokinin, resulting in fluid and electrolyte secretion as well as stimulation of 
peristalsis. It is typically not effective as a sole agent for colonic cleansing; hence it is used 
mainly in combination with other agents. Magnesium is renally excreted and should be used 
in extreme caution in patients with renal insufficiency or renal failure.. Sodium picosulfate 
in combination with magnesium citrate has been compared to 2 liter PEG-ELS with ascorbic 
acid with similar efficacy (73 % versus 84% respectively, p=0.367) and adverse event profile. 
Improved preparation was seen in the ascending colon (p=0.024) and cecum (p=0.003) 
(Worthington et al., 2008). Magnesium citrate in combination with 2 liter PEG-ELS solution 
has also been shown to improve preparation quality and improve patient satisfaction 
compared to 4 liter PEG-ELSs (Sharma et al., 1998). Combination preparations containing 
magnesium citrate also include a 240-mL dose of balanced magnesium solution and 20 mg 
bisacodyl(oral) the evening before the procedure and a 10-mg bisacodyl suppository the 
morning of the procedure (Delegge and Kaplan, 2005).A pulsed rectal irrigation with 
magnesium citrate as also been suggested to enhance preparation for colonoscopy; however, 
this requires skilled nursing for administration and is associated with a high cost (Chang et 
al, 1991). 
2.3 Additional medications/methods used in bowel cleansing 
2.3.1 Bisacodyl 
Bisacodyl is a poorly absorbed diphenylmethane which acts locally on the colon as a 
peristaltic stimulant. Its active metabolites stimulate colonic motility with an onset of action 
between 6 and 10 hours. It is often used as an adjunct with PEG-ELS although this 
combination has not demonstrated a significant difference in the quality of the preparation 
or amount of residual colonic fluid during colonoscopy (Ziegenhagen et al., 1992).Use of 
bisacodyl as an adjunct to PEG-ELS may allow patients to consume a smaller volume of 
PEG necessary for colonic cleansing (Sharma et al., 1998). 
2.3.2 Senna 
Senna is an anthraquinone derivative that is activated by colonic bacteria. These activated 
derivates have a direct effect on intestinal mucosa increasing the rate of colonic motility, 
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enhancing colonic transit and inhibiting water and electrolyte secretion. Like bisacodyl, 
senna can also be used as an adjunct to PEG-ELS. It has also been shown to reduce the 
amount of PEG-ELS required for effective bowel preparation (Iida et al., 1992). 
2.3.3 Flavoring 
Several methods to improve the palatability of both PEG-ELS and NaP solutions have been 
attempted. PEG-ELSs are now available in multiple flavors including cherry, citrus-berry, 
lemon-lime, orange and pineapple. Carbohydrate-electrolyte solutions such as Gatorade® 
and Crystal Light® have also been recommended to improve the taste in PEG and NaP 
solutions(Wexner et al.,2006).Other methods to improve taste that are often used in clinical 
practice include slowing the rate of consumption, chilling the solution and consuming 
lemon slices with preparations. 
2.4 Assessment of bowel preparation quality 
The American Society for Gastrointestinal Endoscopy (ASGE) and American College of 
Gastroenterology (ACG) Taskforce on Quality in Endoscopy have suggested that every 
colonoscopy report should include an assessment of the quality of bowel preparation. They 
proposed the use of terms such as “excellent,” “good,” “fair,” and “poor,” but admitted that 
these terms lack standardized definitions (Rex et al., 2006(A)). 
 One validated measurement of preparation quality is the Boston Bowel Preparation Scale 
(BBPS), which was developed to limit inter-observer variability in the rating of bowel 
preparation quality, while preserving the ability to distinguish various degrees of bowel 
cleanliness (Lai et al., 2009). The subjective terms previously described were replaced by a 3 
point scoring system applied to each of the 3 regions of the colon: the right colon (including 
the cecum and ascending colon), the transverse colon (including the hepatic and splenic 
flexures), and the left colon (including the descending colon, sigmoid colon, and rectum). 
The points are defined as follows: 0 = unprepared colon segment with mucosa not seen 
because of solid stool that cannot be cleared; 1 = portion of mucosa of the colon segment 
seen, but other areas of the colon segment not well seen because of staining, residual stool, 
and/or opaque liquid; 2 = minor amount of residual staining, small fragments of stool 
and/or opaque liquid, but mucosa of colon segment seen well; 3 = entire mucosa of colon 
segment seen well with no residual staining, small fragments of stool or opaque liquid. Each 
of the 3 segment scores is then summed for a total score of 0 to 9, in which 0 is unprepared 
and 9 is entirely clean. If an endoscopist aborts a procedure due to an inadequate 
preparation, then any nonvisualized proximal segments are assigned a score of 0.  An 
instructional video demonstrating the BPPS is available and can be accessed online at 
http://bmc.org/gastroenterology/research.htm (Lai et al., 2009). In a comprehensive 
validation study, the BBPS was found to be a reliable instrument for assessing bowel 
cleanliness during colonoscopy (Calderwood & Jacobson, 2010). 
2.5 Complications of bowel preparation 
2.5.1 Inadequate bowel preparation 
An inadequate preparation for colonoscopy can result in many complications including 
missed lesions, cancelled procedures, increased procedure time, and an increased potential 
in complication rates. Currently, there are no specific guidelines for the management of 
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patients in whom an adequate examination of the colon cannot be achieved due to an 
inadequate preparation. The ASGE has recommended the following “reasonable” approach: 
the same preparation can be repeated if the patient did not consume the preparation as 
prescribed, except not within 24 hours when using NaP because risk of toxicity. In patients 
who properly consumed the preparation, options include repeating the preparation with a 
longer interval of consuming clear liquids only before the preparation, switching to an 
alternative but equally effective preparation, adding another cathartic such as magnesium 
citrate, bisacodyl or senna to the previous regimen, or double administration of the 
preparation during a two-day period (with the exception of NaP). Combining preparations 
(example, PEG ELS and NaP solutions) may also be successful. 
2.5.2 Toxicities of bowel preparation 
With the exception of NaP containing preparations, most bowel preparations have been 
demonstrated to be safe to use in healthy individuals without significant comorbid 
conditions. Caution must always be taken in selecting a bowel preparation for patients with 
renal, hepatic or cardiac disease and those patients at the extremes of age. New data also 
suggests female gender and smaller body size are risk factors for complications of NaP 
preparations (Parakkal & Ehrenpreis, 2010). 
2.5.2.1 Oral sodium phosphate 
As of December 11, 2008 the FDA issued an alert about the safe use of oral NaP products 
and added a black box warning for acute phosphate nephropathy (Food and Drug 
Administration, 2008). The FDA alert also highlighted several patients at risk of developing 
this complication including individuals over the age of 55; patients who are hypovolemic or 
have decreased intravascular volume; people who have baseline kidney disease, bowel 
obstruction or active colitis; and those that are using medications that affect renal perfusion 
(such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor 
blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]). Females of 
smaller body size are an additional risk group (Ehrenpreis, 2009). 
Oral NaP preparations can cause fluid and electrolyte shifts secondary to the hyperosmotic 
nature of the products. It is often associated with the following abnormalities: 
hypernatremia, hypokalemia, hypocalcemia, decreased serum bicarbonate, and 
hyperphosphatemia (Ehrenpreis et al., 1997). Although electrolyte shifts are typically 
transient, clinically significant toxicities have been reported (Vanner et al., 1990). NaP 
preparations can also cause colonic mucosal abnormalities such as aphthoid erosions similar 
to those seen in inflammatory bowel disease and histologic findings including focal active 
inflammation, mucosal disruption and erosion, edema of the lamia propria, mucosal 
hyperemia, focal hemorrhage, lymphoid nodules and ulceration (Rejchrt et al., 2004). 
Physicians are advised to avoid using NaP preparations when evaluating patients with 
inflammatory bowel disease or patients with diarrhea of unknown etiology. 
2.5.2.2 PEG 
The most common adverse effects with PEG ELS are abdominal fullness, nausea and 
bloating. Rare events include Mallory-Weiss tears, esophageal perforation, toxic colitis, pill 
malabsorption, pulmonary aspiration, hypothermia, cardiac arrhythmias, PEG-induced 
pancreatitis and inappropriate antidiuretic hormone secretion (Clark & DiPalma, 2004). The 
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use of PEG-based solutions is contraindicated in patients with gastric outlet obstructions, 
small and large intestinal obstruction, and suspected bowel perforation.  
2.5.2.3 Magnesium Preparations 
Magnesium citrate should be used with caution in patients with renal insufficiency or renal 
failure because it is eliminated by the kidney. Fatal reports and episodes of 
hypermagnesemia have been reported in patients with suspected or known renal failure or 
elderly patients (Schelling, 2000). 
3. Other considerations 
3.1 Antibiotic prophylaxis 
Transient bacteremia can occur during colonoscopy due to bacterial translocation of normal 
colonic flora into the bloodstream. Translocated bacteria may potentially adhere in remote 
tissues such as the endocardium. Antibiotic prophylaxis was commonly used in some high 
risk patients before colonoscopy, primarily to prevent infective endocarditis. However, the 
American Heart Association (AHA) and the American Society of Gastrointestinal 
Endoscopy (ASGE), in 2007 and 2008 respectively, have revised their recommendations 
regarding antibiotic prophylaxis before procedures including colonoscopy (Banerjee et al, 
2008; Wilson et al, 2007). Both societies classify cardiac patients as low, moderate, or high 
risk for endocarditis. New guidelines suggest that, antibiotic prophylaxis before including 
colonoscopy with or without biopsies or polypectomy is no longer recommended in any risk 
group including those considered to be high-risk.  This change in practice came about 
mainly because of a lack of convincing evidence to demonstrate a risk of endocarditis from 
gastrointestinal procedures. In addition, harmless bacteremia occurs in some daily activities 
such as tooth brushing. For example, in a study done by Lockhart et al., routine tooth 
brushing was associated with bacteremia in 23% of subjects (Lockhart et al, 2008). Bhanji et 
al. reported a 46% bacteremia rate (Bhanji et al, 2002), and Banerjee reported a 68% rate 
(Banerjee et al, 2008).  Bacteremia can occur after colonoscopy, with rates ranging from 0-
25%, and an average mean rate of 4.4% (Banerjee et al, 2008; Nelson, 2003). In contrast, a 
study done by Goldman showed that blood cultures were positive in 1% of patients after 
sigmoidoscopy (Goldman, 1985). Microorganisms causing transient bacteremia during and 
after gastrointestinal procedures are generally believed to have little potential to cause 
infective endocarditis. Normal skin floras are the most common organisms isolated from 
blood cultures after colonoscopy (although these could be a contamination during blood 
draw), (Llach et al, 1999; Levy, 2007). Despite more than 16 million colonoscopies and 
sigmoidoscopies that are done in each year in the United Stated (Seeff et al, 2004), there have 
been only 15 cases of infective endocarditis having a temporal relation with these 
procedures.  The potential side effects of prophylactic antibiotics to prevent an extremely 
small number of cases of infective endocarditis are felt to clearly outweigh their possible 
benefit (Banerjee et al, 2008; Wilson et al, 2007; Van der Meer, 1992).  
In cirrhotic patients with or without ascites in the absence of gastrointestinal bleeding who 
undergo colonoscopy, the risk of bacteremia is low. Llach et al. prospectively studied 58 
patients underwent colonoscopy. Four of these patients had positive blood cultures; none 
developed symptoms or signs of infections (Llach et al, 1999).  
Patients on peritoneal dialysis may be at risk for infectious complications of colonoscopy.  In 
fact, there are several case reports of peritonitis in patients on peritoneal dialysis after 
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patients in whom an adequate examination of the colon cannot be achieved due to an 
inadequate preparation. The ASGE has recommended the following “reasonable” approach: 
the same preparation can be repeated if the patient did not consume the preparation as 
prescribed, except not within 24 hours when using NaP because risk of toxicity. In patients 
who properly consumed the preparation, options include repeating the preparation with a 
longer interval of consuming clear liquids only before the preparation, switching to an 
alternative but equally effective preparation, adding another cathartic such as magnesium 
citrate, bisacodyl or senna to the previous regimen, or double administration of the 
preparation during a two-day period (with the exception of NaP). Combining preparations 
(example, PEG ELS and NaP solutions) may also be successful. 
2.5.2 Toxicities of bowel preparation 
With the exception of NaP containing preparations, most bowel preparations have been 
demonstrated to be safe to use in healthy individuals without significant comorbid 
conditions. Caution must always be taken in selecting a bowel preparation for patients with 
renal, hepatic or cardiac disease and those patients at the extremes of age. New data also 
suggests female gender and smaller body size are risk factors for complications of NaP 
preparations (Parakkal & Ehrenpreis, 2010). 
2.5.2.1 Oral sodium phosphate 
As of December 11, 2008 the FDA issued an alert about the safe use of oral NaP products 
and added a black box warning for acute phosphate nephropathy (Food and Drug 
Administration, 2008). The FDA alert also highlighted several patients at risk of developing 
this complication including individuals over the age of 55; patients who are hypovolemic or 
have decreased intravascular volume; people who have baseline kidney disease, bowel 
obstruction or active colitis; and those that are using medications that affect renal perfusion 
(such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor 
blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]). Females of 
smaller body size are an additional risk group (Ehrenpreis, 2009). 
Oral NaP preparations can cause fluid and electrolyte shifts secondary to the hyperosmotic 
nature of the products. It is often associated with the following abnormalities: 
hypernatremia, hypokalemia, hypocalcemia, decreased serum bicarbonate, and 
hyperphosphatemia (Ehrenpreis et al., 1997). Although electrolyte shifts are typically 
transient, clinically significant toxicities have been reported (Vanner et al., 1990). NaP 
preparations can also cause colonic mucosal abnormalities such as aphthoid erosions similar 
to those seen in inflammatory bowel disease and histologic findings including focal active 
inflammation, mucosal disruption and erosion, edema of the lamia propria, mucosal 
hyperemia, focal hemorrhage, lymphoid nodules and ulceration (Rejchrt et al., 2004). 
Physicians are advised to avoid using NaP preparations when evaluating patients with 
inflammatory bowel disease or patients with diarrhea of unknown etiology. 
2.5.2.2 PEG 
The most common adverse effects with PEG ELS are abdominal fullness, nausea and 
bloating. Rare events include Mallory-Weiss tears, esophageal perforation, toxic colitis, pill 
malabsorption, pulmonary aspiration, hypothermia, cardiac arrhythmias, PEG-induced 
pancreatitis and inappropriate antidiuretic hormone secretion (Clark & DiPalma, 2004). The 
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use of PEG-based solutions is contraindicated in patients with gastric outlet obstructions, 
small and large intestinal obstruction, and suspected bowel perforation.  
2.5.2.3 Magnesium Preparations 
Magnesium citrate should be used with caution in patients with renal insufficiency or renal 
failure because it is eliminated by the kidney. Fatal reports and episodes of 
hypermagnesemia have been reported in patients with suspected or known renal failure or 
elderly patients (Schelling, 2000). 
3. Other considerations 
3.1 Antibiotic prophylaxis 
Transient bacteremia can occur during colonoscopy due to bacterial translocation of normal 
colonic flora into the bloodstream. Translocated bacteria may potentially adhere in remote 
tissues such as the endocardium. Antibiotic prophylaxis was commonly used in some high 
risk patients before colonoscopy, primarily to prevent infective endocarditis. However, the 
American Heart Association (AHA) and the American Society of Gastrointestinal 
Endoscopy (ASGE), in 2007 and 2008 respectively, have revised their recommendations 
regarding antibiotic prophylaxis before procedures including colonoscopy (Banerjee et al, 
2008; Wilson et al, 2007). Both societies classify cardiac patients as low, moderate, or high 
risk for endocarditis. New guidelines suggest that, antibiotic prophylaxis before including 
colonoscopy with or without biopsies or polypectomy is no longer recommended in any risk 
group including those considered to be high-risk.  This change in practice came about 
mainly because of a lack of convincing evidence to demonstrate a risk of endocarditis from 
gastrointestinal procedures. In addition, harmless bacteremia occurs in some daily activities 
such as tooth brushing. For example, in a study done by Lockhart et al., routine tooth 
brushing was associated with bacteremia in 23% of subjects (Lockhart et al, 2008). Bhanji et 
al. reported a 46% bacteremia rate (Bhanji et al, 2002), and Banerjee reported a 68% rate 
(Banerjee et al, 2008).  Bacteremia can occur after colonoscopy, with rates ranging from 0-
25%, and an average mean rate of 4.4% (Banerjee et al, 2008; Nelson, 2003). In contrast, a 
study done by Goldman showed that blood cultures were positive in 1% of patients after 
sigmoidoscopy (Goldman, 1985). Microorganisms causing transient bacteremia during and 
after gastrointestinal procedures are generally believed to have little potential to cause 
infective endocarditis. Normal skin floras are the most common organisms isolated from 
blood cultures after colonoscopy (although these could be a contamination during blood 
draw), (Llach et al, 1999; Levy, 2007). Despite more than 16 million colonoscopies and 
sigmoidoscopies that are done in each year in the United Stated (Seeff et al, 2004), there have 
been only 15 cases of infective endocarditis having a temporal relation with these 
procedures.  The potential side effects of prophylactic antibiotics to prevent an extremely 
small number of cases of infective endocarditis are felt to clearly outweigh their possible 
benefit (Banerjee et al, 2008; Wilson et al, 2007; Van der Meer, 1992).  
In cirrhotic patients with or without ascites in the absence of gastrointestinal bleeding who 
undergo colonoscopy, the risk of bacteremia is low. Llach et al. prospectively studied 58 
patients underwent colonoscopy. Four of these patients had positive blood cultures; none 
developed symptoms or signs of infections (Llach et al, 1999).  
Patients on peritoneal dialysis may be at risk for infectious complications of colonoscopy.  In 
fact, there are several case reports of peritonitis in patients on peritoneal dialysis after 
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colonoscopy especially following polypectomy (Bac et al, 1994; Ray et al, 1990). The 2005 
International Society for Peritoneal Dialysis (ISPD) recommendations state that these 
patients have antibiotic prophylaxis before any procedure involving abdomen and pelvis 
including colonoscopy, and emptying the peritoneal fluid prior to the  procedure (Piraino et 
al, 2005); however, these prevention strategies were not addressed in 2010 ISPD guidelines 
(Li et al, 2010). 
Antibiotic prophylaxis is not recommended by the ASGE before colonoscopy or any other 
GI procedures in patients who have prosthetic vascular grafts or cardiovascular devices 
such as pacemakers (Banerjee et al, 2008). However, the AHA recommends antibiotic 
prophylaxis for procedures occurring within the first 6 months of prosthetic vascular grafts 
while graft epithelialization is occurring (Wilson et al, 2007). 
Antibiotic prophylaxis is not recommended for patients who have prosthetic orthopedic 
devices undergoing colonoscopy, due to their low risk of infection (Banerjee et al, 2008). 
However, scattered cases of infections in prosthetic joints after colonoscopy have been 
reported (Vanderhooft et al, 1994; Cornelius et al, 2003). 
3.2 Management of antiplatelet agents 
Antiplatelet agents are used widely to treat patients with cardiovascular and 
cerebrovascular diseases as well as acute and chronic pain.  Aspirin and other nonsteroidal 
anti-inflammatory drugs (NSAID) are not believed to increase the risk of significant 
bleeding after colonoscopy whether biopsies and/or polypectomies are performed. Use of 
aspirin was not a risk factor for polypectomy-associated bleeding in a study of 1657 patients 
(Hui et al, 2004). Recommendations regarding the management of antithrombotic agents 
before endoscopic procedures published by the ASGE in 2009 classify the procedures from 
low-risk to higher-risk (see Table2). In addition, cardiovascular conditions are also classified 
from low-risk to higher-risk (see Table 3), (Anderson et al, 2009). Colonoscopy with or 
without biopsy is considered a low risk procedure, however if polypectomy is done, the risk 
is considered higher. The ASGE recommends that aspirin and NSAIDs should not be 
discontinued prior to colonoscopy if one of them is used alone and if their use is necessary 
in any of risk groups. There is some evidence that combination of aspirin and other NSAIDs 
increases the risk of bleeding after polypectomy (Grossman et al, 2010), thus discontinuation 
of NSAIDs two to three days before polypectomy is recommended in patients on combined 
therapy. 
Dipyridamole, another antiplatelet agent, used either  alone or in combination with aspirin 
may be continued in patients undergoing colonoscopy with no significant risk of bleeding, 
however its safety is unknown in high risk procedures such as polypectomy (Zuckerman et 
al, 2005). 
Thienopyridines (Ticlopidine, clopidogrel, prasugrel) are newer antiplatelet agents. The 
AHA recommends their use for a minimum of one month after placement of bare metal 
stents and one year for drug-eluting stents (King et al, 2008). Use of clopidogrel alone is not 
associated with an increased risk of post-polypectomy bleeding, however when combined 
with other antiplatelet agents, bleeding risk is increased (Singh et al, 2010). Due to the high 
rate of stent thrombosis associated with early cessation of dual antiplatelet (clopidogrel with 
aspirin), it is recommended that discontinuation should be avoided whenever possible 
(Iakovou et al, 2005). The ASGE recommends not discontinuing thienopyridines in patients 
 
Preparing for Colonoscopy 
 
27 
undergoing low-risk procedures including colonoscopy with or without biopsy (Anderson 
et al, 2009). In patients undergoing high-risk procedures including polypectomy, 
endoscopists are advised to consider the patient’s risk for thromboembolic phenomenon. If 
the patient is considered to have a low-risk condition, thienopyridines can be discontinued 
7-10 days before the procedure. Alternatively, procedures should be postponed until the 
time when thromboembolic risk is low (Anderson et al, 2009). In low-risk patients who 
discontinue thienopyridines, continuation of aspirin alone if they are on dual antiplatelet 
therapy or initiation of aspirin before procedure should be considered. This may decrease 
the risk of thromboembolic events without increasing the chance of developing significant 
bleeding. Thienopyridines should be restarted as soon as safely possible with consideration 
for their underlying indication and the procedure that has been performed (Anderson et al, 
2009). 
Glycoprotein IIb/IIIa receptor inhibitors (Epitifibatide, tirofiban, abciximab) are 
administered in some patients of acute coronary syndrome, however when elective 
colonoscopy is considered, patients are typically not taking one of these drugs. When 
patients require emergent colonoscopy for acute GI bleeding, these antiplatelet agents 
should be discontinued (Anderson et al, 2009).  
In patients who develop GI bleeding while on any anti-platelet agents, the decision to 
continue, stop, or reverse the antiplatelet effect should be tailored case-by-case, based on the 
severity of bleeding, the risk of thromboembolic events. A discussion with relevant 
consultants in this setting is advised. Diagnostic and therapeutic colonoscopy in the setting 
of acute lower GI bleeding while using antiplatelet agents has been deemed to be safe and is 
recommended (Anderson et al, 2009). 
 
Low risk procedure                                   High risk procedures 
Diagnostic(EGD, colonoscopy, flexible 
sigmoidoscopy) including biopsy Polypectomy 
Enteroscopy and diagnostic balloon-
assisted enteroscopy Therapeutic balloon-assisted enteroscopy 
ERCP without sphincterotomy Endoscopic homeostasis 
Enteral stent deployment(without dilation) Tumor ablation by any technique 
Capsule endoscopy Pneumatic or bougie dilation 
EUS without FNA Biliary or pancreatic sphincterotomy 
 PEG placement 
 EUS with FNA 
 Cystogastrostomy 
 Treatment of varices 
Table 2. Procedure risk for bleeding: adapted from ASGE guidelines (Anderson et al, 2009). 
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colonoscopy especially following polypectomy (Bac et al, 1994; Ray et al, 1990). The 2005 
International Society for Peritoneal Dialysis (ISPD) recommendations state that these 
patients have antibiotic prophylaxis before any procedure involving abdomen and pelvis 
including colonoscopy, and emptying the peritoneal fluid prior to the  procedure (Piraino et 
al, 2005); however, these prevention strategies were not addressed in 2010 ISPD guidelines 
(Li et al, 2010). 
Antibiotic prophylaxis is not recommended by the ASGE before colonoscopy or any other 
GI procedures in patients who have prosthetic vascular grafts or cardiovascular devices 
such as pacemakers (Banerjee et al, 2008). However, the AHA recommends antibiotic 
prophylaxis for procedures occurring within the first 6 months of prosthetic vascular grafts 
while graft epithelialization is occurring (Wilson et al, 2007). 
Antibiotic prophylaxis is not recommended for patients who have prosthetic orthopedic 
devices undergoing colonoscopy, due to their low risk of infection (Banerjee et al, 2008). 
However, scattered cases of infections in prosthetic joints after colonoscopy have been 
reported (Vanderhooft et al, 1994; Cornelius et al, 2003). 
3.2 Management of antiplatelet agents 
Antiplatelet agents are used widely to treat patients with cardiovascular and 
cerebrovascular diseases as well as acute and chronic pain.  Aspirin and other nonsteroidal 
anti-inflammatory drugs (NSAID) are not believed to increase the risk of significant 
bleeding after colonoscopy whether biopsies and/or polypectomies are performed. Use of 
aspirin was not a risk factor for polypectomy-associated bleeding in a study of 1657 patients 
(Hui et al, 2004). Recommendations regarding the management of antithrombotic agents 
before endoscopic procedures published by the ASGE in 2009 classify the procedures from 
low-risk to higher-risk (see Table2). In addition, cardiovascular conditions are also classified 
from low-risk to higher-risk (see Table 3), (Anderson et al, 2009). Colonoscopy with or 
without biopsy is considered a low risk procedure, however if polypectomy is done, the risk 
is considered higher. The ASGE recommends that aspirin and NSAIDs should not be 
discontinued prior to colonoscopy if one of them is used alone and if their use is necessary 
in any of risk groups. There is some evidence that combination of aspirin and other NSAIDs 
increases the risk of bleeding after polypectomy (Grossman et al, 2010), thus discontinuation 
of NSAIDs two to three days before polypectomy is recommended in patients on combined 
therapy. 
Dipyridamole, another antiplatelet agent, used either  alone or in combination with aspirin 
may be continued in patients undergoing colonoscopy with no significant risk of bleeding, 
however its safety is unknown in high risk procedures such as polypectomy (Zuckerman et 
al, 2005). 
Thienopyridines (Ticlopidine, clopidogrel, prasugrel) are newer antiplatelet agents. The 
AHA recommends their use for a minimum of one month after placement of bare metal 
stents and one year for drug-eluting stents (King et al, 2008). Use of clopidogrel alone is not 
associated with an increased risk of post-polypectomy bleeding, however when combined 
with other antiplatelet agents, bleeding risk is increased (Singh et al, 2010). Due to the high 
rate of stent thrombosis associated with early cessation of dual antiplatelet (clopidogrel with 
aspirin), it is recommended that discontinuation should be avoided whenever possible 
(Iakovou et al, 2005). The ASGE recommends not discontinuing thienopyridines in patients 
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undergoing low-risk procedures including colonoscopy with or without biopsy (Anderson 
et al, 2009). In patients undergoing high-risk procedures including polypectomy, 
endoscopists are advised to consider the patient’s risk for thromboembolic phenomenon. If 
the patient is considered to have a low-risk condition, thienopyridines can be discontinued 
7-10 days before the procedure. Alternatively, procedures should be postponed until the 
time when thromboembolic risk is low (Anderson et al, 2009). In low-risk patients who 
discontinue thienopyridines, continuation of aspirin alone if they are on dual antiplatelet 
therapy or initiation of aspirin before procedure should be considered. This may decrease 
the risk of thromboembolic events without increasing the chance of developing significant 
bleeding. Thienopyridines should be restarted as soon as safely possible with consideration 
for their underlying indication and the procedure that has been performed (Anderson et al, 
2009). 
Glycoprotein IIb/IIIa receptor inhibitors (Epitifibatide, tirofiban, abciximab) are 
administered in some patients of acute coronary syndrome, however when elective 
colonoscopy is considered, patients are typically not taking one of these drugs. When 
patients require emergent colonoscopy for acute GI bleeding, these antiplatelet agents 
should be discontinued (Anderson et al, 2009).  
In patients who develop GI bleeding while on any anti-platelet agents, the decision to 
continue, stop, or reverse the antiplatelet effect should be tailored case-by-case, based on the 
severity of bleeding, the risk of thromboembolic events. A discussion with relevant 
consultants in this setting is advised. Diagnostic and therapeutic colonoscopy in the setting 
of acute lower GI bleeding while using antiplatelet agents has been deemed to be safe and is 
recommended (Anderson et al, 2009). 
 
Low risk procedure                                   High risk procedures 
Diagnostic(EGD, colonoscopy, flexible 
sigmoidoscopy) including biopsy Polypectomy 
Enteroscopy and diagnostic balloon-
assisted enteroscopy Therapeutic balloon-assisted enteroscopy 
ERCP without sphincterotomy Endoscopic homeostasis 
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Table 2. Procedure risk for bleeding: adapted from ASGE guidelines (Anderson et al, 2009). 
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Low risk condition                                                High risk condition 
Uncomplicated or paroxysmal non-
valvular atrial fibrillation 
Atrial fibrillation associated with valvular 
heart disease, prosthetic valves, active 
congestive heart failure, left ventricular 
ejection fraction <35%, history of a 
thromboembolic event, hypertension, 
diabetes mellitus, or age>75 year 
Bio prosthetic valve Mechanical valve in any position and previous thromboembolic event 
Mechanical valve in aortic position Mechanical valve in mitral position 
Deep vein thrombosis Recent (<1 year) placed coronary stent 
 Acute coronary syndrome 
 Non-stented percutaneous coronary intervention after myocardial infarction 
Table 3. Condition risk for thromboembolic event:  adapted from ASGE guidelines 
(Anderson et al, 2009). 
3.3 Management of anticoagulants 
The approach to the performance of colonoscopy in patients receiving anticoagulation 
agents (warfarin, heparin, low-molecular weight heparins) is another commonly 
encountered dilemma for the gastroenterologist. Using warfarin is not believed to increase 
the risk of significant bleeding in patients undergoing colonoscopy and other low-risk 
procedures (see table 2). The ASGE recommends continuation of warfarin for these 
procedures (Anderson et al, 2009). In high-risk procedures including polypectomy, there is 
an increased risk of bleeding (Hui et al, 2004). If patient is in a low thromboembolic risk 
group (see table 3), warfarin should be discontinued before a high-risk procedure, until the 
international normalized ratio (INR) is normal or nearly normal (Anderson et al, 2009). 
Vitamin K should be avoided since it delays the development of a therapeutic INR once 
warfarin is resumed. If patient is in a high thromboembolic risk group, bridging therapy 
(discontinue warfarin and administer heparin or LMWH) should be considered, however 
deferring the procedure to a time when the thromboembolic risk is low, is a better strategy 
whenever possible, depending on the degree of emergency of colonoscopy. The appropriate 
time to reinitiate warfarin and other anticoagulants after colonoscopy and other procedures 
is not clear. The ASGE recommends resumption of warfarin on the evening after procedure 
and heparin 2-6 hours after the procedure; however the risk of bleeding versus the risk of 
thromboembolic events should be weighed carefully and discussion with relevant 
consultants is suggested (Anderson et al, 2009).  
4. Special considerations for colonoscopy preparations 
4.1 Elderly 
Age does not, by itself, increase the risk to colonoscopy. Colonoscopy can be performed in 
octogenarians and older patients (Lagares-Garcia et al, 2001; Lukens et al, 2002). A 
significant problem encountered in the performance of colonoscopy in the elderly is the 
achievement of adequate bowel preparation. Dementia, cerebrovascular accident, diabetes 
mellitus, renal failure, chronic obstructive pulmonary disease, chronic constipation, use of 
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narcotics and tricyclic antidepressants are conditions that are associated with poor bowel 
preparation (Reilly & Walker, 2004; Ness et al; 2001; Taylor & Schubert, 2001).  All of these 
conditions are more common among elderly, however, even after eliminating all these 
independent predictors for inadequate bowel preparation, age still remains an independent 
risk factor for inadequate preparation, (Qureshi et al, 2000; Ure et al, 1995).  
Colonoscopy preparations often cause fecal incontinence in elderly patients, regardless of 
the type of bowel preparation, due to the large volume rectal output in a short time that 
these preparations induce. Thomson et al. found that approximately 25% of elderly 
experienced at least one episode of fecal incontinence during bowel preparation for 
colonoscopy (Thomson et al, 1996). 
The elderly are at increased risk of severe electrolyte imbalances from sodium phosphate 
containing colonoscopy preparations (Beloosesky et al, 2003; Gumurdulu et al, 2004). 
Elderly are also more likely to have comorbidities including renal failure, congestive heart 
failure, and cirrhosis that increase risk for electrolyte abnormalities and sudden change in 
intravascular volume. Additionally, the  elderly are more likely to be on  medications such 
as diuretics, nonsteroidal anti-inflammatory drugs(NSAIDs) and angiotensin converting 
enzyme inhibitors that are other potential causes for electrolyte abnormalities and change in 
intravascular volume when NaP is used (Anderson et al 2009; Ainley et al, 2005; Desmeules 
et al, 2003). Of interest, studies have suggested that the efficacy of sodium phosphate is 
similar to nonelderly adults and comparable with PEG (Thomson et al, 1996; Seinela et al, 
2003). 
Magnesium citrate causes electrolyte and fluid disturbances, especially in patients with 
renal dysfunction. Cases of hypermagnesemia have been reported in elderly patients after 
magnesium citrate preparations even without known kidney disease (Kontani et al, 2005; 
Schelling, 2000). 
Polyethylene glycol (PEG) does not, in general, cause fluid and electrolytes imbalance.  
However, a study done by Ho et al. showed that hypokalemia can occur after PEG 
preparation (Ho et al, 2010). Due to its large volume, PEG is contraindicated in patients with 
impaired swallowing function, (as seen in patients with stroke, dementia and Parkinson’s 
disease) all of which are more common among the elderly.  If colonoscopy is necessary in 
patients with these problems, a nasogastric tube can be inserted to administer the solution. 
However, it is possible that this approach does not decrease the risk of aspiration (Marschall 
et al, 1998).  
4.2 Female patients 
There is no data regarding the differences between men and women related to the success of 
bowel preparation for colonoscopy.  However, there are data regarding differences in 
completion of colonoscopy, procedure tolerance, difficulty of the procedure rated by 
colonoscopist, and detection of polyps. Completion of colonoscopy is less likely in females, 
especially if there is a history of hysterectomy (Church, 1994). Women have longer colons 
comparing to men, resulting in requirement for more time to perform colonoscopy, more 
discomfort to the patients, and increased technical difficulties in performance of the 
procedure. In a study performed by Saunders et al., female colons were 10 cm longer than 
men’s (P=0.005).  Technically difficult examinations were reported in 31% of women 
comparing to 16% of men (Saunders et al, 1996). Female gender was also an independent 
predictor of difficult colonoscopy in a study performed by Anderson (Anderson et al 2001).  
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Low risk condition                                                High risk condition 
Uncomplicated or paroxysmal non-
valvular atrial fibrillation 
Atrial fibrillation associated with valvular 
heart disease, prosthetic valves, active 
congestive heart failure, left ventricular 
ejection fraction <35%, history of a 
thromboembolic event, hypertension, 
diabetes mellitus, or age>75 year 
Bio prosthetic valve Mechanical valve in any position and previous thromboembolic event 
Mechanical valve in aortic position Mechanical valve in mitral position 
Deep vein thrombosis Recent (<1 year) placed coronary stent 
 Acute coronary syndrome 
 Non-stented percutaneous coronary intervention after myocardial infarction 
Table 3. Condition risk for thromboembolic event:  adapted from ASGE guidelines 
(Anderson et al, 2009). 
3.3 Management of anticoagulants 
The approach to the performance of colonoscopy in patients receiving anticoagulation 
agents (warfarin, heparin, low-molecular weight heparins) is another commonly 
encountered dilemma for the gastroenterologist. Using warfarin is not believed to increase 
the risk of significant bleeding in patients undergoing colonoscopy and other low-risk 
procedures (see table 2). The ASGE recommends continuation of warfarin for these 
procedures (Anderson et al, 2009). In high-risk procedures including polypectomy, there is 
an increased risk of bleeding (Hui et al, 2004). If patient is in a low thromboembolic risk 
group (see table 3), warfarin should be discontinued before a high-risk procedure, until the 
international normalized ratio (INR) is normal or nearly normal (Anderson et al, 2009). 
Vitamin K should be avoided since it delays the development of a therapeutic INR once 
warfarin is resumed. If patient is in a high thromboembolic risk group, bridging therapy 
(discontinue warfarin and administer heparin or LMWH) should be considered, however 
deferring the procedure to a time when the thromboembolic risk is low, is a better strategy 
whenever possible, depending on the degree of emergency of colonoscopy. The appropriate 
time to reinitiate warfarin and other anticoagulants after colonoscopy and other procedures 
is not clear. The ASGE recommends resumption of warfarin on the evening after procedure 
and heparin 2-6 hours after the procedure; however the risk of bleeding versus the risk of 
thromboembolic events should be weighed carefully and discussion with relevant 
consultants is suggested (Anderson et al, 2009).  
4. Special considerations for colonoscopy preparations 
4.1 Elderly 
Age does not, by itself, increase the risk to colonoscopy. Colonoscopy can be performed in 
octogenarians and older patients (Lagares-Garcia et al, 2001; Lukens et al, 2002). A 
significant problem encountered in the performance of colonoscopy in the elderly is the 
achievement of adequate bowel preparation. Dementia, cerebrovascular accident, diabetes 
mellitus, renal failure, chronic obstructive pulmonary disease, chronic constipation, use of 
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narcotics and tricyclic antidepressants are conditions that are associated with poor bowel 
preparation (Reilly & Walker, 2004; Ness et al; 2001; Taylor & Schubert, 2001).  All of these 
conditions are more common among elderly, however, even after eliminating all these 
independent predictors for inadequate bowel preparation, age still remains an independent 
risk factor for inadequate preparation, (Qureshi et al, 2000; Ure et al, 1995).  
Colonoscopy preparations often cause fecal incontinence in elderly patients, regardless of 
the type of bowel preparation, due to the large volume rectal output in a short time that 
these preparations induce. Thomson et al. found that approximately 25% of elderly 
experienced at least one episode of fecal incontinence during bowel preparation for 
colonoscopy (Thomson et al, 1996). 
The elderly are at increased risk of severe electrolyte imbalances from sodium phosphate 
containing colonoscopy preparations (Beloosesky et al, 2003; Gumurdulu et al, 2004). 
Elderly are also more likely to have comorbidities including renal failure, congestive heart 
failure, and cirrhosis that increase risk for electrolyte abnormalities and sudden change in 
intravascular volume. Additionally, the  elderly are more likely to be on  medications such 
as diuretics, nonsteroidal anti-inflammatory drugs(NSAIDs) and angiotensin converting 
enzyme inhibitors that are other potential causes for electrolyte abnormalities and change in 
intravascular volume when NaP is used (Anderson et al 2009; Ainley et al, 2005; Desmeules 
et al, 2003). Of interest, studies have suggested that the efficacy of sodium phosphate is 
similar to nonelderly adults and comparable with PEG (Thomson et al, 1996; Seinela et al, 
2003). 
Magnesium citrate causes electrolyte and fluid disturbances, especially in patients with 
renal dysfunction. Cases of hypermagnesemia have been reported in elderly patients after 
magnesium citrate preparations even without known kidney disease (Kontani et al, 2005; 
Schelling, 2000). 
Polyethylene glycol (PEG) does not, in general, cause fluid and electrolytes imbalance.  
However, a study done by Ho et al. showed that hypokalemia can occur after PEG 
preparation (Ho et al, 2010). Due to its large volume, PEG is contraindicated in patients with 
impaired swallowing function, (as seen in patients with stroke, dementia and Parkinson’s 
disease) all of which are more common among the elderly.  If colonoscopy is necessary in 
patients with these problems, a nasogastric tube can be inserted to administer the solution. 
However, it is possible that this approach does not decrease the risk of aspiration (Marschall 
et al, 1998).  
4.2 Female patients 
There is no data regarding the differences between men and women related to the success of 
bowel preparation for colonoscopy.  However, there are data regarding differences in 
completion of colonoscopy, procedure tolerance, difficulty of the procedure rated by 
colonoscopist, and detection of polyps. Completion of colonoscopy is less likely in females, 
especially if there is a history of hysterectomy (Church, 1994). Women have longer colons 
comparing to men, resulting in requirement for more time to perform colonoscopy, more 
discomfort to the patients, and increased technical difficulties in performance of the 
procedure. In a study performed by Saunders et al., female colons were 10 cm longer than 
men’s (P=0.005).  Technically difficult examinations were reported in 31% of women 
comparing to 16% of men (Saunders et al, 1996). Female gender was also an independent 
predictor of difficult colonoscopy in a study performed by Anderson (Anderson et al 2001).  
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In another study, looping of the colonoscope was more frequent (P = 0.0002) and the 
procedure was more painful (P = 0.0140) in women than in men (Shah et al, 2002). Detection 
of polyps and adenomas were lower in post-hysterectomy women compared to women 
without a hysterectomy (P= 0.008). In addition,  sigmoidoscopy was more painful (p < 
0.001), more difficult (p < 0.001), and less extensive (p < 0.0001) in this group, (Adams et al, 
2003). Women, especially of smaller stature are at increased risk of electrolyte abnormalities 
and renal injury from NaP-containing colonoscopy preparations. 
4.3 Pregnancy 
While the safety of colonoscopy and sigmoidoscopy has been established in the general 
population, colonoscopy during pregnancy has only been described in small case series and 
case reports.  The main two concerns in performing colonoscopy during pregnancy are 
maternal and fetal complications including usual complications of colonoscopy, premature 
delivery, low birth weight, fetal anomalies, placental abruption, fetal compression, 
medication toxicity, and stillbirth. In a retrospective study by Cappell et al. there were no 
maternal complications in 48 flexible sigmoidoscopies and 8 colonoscopies performed in 
pregnant women done during different trimesters (Cappell et al, 1996). Effects of the 
procedure on vital signs, including oxygen saturation, were clinically and statistically 
insignificant. Four fetal demises were reported in the study, but all 4 cases occurred in high-
risk pregnancies and at least 2 months after the procedure.  The group who underwent 
colonoscopy or sigmoidoscopy had similar outcomes in term of premature delivery, low 
birth weight, and cesarean section compared to aged-matched pregnant women who did 
not undergo endoscopy (Cappell et al, 1996). In another retrospective study from the same 
authors, there were no major maternal complications in 20 pregnant women undergoing 
colonoscopy. Mild, transient hypotension occurred in 2 patients (Cappell et al, 2010). The 
colonic preparations in their study included PEG, sodium phosphate, magnesium citrate, 
and water/saline enemas.  Anesthetics and sedative medications that were administered 
during colonoscopy included meperidine (category B drug during pregnancy), morphine 
(category C), fentanyl (category C), midazolam (category D), diazepam (category D), 
propofol (category B),  and thiopental (category C). Six patients underwent the procedure 
without anesthesia.  No fetal distress occurred during colonoscopy in the 6 patients who 
underwent fetal heart rate monitoring. In this study, also, there were no statistical 
differences between study group and the national average for pregnancy outcomes or a 
matched group in term of fetal outcomes including involuntary abortion, premature 
delivery, low birth weight, low Apgar score, cesarean section rate, congenital defects or 
stillbirth. Despite the estimate that 1500 colonoscopies are done annually during pregnancy 
in the United States, there are no prospective studies on colonoscopy in pregnancy (Cappell 
et al, 2010). Based on the aforementioned retrospective studies, it appears that both 
colonoscopy and sigmoidoscopy are safe in pregnancy. Even though PEG, NaP and 
magnesium citrate are category C drugs, they were administered for colonoscopy 
preparation without maternal or fetal complications (Cappell et al, 2010, although our group 
would strongly advise against the use of NaP containing preparations in these patients ). 
The diagnostic and therapeutic yield for colonoscopy or sigmoidoscopy is highest for rectal 
bleeding compared to abdominal pain, constipation, or diarrhea (Cappell et al, 1996; Cappell 
et al, 2010). The safest timing for colonoscopy or sigmoidoscopy during pregnancy is not 
known, however, sigmoidoscopies were performed almost equally in all three trimesters in 
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the first study while colonoscopies took place primarily in the second trimester in the 
second study by Cappell, (Cappell et al, 1996; Cappell et al, 2010). The ASGE recommends 
using PEG-ESL for colonoscopy preparation during pregnancy (Anderson et al, 2009). 
However, there are no controlled studies on the use and safety of PEG during pregnancy.  
The ASGE also suggests that colonoscopy should only be performed when the potential 
benefit outweighs the potential risks. ASGE guidelines for endoscopy in pregnant and 
lactating women published in 2005 recommend the following: procedures must always have 
a strong indication, defer to second trimester if possible, use category A or B sedative 
medications with the lowest effective dose, minimize procedure time, place pregnant 
patients with a left pelvic tilt or left lateral position. However, these recommendations are 
based on expert opinions rather than solid evidence based data (Qureshi et al, 2005).  
4.4 Low body weight 
Lower body mass index (BMI) has been associated with more difficult colonoscopy, lower 
cecal intubation rate, longer insertion time and more painful colonoscopy (Anderson et al, 
2001; Chung et al, 2007); however there are no data regarding if bowel preparation affects 
these findings. There are also no data to indicate that changes need to be made in the 
duration of the preparation, timing, and the amount of lavage solutions administered in the 
preparation for colonoscopy in patients with a low BMI. A pharmacokinetic analysis of 
liquid NaP colonoscopy preparation performed by our group has demonstrated that lower 
body weight individuals, particularly females, develop more pronounced 
hyperphosphatemia, acidosis, and decreased ionized calcium than normal weight or obese 
individuals when using these preparations (Ehrenpreis, 2009). 
4.5 Possible inflammatory bowel disease, ischemic colitis, or non-steroidal anti-
inflammatory drug-induced colitis 
Colonic mucosal changes that mimic grossly inflammatory bowel disease (IBD) changes or 
non-steroidal anti-inflammatory drug-induced colitis have been described with NaP 
preparations. Colonoscopic findings include aphthoid lesions, erosions and ulcers (Rejchrt et 
al, 2004).  Histologically, focal nonspecific inflammation, mucosal erosion, edema of the 
lamina propria, focal hemorrhage, and ulceration are seen (Rejchrt et al, 2004). In early 
studies, these mucosal changes were seen in more than 24% of patients who used NaP for 
bowel preparation (Zwas et al, 1996). More recent studies with a larger number of patients 
suggest that these changes occur in 3.3% of patients using these preparations (Rejchrt et al, 
2004). Due to these potential mucosal changes, AGSE discourages the use of NaP as a bowel 
cleanser in the initial colonoscopy in patients with a suspicion of IBD (Anderson et al, 2009).  
4.6 Diabetus mellitus 
Bowel preparation seems to be less effective in diabetic patients. In a study done by Taylor 
and Schubert, there was a significant difference in the quality of the bowel preparations with 
PEG ELS between diabetic and non-diabetic patients (p < 0.001) (Taylor & Schubert, 2001). 
Only 62% of the diabetic group had a preparation rated as good or better compared to 97% 
of the non-diabetic group (p < 0.001) (Taylor & Schubert, 2001). In this study, 9% of diabetic 
patients had a preparation rated as poor or futile, necessitating repeat colonoscopy 
compared to none in patients without diabetes (p < 0.01). Among the diabetic group, there 
was no difference in bowel preparation between patients on insulin and not on insulin, 
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In another study, looping of the colonoscope was more frequent (P = 0.0002) and the 
procedure was more painful (P = 0.0140) in women than in men (Shah et al, 2002). Detection 
of polyps and adenomas were lower in post-hysterectomy women compared to women 
without a hysterectomy (P= 0.008). In addition,  sigmoidoscopy was more painful (p < 
0.001), more difficult (p < 0.001), and less extensive (p < 0.0001) in this group, (Adams et al, 
2003). Women, especially of smaller stature are at increased risk of electrolyte abnormalities 
and renal injury from NaP-containing colonoscopy preparations. 
4.3 Pregnancy 
While the safety of colonoscopy and sigmoidoscopy has been established in the general 
population, colonoscopy during pregnancy has only been described in small case series and 
case reports.  The main two concerns in performing colonoscopy during pregnancy are 
maternal and fetal complications including usual complications of colonoscopy, premature 
delivery, low birth weight, fetal anomalies, placental abruption, fetal compression, 
medication toxicity, and stillbirth. In a retrospective study by Cappell et al. there were no 
maternal complications in 48 flexible sigmoidoscopies and 8 colonoscopies performed in 
pregnant women done during different trimesters (Cappell et al, 1996). Effects of the 
procedure on vital signs, including oxygen saturation, were clinically and statistically 
insignificant. Four fetal demises were reported in the study, but all 4 cases occurred in high-
risk pregnancies and at least 2 months after the procedure.  The group who underwent 
colonoscopy or sigmoidoscopy had similar outcomes in term of premature delivery, low 
birth weight, and cesarean section compared to aged-matched pregnant women who did 
not undergo endoscopy (Cappell et al, 1996). In another retrospective study from the same 
authors, there were no major maternal complications in 20 pregnant women undergoing 
colonoscopy. Mild, transient hypotension occurred in 2 patients (Cappell et al, 2010). The 
colonic preparations in their study included PEG, sodium phosphate, magnesium citrate, 
and water/saline enemas.  Anesthetics and sedative medications that were administered 
during colonoscopy included meperidine (category B drug during pregnancy), morphine 
(category C), fentanyl (category C), midazolam (category D), diazepam (category D), 
propofol (category B),  and thiopental (category C). Six patients underwent the procedure 
without anesthesia.  No fetal distress occurred during colonoscopy in the 6 patients who 
underwent fetal heart rate monitoring. In this study, also, there were no statistical 
differences between study group and the national average for pregnancy outcomes or a 
matched group in term of fetal outcomes including involuntary abortion, premature 
delivery, low birth weight, low Apgar score, cesarean section rate, congenital defects or 
stillbirth. Despite the estimate that 1500 colonoscopies are done annually during pregnancy 
in the United States, there are no prospective studies on colonoscopy in pregnancy (Cappell 
et al, 2010). Based on the aforementioned retrospective studies, it appears that both 
colonoscopy and sigmoidoscopy are safe in pregnancy. Even though PEG, NaP and 
magnesium citrate are category C drugs, they were administered for colonoscopy 
preparation without maternal or fetal complications (Cappell et al, 2010, although our group 
would strongly advise against the use of NaP containing preparations in these patients ). 
The diagnostic and therapeutic yield for colonoscopy or sigmoidoscopy is highest for rectal 
bleeding compared to abdominal pain, constipation, or diarrhea (Cappell et al, 1996; Cappell 
et al, 2010). The safest timing for colonoscopy or sigmoidoscopy during pregnancy is not 
known, however, sigmoidoscopies were performed almost equally in all three trimesters in 
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the first study while colonoscopies took place primarily in the second trimester in the 
second study by Cappell, (Cappell et al, 1996; Cappell et al, 2010). The ASGE recommends 
using PEG-ESL for colonoscopy preparation during pregnancy (Anderson et al, 2009). 
However, there are no controlled studies on the use and safety of PEG during pregnancy.  
The ASGE also suggests that colonoscopy should only be performed when the potential 
benefit outweighs the potential risks. ASGE guidelines for endoscopy in pregnant and 
lactating women published in 2005 recommend the following: procedures must always have 
a strong indication, defer to second trimester if possible, use category A or B sedative 
medications with the lowest effective dose, minimize procedure time, place pregnant 
patients with a left pelvic tilt or left lateral position. However, these recommendations are 
based on expert opinions rather than solid evidence based data (Qureshi et al, 2005).  
4.4 Low body weight 
Lower body mass index (BMI) has been associated with more difficult colonoscopy, lower 
cecal intubation rate, longer insertion time and more painful colonoscopy (Anderson et al, 
2001; Chung et al, 2007); however there are no data regarding if bowel preparation affects 
these findings. There are also no data to indicate that changes need to be made in the 
duration of the preparation, timing, and the amount of lavage solutions administered in the 
preparation for colonoscopy in patients with a low BMI. A pharmacokinetic analysis of 
liquid NaP colonoscopy preparation performed by our group has demonstrated that lower 
body weight individuals, particularly females, develop more pronounced 
hyperphosphatemia, acidosis, and decreased ionized calcium than normal weight or obese 
individuals when using these preparations (Ehrenpreis, 2009). 
4.5 Possible inflammatory bowel disease, ischemic colitis, or non-steroidal anti-
inflammatory drug-induced colitis 
Colonic mucosal changes that mimic grossly inflammatory bowel disease (IBD) changes or 
non-steroidal anti-inflammatory drug-induced colitis have been described with NaP 
preparations. Colonoscopic findings include aphthoid lesions, erosions and ulcers (Rejchrt et 
al, 2004).  Histologically, focal nonspecific inflammation, mucosal erosion, edema of the 
lamina propria, focal hemorrhage, and ulceration are seen (Rejchrt et al, 2004). In early 
studies, these mucosal changes were seen in more than 24% of patients who used NaP for 
bowel preparation (Zwas et al, 1996). More recent studies with a larger number of patients 
suggest that these changes occur in 3.3% of patients using these preparations (Rejchrt et al, 
2004). Due to these potential mucosal changes, AGSE discourages the use of NaP as a bowel 
cleanser in the initial colonoscopy in patients with a suspicion of IBD (Anderson et al, 2009).  
4.6 Diabetus mellitus 
Bowel preparation seems to be less effective in diabetic patients. In a study done by Taylor 
and Schubert, there was a significant difference in the quality of the bowel preparations with 
PEG ELS between diabetic and non-diabetic patients (p < 0.001) (Taylor & Schubert, 2001). 
Only 62% of the diabetic group had a preparation rated as good or better compared to 97% 
of the non-diabetic group (p < 0.001) (Taylor & Schubert, 2001). In this study, 9% of diabetic 
patients had a preparation rated as poor or futile, necessitating repeat colonoscopy 
compared to none in patients without diabetes (p < 0.01). Among the diabetic group, there 
was no difference in bowel preparation between patients on insulin and not on insulin, 
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those with hemoglobin A1c (Hb A1c) values >8% and those with values <8%, and those 
with and without diabetic neuropathy (Taylor & Schubert, 2001). In another study done by 
Oztur et al. using NaP as a bowel cleansing agent, optimal bowel cleansing was achieved in 
70% diabetics compared to 94%in the  non-diabetic group (P = 0.002).  Among the diabetic 
patients, there was a significant correlation between the quality of bowel cleansing and 
HbA1c level, duration of diabetes mellitus, and presence of late complications of diabetes (P 
<0.05) (Ozturk et al, 2010). Of note, both of the aforementioned studies were small. In a 
larger study of 362 patients, diabetes was independent predictor of poor bowel cleansing in 
patients using PEG as the agent for preparation (Chung et al, 2009).  
4.7 Colonoscopy preparation in children  
Colonoscopy is relatively uncommon in pediatric population. There are no uniform 
protocols or national guidelines for colonoscopy preparation. PEG ESL is the most common 
bowel cleansing agent used in pediatrics.  However the large volume and potentially 
unpleasant taste of these solutions has been a major limitation in their use. Placement of a 
nasogastric tube has been used in some studies. In one study, PEG ESL was better tolerated 
than total gut irrigation using normal saline with added potassium.  Both regimens 
demonstrated equivalency for side effects and efficacy (Chattopadhyay et al, 2004). PEG-
3350 without electrolytes (Miralax) has been increasingly used for bowel cleansing for 
colonoscopy in children.  PEG 3350 solution was first studied with a 4 day regimen, 
showing safety, efficacy, and tolerability in children (Safder et al, 2008). A subsequent study 
showed that even a one day regimen of PEG-3350 is effective in 93% of children (Adamiak et 
al, 2010). 
Bisacodyl with NaP enemas has been tested in different studies with a high rate of 
compliance and bowel preparation. In a study of 98 children between 30 months to 12 years 
of age, the compliance of the bisacodyl with NaP enema group was 100%, compared to 88% 
in PEG group. Good to excellent bowel preparation achieved in 95% in bisacodyl with NaP 
enema group compared to 88% in PEG ESL group (Shaoul & Haloon L, 2007).  However, 
another study of 70 children did not show the same results. PEG ESL was superior for bowel 
cleansing (p < 0.0001) but was inferior to NaP  enema in terms of tolerance and compliance 
(p < 0.003) (Dahshan et al, 1999).  
Oral NaP was studied for use as a bowel preparation for pediatric colonoscopy.  One study 
showed that NaP was superior to PEG-based solutions in term of tolerance, compliance and 
bowel cleansing (Gremse et al, 1996). However, there is potential risk of electrolytes and 
fluid disturbance in NaP. Our group recommends avoidance of these preparations in 
children. 
Magnesium citrate was used combined with senna (X-prep) in some pediatric patients. This 
combination was shown to be superior to bisacodyl combined with a NaP enema (p < 
0.0001), but inferior to PEG ELS (p < 0.075) in term of quality of bowel cleansing (Dahshan et 
al, 1999). Overall tolerance and compliance were significantly better than PEG ELS (p < 
0.003) (Dahshan et al, 1999). In another study, magnesium citrate was used with bisacodyl 
and demonstrated to be superior to NaP (P = .013) in term of bowel cleansing. Both 
regimens were equivalent for tolerance and compliance (El-Baba et al, 2006). In a third study 
of  48 children, magnesium citrate was used with a NaP enema for a 3 days protocol and 
compared to a one day regimen of oral NaP alone (Sabri et al, 2008). Bowel cleansing was 
similar in two groups (71% good or excellent) and side effects were similar except nausea 
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which was more frequent in NaP.  However, patients stated that they were more willing to 
repeat NaP alone compared to the combination regimen (77%vs 32%, respectively, P < 0.006) 
(Sabri et al, 2008).  
5. Conclusion 
The choice of bowel preparation for colonoscopy should be individualized after thorough 
patient screening. Next generation lower volume regimens have been developed that are 
well tolerated and preferred by the patients over traditional larger volume bowel 
preparations. NaP preparations are generally more effective and better tolerated than PEG-
ELSs. However there is increasing concern regarding toxicity of NaP formulations, 
especially in light of the availability of newer, potentially better tolerated preparations.  
6. Future research 
There is ongoing research to develop safe bowel preparation regimens that provide good 
bowel cleansing along with better patient tolerability and low side effect profile. Further 
research is also needed for effect of bowel preparations in the elderly, pregnant women and 
children as well as in patients with significant morbidities. Gender based risk of adverse 
effects is a newly studied phenomenon that requires additional study. 
7. References 
Adamiak, T; Altaf, M; Jensen, M.K; Sultan, M; Ramprasad, J; Ciecierega, T; Sherry, K & 
Miranda, A (2010). One-day bowel preparation with polyethylene glycol 3350: an 
effective regimen for colonoscopy in children. Gastrointest Endosc, Vol.71, No.3, 
(Mar 2010), pp.573-7, ISSN: 0016-5107. 
Adams, C; Cardwell, C; Cook, C; Edwards, R; Atkin, W.S & Morton, D.G (2003). Effect of 
hysterectomy status on polyp detection rates at screening flexible sigmoidoscopy. 
Gastrointest Endosc, Vol.57, No.7, (Jun 2003), pp.848-53, ISSN: 0016-5107. 
Ainley, E.J; Winwood, P.J & Begley, J.P (2005). Measurement of serum electrolytes and 
phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. 
Dig Dis Sci, Vol.50, No.7, (2005), pp.1319-23, ISSN: 0163-2116. 
American Society for Gastrointestinal Endoscopy. (2000).  Appropriate use of 
gastrointestinal endoscopy. Gastrointestinal endoscopy. Vol.52, No.6, (2000), pp.831-
837, ISSN: 0016-5107. 
Anderson, J.C; Messina, C.R; Cohn, W; Gottfried, E; Ingber, S; Bernstein, G; Coman, E & 
Polito, J (2001). Factors predictive of difficult colonoscopy. Gastrointest Endosc, 
Vol.54, No.5, (Nov 2001), pp.558-62, ISSN: 0016-5107. 
Anderson, M.A; Ben-Menachem, T; Gan, S.I; Appalaneni, V; Banerjee, S; Cash, B.D; Fisher, 
L; Harrison, M.E; Fanelli, R.D; Fukami, N; Ikenberry, S.O; Jain, R; Khan, K; Krinsky, 
M.L; Lichtenstein, D.R; Maple, J.T; Shen, B; Strohmeyer, L; Baron, T & Dominitz, 
J.A (2009). ASGE Standards of Practice Committee. Management of antithrombotic 
agents for endoscopic procedures. Gastrointest Endosc, Vol.70, No.6, (Dec 2009), 
pp.1060-70, ISSN: 0016-5107. 
Aronchick, CA; Lipshutz, WH; Wright, SH; Dufrayne, F & Bergman, G. (2000).A novel 
tableted purgative for colonoscopic preparation: efficacy and safety comparisons 
 
Endoscopic Procedures in Colon and Rectum 
 
32
those with hemoglobin A1c (Hb A1c) values >8% and those with values <8%, and those 
with and without diabetic neuropathy (Taylor & Schubert, 2001). In another study done by 
Oztur et al. using NaP as a bowel cleansing agent, optimal bowel cleansing was achieved in 
70% diabetics compared to 94%in the  non-diabetic group (P = 0.002).  Among the diabetic 
patients, there was a significant correlation between the quality of bowel cleansing and 
HbA1c level, duration of diabetes mellitus, and presence of late complications of diabetes (P 
<0.05) (Ozturk et al, 2010). Of note, both of the aforementioned studies were small. In a 
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1. Introduction 
Colorectal cancer is the third most cancer in the US and the second most cause of cancer 
deaths. The general lifetime risk of developing cancer in the United States is about 6%. 
Colorectal cancer almost always develops from precancerous polyps (abnormal growths) in 
the colon or rectum. There are various screening tests available for the colon cancer.  High 
sensitivity FOBT, flexible sigmoidoscopy and colonoscopy are the most commonly used 
ones. Flexible sigmoidoscopy only checks for polyps or cancer inside the rectum and lower 
third of the colon, while colonoscopy also checks for colon polyps or cancer inside the 
rectum and the entire colon. It is also used as a follow-up test if anything unusual is found 
during one of the other screening tests. Other screening tests being studied are virtual 
colonoscopy and stool DNA test- though currently these are not covered uniformly by the 
insurance companies.  
Colonoscopy is a very important screening test that is thought to be playing a pivotal role in 
the decline of the colorectal cancer rates in the developed countries by facilitating the early 
detection and the removal of the adenomatous polyps. Guidelines from national societies 
recommend routine screening for colorectal cancer starting the age of 50 years in patients at 
average risk. Adequate bowel preparation is important in assuring the quality and accuracy 
of the colonoscopy (see figure 1).  However, preparing for a colonoscopy can be frustrating 
for the patients. It is the role of the care providers to take time to explain to the patients how 
exactly they should approach in order to avoid any failures and repeat exams which can be 
agonizing for the patient. Regardless of the preparation selected, the potential financial 
burden of a repeat colonoscopy and preparation can be huge. Specifically, the patient may 
be required to pay additional co-pay for each examination and the financial intermediary 
may deem repeat examinations unnecessary. In these instances, the patient may be 
responsible for payment in full for repeat examination incurred due to inadequate bowel 
preparation.1 This can be prevented by handing out patient instruction sheet along with the 
bowel preparation that can be used as a step by step guide before the colonoscopy. Patients 
should be motivated to ask questions or call doctor’s office if they have any trouble or do 
not understand the patient instructions.  
The most important factor affecting the quality of colonoscopy results is the extent of bowel 
cleansing. Patient tolerance of his/her colonoscopy bowel preparation- regimen affects 
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patient compliance and henceforth his willingness to undergo repeated examinations. 
Patient compliance becomes a pivotal factor as it has been shown that inadequate bowel 
preparation reduces the quality of colonoscopy. This in turn leads to increased procedural 
risks and hinders the better visualization of the colonic mucosa increasing missed polyp 
detection rates2,3  There are myriad of the bowel preparation agents available in the market 
which can make the right choice difficult. The next section describes in detail the commonly 
used bowel preparation agents and measures that can enhance patient compliance and 
acceptability of the bowel regimen prescribed to them. 
 
 
Image A                                                         Image B 
 
Image C                                                        Image D 
Fig. 1. Displays the images of colon with adequate and inadequate bowel preparation. 
Bowel preparation is excellent in images A and B allowing optimal visualization of a polyp 
in image B. In contrast, Images C and D have inadequate bowel preparation with solid or 
semisolid debris that partially obscures view of the mucosa. 
(copyright permission taken from Cleveland Clinic) 
2.1 Choosing the right bowel preparation agent 
In general, the bowel preparation agents can be classified into one of three categories: 
  Polyethylene glycol (PEG) solutions, which work as high-volume gut lavage solutions 
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  Osmotic agents (sodium phosphate, magnesium citrate,  etc.) which draw extracellular 
fluid across the bowel wall and into the lumen  
 Stimulants (castor oil, senna, sodium picosulfte, and bisacodyl), which work by 
increasing smooth muscle activity within the wall of the colon. 
In current conditions, often  the decision rests between using PEG or one of the osmotic 
agents.  Stimulants are now mainly used as adjuncts to bowel preparation.  Details about 
each agent and their pros and cons are specified below:  
2.1.1 Polyethylene glycol 
PEG solutions are the most commonly used bowel preparation options. They are non-
absorbable and thus pass through the bowel without any net absorption and thus do not 
induce any substantial shifts in fluid and electrolyte levels.  
Most of the commercially available PEG Preparations can be classified into the following 
three groups – 
Standard PEG solution 
Traditionally, 4 L PEG solution (CoLyte, GoLYTELY) are given the night before the 
colonoscopy. These are inexpensive and covered by the insurance companies. The main 
disadvantage is the poor palatability and large volume which causes compliance issues with 
5-15% of the patients. 4,5  Large volumes are required to achieve a cleansing effect, and since 
this can be difficult to tolerate, nowadays split-dosing is recommended to enhance patient 
compliance (see patient instructions for details on split-dose standard PEG solutions).  
Flavored PEG solutions  
In order to decrease the salty-taste and “rotten-egg” smell from standard sulfate containing 
PEG solutions, attempts have been made to make sulfate free  PEG solutions(SF-PEG).  SF-
PEG solutions in US are available in various flavors (NuLytely and TriLyte). The patient 
tolerance is better and it is as effective as PEG in terms of effective colonic cleansing. 6 
Low volume PEG solutions 
Drinking large volume like 4 L is one of the main issues with the standard PEG solutions. 
Hence, several efforts have been made to reduce the volume related side effects like bloating 
(see section below-making bowel preparation more tolerable). Low-volume polyethylene 
glycol preparations such as HalfLytely and MoviPrep were developed to improve patient 
tolerance by reducing the amount of solution required, while maintaining efficacy by 
adding bisacodyl or ascorbic acid. 7-10 
Advantages of PEG solutions 
 Standard PEG solutions are affordable and  covered by most insurance 
 Safe in  patients with the electrolyte disorders 
 Safe in advanced liver disease  
 Can be administered safely in poorly compensated congestive heart failure or renal 
failure (under supervision) 
Disadvantages 
 Large amount of solution 4L required to achieve a cathartic effect and this affects the 
patient compliance terribly 
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 Poor salty taste in standard sulfate containing solutions affecting compliance 
 Contraindicated in patients with allergies to PEG compounds, gastric outlet 
obstruction, high grade small bowel obstruction, significant colon obstruction, 
perforation, diverticulitis and hemodynamic instability   
 Rarely are they associated with Mallory Weiss tear, toxic colitis, pulmonary aspiration, 
hypothermia, cardiac arrhythmias, and pancreatitis, SIADH 11,12 
2.1.2 Making bowel preparation more tolerable  
As mentioned in previous section, drinking large volume like 4 L is one of the main issues 
with the PEG solutions. Several efforts have been made towards reducing the volume 
related side effects like bloating and hence trying to increase the patient compliance (see 
table 1 for list of measures that are recommended to enhance patient acceptability of PEG 
solutions) 
There are many studies that have compared the efficacy compared to the traditional large 
volume PEG solutions. One such study compared full volume 4L PEG with low volume 2L 
PEG combined with magnesium citrate have demonstrated equal efficacy of colon cleansing 
but with improved overall patient tolerance.13 Preparation like HalfLytely  uses 2 L of PEG 
solution in combination of bisacodyl in an attempt to achieve similar efficacy.14 Low-volume 
polyethylene glycol preparations such as HalfLytely and MiraLax were developed to 
improve patient tolerance by reducing the amount of solution required, while still 
maintaining efficacy by adding bisacodyl or magnesium citrate. Studies in the past had 
shown 2-L solutions to be as effective as 4-L solutions in terms of colon cleansing, and to be 
better tolerated. 13-15  though some believe that  4 L PEG treatment is sometimes better than 
36 mg senna and 2 L PEG because of fewer failures.  
Studies have also compared low-volume PEG + ascorbic acid with the full dose PEG and 
concluded that the low volume had comparable efficacy as high-volume PEG solution but 
had superior palatability16 However it was noted that the cleansing results were worse if 
patients received the full dose PEG + Ascorbic acid the evening before the procedure 
compared to the split dose. The data supported the administration of PEG + Ascorbic acid as 
a split dose before the procedure.17  
Studies have also compared conventional volume (4 L) of PEG-ELS with those of a low 
volume (2 L) in combination with pretreatment using different laxatives, such as 
magnesium hydroxide (milk of magnesia) and olive oil.  Addition of Olive oil was found to 
be superior in these studies.i8 
Another approach in increasing patient compliance by making these bowel preparation 
more palatable are adding flavors : PEG-electrolyte solutions are available in multiple 
flavors such as cherry, citrus-berry, lemon-lime, orange, and pineapple. Gatorade, Crystal 
Lite, and carbohydrate-electrolyte solutions have been used to improve palatability in both 
PEG and NaP solutions.   
Combining over-the-counter (OTC) PEG-3350 laxative powder (MiraLAX) and Gatorade or 
Crystal Light (or other clear liquid of choice) has also been shown to improve the taste and 
tolerability of the preparation. MiraLAX is gaining acceptance as a bowel cleanser for 
colonoscopy  Although beneficial and common in certain regions of the US, combining OTC 
PEG laxative powder with clear fluids is not an official FDA approved preparation for 
bowel preparation and its use is considered off-label. Studies have shown the quality of split 
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dose Miralax bowel preparation is inferior compared to the 4L split dose Golytely for 
screening colonoscopies. 19,20 
 
Options Comments
Using split-bowel preparation 
Enhances acceptability as well as 
efficacy of bowel preparation. Should 
be standard of care for all afternoon 
colonoscopies and, if practical, for 
morning colonoscopies 
Utilizing low volume or sulfate free solution  May enhance acceptability but at an added cost to patient 
Chilling the solution Enhances acceptability without impacting cost or efficacy 
Adding lemon slices or sugar-free flavor 
enhancers (such as Crystal Light) or lemon juice 
Enhances acceptability without 
impacting cost or efficacy. Flavors 
should not be red colored. 
Adding metoclopramide (5 to 10 mg) orally to 
prevent or treat nausea 
Metaclopramide can be substituted 
with other anti-nausea medications. 
Use of anti-nausea medications is 
optional 
Adding magnesium citrate (1 bottle, about 300 
mL) in patients without renal insufficiency, or 
bisacodyl (two to four tablets of 5 mg each), so that 
the volume can be less15,16 
Some commercially prepared agents 
come prepackaged with bisacodyl or 
senna tablets. Shown to have 
equivalent efficacy as standard 4 L 
PEG solutions. 
Stopping further ingestion of solution once the 
stool is watery and clear on the morning of the 
procedure (for patients who can clearly 
understand and follow bowel preparation 
instructions)  
Shown to be beneficial in some 
studies. Still not widely practiced. 
Giving the solution by nasogastric tube (at a rate 
of 1.2–1.8 L per hour) in patients with swallowing 
dysfunction or altered mental status 
Especially relevant for hospitalized 
patients who have easy access to 
personnel to place nasogastric tube. 
Table 1. Measures that can increase patient acceptability of peg solutions 
The recently updated guidelines on colorectal cancer screening by the American College of 
Gastroenterology recommend the best practice of “ split-dosing ”  for both PEG  and sodium 
phosphate preparations. This is based on the data from numerous studies that have shown 
that split-dosing of bowel preparations (i.e., administering the first half of an agent the night 
before and the second half the day of colonoscopy) achieves better results than administering a 
single dose the day before the procedure.  When all of the bowel preparation is given on the 
day before examination, the interval between the last dose of preparation and the performance 
of colonoscopy is prolonged, the probability of poor preparation increases dramatically, 
particularly in the cecum and ascending colon. Splitting decreases the time between the end of 
bowel preparation and the start of colonoscopy leading to improved efficacy. In addition, 
improve tolerability results from the fact that patients have to take only half the dose at a given 
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time. Many institutions, including ours, now routinely advise split regimens for all afternoon 
colonoscopies. However, for morning colonoscopies, especially when patients have to travel 
long distances on day of colonoscopies, splitting may have some practical limitations. Since 
patients are advised not to drink or eat at least 2 hours before colonoscopy to prevent the risk 
of aspiration during sedation, patients may have to get up early AM (some time between 3 and 
5 AM) to take second half of split dosing and still may have to evacuate bowel many times 
during travel. 21-25 
2.1.3 Sodium phoshphate (NaP) 
Sodium phosphate is commonly used for bowel cleansing before colonoscopy. It is an 
osmotic laxative that draws water into the bowel lumen to promote colonic cleansing. 
Retention of water in the lumen of the colon stimulates peristalsis and bowel movements.  
In December 2008, the FDA issued a black boxed warning for prescription oral sodium 
phosphate about the potential for acute phosphate nephropathy.  Despite the boxed 
warning, studies suggest that oral sodium phosphate is a safe choice in properly screened 
patients.26 A 2007 cohort study of 7,897 patients with normal renal function compared oral 
sodium phosphate and polyethylene glycol before colonoscopy. The risk of renal 
dysfunction was the same in both groups 27 
Advantages 
 Affordable 
 More tolerable to the patient 
 No need for the ingestion of large volumes such as in PEG 
Disadvantage 
 Case reports linking NaP bowel preparation products to acute and chronic renal 
insufficiency were published in 2002 28 
 Renal failure due to hyerposphatemia (acute phosphate nephropathy) has also been 
reported in patients with normal kidney function. 29  
 Studies have shown that older patients have a decrease in glomerular filtration rate for 
six months after oral sodium phosphate intake in older patients with normal baseline 
creatinine levels. 30 
Risk factors that increase the potential for NaP related side effects include: 
 chronic kidney disease,  
 bowel obstruction, and  
 active colitis.  
 medications (e.g., diuretics, ACE inhibitors, angiotensin receptor blockers, nonsteroidal 
anti-inflammatory drugs)  
 hypovolemia 
Commercially available NaP products  
Though no longer available over the counter, NaP can still be prescribed by the physicians. 
Visicol and Osmoprep are the two tablets forms available. NaP-based bowel preparations 
are easy, quick, and safe to use.  Many people prefer these products because of that fact that 
it is a pill preparation. This gives patients the choice of what clear fluids to take it with.  In 
clinical trials, 95% of people who took OsmoPrep said they would choose it again.31 
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However the drawback is the large amount of the tablets that need to be consumed. Visicol 
is a bowel purgative that contains microcrystalline cellulose (MCC) residue that impairs full 
visibility during a colonoscopy.  Colonoscopic visualization is decreased by MCC when NaP 
is used alone but is improved by the addition of laxatives on the previous day.31 Split dosing 
with MCC Residue Free –NaP (RF-NaP, OsmoPrep) was associated with high overall Colon 
Cleansing and achieved response rates of 90%, 97%, and 100% for 28, 32, and 40 tablets, 
respectively, compared with 86% for Visicol. In addition, RF-NaP evening-only regimen 
response rates were 90% (32 tablets) and 72% (28 tablets). Transient shifts in electrolyte 
levels were reduced, and GI adverse events were less common with lower RF-NaP dose 
regimens. 32 
There have been many randomized controlled trials (RCTs) comparing polyethylene 
glycol (PEG) with sodium phosphate (NaP). Meta-analysis comparing RCTs published 
between 1990 and 2008 comparing 4-L PEG with two 45 mL doses of NaP in adults 
undergoing elective colonoscopy showed that NaP was more likely to be completed and 
to result in an excellent or good quality preparation. 33 A split-dose regimen that 
administered the first dose of sodium phosphate on the previous evening and a second 
dose on the morning of the procedure (10-12 hours apart) was significantly more effective 
than PEG-based regimens for colorectal cleansing in preparation for colonoscopy, 
sigmoidoscopy or colorectal surgery. A regimen that administered both doses of oral 
sodium phosphate on the day prior to the procedure offered no colorectal cleansing 
advantage over PEG-based regimens and was significantly less effective than the split-
dose NaP administration (i.e. regimen that administered one dose on the previous 
evening and a second dose on the morning of the procedure). Also, it has been shown that 
three doses (administered 10 minutes apart) of 15 mL of oral sodium phosphate solution, 
each diluted in 250 mL of clear fluid was associated with less vomiting than one 45 mL 
dose of the solution diluted in 250 mL of clear fluid .34 
2.1.4 Magnesium citrate and oral sodium picosulfate  
Oral sodium picosulfate + magnesium citrate , consisting of sodium picosulfate (a stimulant 
laxative) and magnesium citrate (an osmotic laxative), is approved for use in adults 
(CitraFleet; Picolax) and/or adolescents and children (Picolax) in Europe and Australia as a 
colorectal cleansing agent prior to any diagnostic procedure (e.g. colonoscopy or x-ray 
examination) requiring a clean bowel and/or surgery. It is dispensed in powder form 
(sodium picosulfate 0.01 g, magnesium oxide 3.5 g, citric acid 12.0 g per sachet), with the 
magnesium oxide and citric acid components forming magnesium citrate when the powder 
is dissolved in water. It acts locally in the colon as both a stimulant laxative, by increasing 
the frequency and the force of peristalsis (sodium picosulfate component), and as an osmotic 
laxative, by retaining fluids in the colon (magnesium citrate component), to clear the colon 
and rectum of fecal contents. Sodium picosulfate/magnesium citrate may be associated with 
a dehydrating effect, as evidenced by a reduction in bodyweight and increased hemoglobin 
levels; some at-risk patients may experience postural hypotension and older patients.35A 
study investigating  the quality of cleansing of sodium picosulfate (Picopreparation-3™, 
Pharmatel Fresenius Kabi Pty Ltd, Pymble, NSW, Australia) with different administration 
schedules concluded the worse quality of bowel preparation was associated with the 
afternoon procedures and the prior history of the constipation.36 
 
Endoscopic Procedures in Colon and Rectum 
 
48
time. Many institutions, including ours, now routinely advise split regimens for all afternoon 
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osmotic laxative that draws water into the bowel lumen to promote colonic cleansing. 
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For countries which do not have sodium picosulfate, a reasonable alternative is magnesium 
citrate (1 bottle, around 300 mL) the evening before the procedure plus either bisacodyl 
tablets at the same time as the magnesium citrate or enema immediately before the 
procedure. However, literacy comparing efficacy of magnesium citrate in combination with 
bisacodyl or enemas and PEG or NaP solutions, is sparse. 
2.2 Adjuncts to bowel preparation  
2.2.1 Diet  
Dietary modifications alone, such as clear liquids, are inadequate for colonoscopy but have 
proven benefit as an adjunct to other cleansing methods by decreasing the formation of solid 
residue. Clear liquids also help maintain adequate hydration during bowel preparation and 
are recommended with all bowel preparation regimens. 
2.2.2 Stimulant laxatives  
High dose senna has been used alone for bowel preparation and studies have shown 
comparable efficacy and better compliance. But the limiting factors were higher incidence of 
abdominal pain. Recently, the adjunctive use of low dose senna with PEG solutions has been 
demonstrated to improve the quality of bowel preparation36   and to reduce the amount of 
PEG-ELS required for effective bowel preparation. 41. This also reduces the abdominal pain 
reported with high dose senna. Bisacodyl (2-4 tablets of 5 mg each) and low-dose senna (36 
mg, about 4 tablets of 8.6 mg Sennakot) are now commonly used as an adjunct to low-
volume PEG, achieving similar results to full-volume PEG. Based on the type of study, these 
agents are given within 2 to 6 hours before starting of PEG solution. 37 
2.2.3 Hyperosmolar laxatives 
Magnesium citrate   (1 bottle, about 300 cc) alone is also commonly used as an adjunct to low 
volume PEG solution with equivalent efficacy to high volume PEG solutions .  In contrast, 
the routine use of non-absorbable carbohydrates such as mannitol and lactulose is not 
favored for bowel preparation since the hydrogen gas produced by bacterial fermentation of 
the non-absorbed carbohydrates increases the risk of explosion during electrosurgical 
procedures. 38 
2.2.4 Antiemetic agents  
Metaclopramide (5- 10 mg), a dopamine antagonist gastroprokinetic that sensitizes tissues to 
the action of acetylcholine,is commonly used to address the nausea or vomiting associated 
with bowel preparation agents. 39 
In patients who are intolerant to metaclopramide or are at high-risk for metaclopramide 
related side effects (such as in elderly), alternative anti-emetic agents such as promethazine 
(Phenergan) or ondansetron (Zofran) can be prescribed. 
2.2.5 Antifoaming agent  
Simethicone (3 tablets of 80 mg each, total 240 mg dose), an anti-flatulent, anti-gas agent, is 
prescribed by many gastroenterologists in an attempt to reduce bubbles during colonoscopy 
and improve the visibility. It works by reducing the surface tension of air bubbles and 
causing the coalescence of small bubbles into larger ones that pass more easily with belching 
or flatulence. 40 
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2.2.6 Enemas  
Enemas are sufficient for flexible sigmoidoscopies but when used alone do not permit 
adequate visualization of the proximal colon during colonoscopies. They are best used as 
adjuncts to other bowel preparation agents when patients present with poor distal colon 
preparation for colonoscopy. Enemas are also useful in washing out the distal segment of 
bowel in patients with a proximal stoma or a de-functioned distal colon. There have been 
studies comparing magnesium citrate with hypertonic enemas or oral bisacodyl as the 
bowel preparation for sigmoidoscopy over the use of hypertonic phosphate enemas alone. It 
was shown that there is no statistical difference between the quality of the three bowel 
preparations.42 In one study inadequately prepared patients during a 19-month period were 
successfully cleansed of their retained fecal contents with enemas, permitting satisfactory 
colonoscopic examinations. 21 Thus, for the management of patients who are sub-optimally 
prepared for colonoscopic examination because of retained fecal material the use of 
colonoscopic enema proves to be effective by avoiding the need for postponement of the 
procedure.43 
The common types of enema are tap water, soap suds, Fleet (NaP), Fleet-Bisacodyl and 
mineral oil enemas 
2.2.7 Tap water enemas 
500 cc to 1L tap water enemas are commonly used for bowel cleansing on the evening prior 
or the morning of the procedure along with the dietary restrictions and cathartics, especially 
for flexible sigmoidoscopies.  They usually work within 10–15 minutes but may need to be 
repeated one or two times to thoroughly cleanse the bowel in preparation for a bowel exam 
or bowel surgery. In general, tap water enemas are thought to be mild enemas and may be 
less effective than other forms of enemas. They have fewer side effects than NaP enemas 
though large or repeated amounts of tap water can still lead to electrolyte imbalances as the 
water is absorbed through the rectum and colon. Some people differentiate between high 
and low enemas. A high enema is usually administered at higher pressure and with larger 
volume (1,000 cc), and the patient is asked to change position several times in order for the 
fluid to flow up into the bowel. A low enema is administered at lower pressure, using about 
500 cc of fluid. 
2.2.8 Soap suds enemas 
Soap suds enemas are thought to be more effective than plain tap water enemas. Soaps act 
as surfactant and make water a more aggressive solvent. This allows the bowel content to 
become more liquid. Soaps are also irritant to colon and lead to increased peristalsis and 
evacuation of bowel content. Some soaps are safer to use than others. In general, 2 to 3 drops 
of hand soap are added into an enema bag filled with 2 quarts of warm filtered water. 
2.2.9 NaP enemas 
Sodium Biphosphate (Fleet enemas) can be used for bowel cleansing before sigmoidoscopy. 
However this should be avoided in elderly and in those with renal failure because of the risk 
of developing hyperphosphatemia and subsequent hypocalcemia. In one study, one 
hundred and two consecutive patients were randomized: 56 to the Fleet enema group and 
46 to the Picolax group (sodium picosulfate + magnesium citrate). It was found that Fleet 
enemas provided a significantly superior bowel preparation with 93% being judged as 
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adequate or better as opposed to 74% in the Picolax group. In addition Fleet enemas were 
associated with lesser adverse symptoms. It was thus concluded that Fleet enema is superior 
to Picolax in terms of bowel preparation for flexible sigmoidoscopy and the incidence of 
associated adverse symptoms.44 
2.2.10 Mineral oil enemas  
Mineral Oil is a lubricant laxative that works by slowing the absorption of water from the 
bowel which softens the stool. They are best reserved for refractory constipation. Possible 
side effects of mineral oil enema are: 
 Bloating, diarrhea, gas, nausea, stomach cramps. 
 Mineral oil enema is not recommended for use in children younger than 2 years of age. 
Safety and effectiveness in this age group have not been confirmed. 
 Pregnancy and Breastfeeding: If the patient becomes pregnant, it is advised to discuss 
with their doctor the benefits and risks of using Mineral Oil Enema during pregnancy. 
It is unknown if Mineral Oil Enema is excreted in breast milk. Breastfeeding patients 
must discuss the potential side effects with their doctor.  
 Patients should seek medical attention right away if any of these SEVERE side effects 
occur:  
 Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; 
swelling of the mouth, face, lips, or tongue); dizziness.  
 Failure to have a bowel movement within 6 to 8 hours after using Mineral Oil 
Enema; fainting; muscle cramps or pain; rectal bleeding; swelling, pain, or 
irritation; weakness 
2.2.11 Bisacodyl enemas 
A  laxative which is used for treating constipation can also be used to empty the bowel 
before surgery and examinations such as X-Ray procedures using Barium enema. Bisacodyl 
can be used as tablet, suppository or as enema. It can also be combined with NaP and other 
enemas. However due precautions must be taken in the following cases. 
1. If the patient is allergic to Bisacodyl, aspirin or any ingredients in these products.   
2. In case the patient is pregnant, Breast-feeding or plans to become pregnant. 
The side effects that may be experienced during the use of Bisacodyl enema are: 
 stomach cramps 
 upset stomach 
 diarrhea 
 stomach and intestinal irritation 
 faintness 
 irritation or burning in the rectum (from suppositories)  
2.2.12 Nasogastric tubes  
Nasogastric tubes have been used to instill colonic preparations, especially for inpatients not 
able to drink PEG solutions or those who are unresponsive or mechanically ventilated. It can 
also be useful for rapid bowel cleansing  
(within 2 to 3 hours) for patients with lower gastrointestinal bleeding. However, routine use 
of nasogastric tube solely for bowel preparation is discouraged as it can lead to severe 
complications, such as aspiration, in addition to trauma, during insertion. 44 
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2.3 Special situations  
2.3.1 Capsule endoscopy  
Our practice has been to place all patients on clear liquid diet and limit the bowel 
preparation to patients who have recently taken or actively taking iron supplements. 
On the other hand, some practices routinely use oral bowel preparation for capsule 
endoscopy not only to clean the colon, but also to promote capsule propulsion. For 
hospitalized patients who are unable to take bowel preparation easily, we recommend 
use of nasogastric tube to deliver PEG solutions before capsule endoscopy, whenever 
indicated.  
2.3.2 Pouchoscopy 
Patients are usually prepared by taking clear liquids for 1 day before the procedure. Some 
practices (including ours) routinely use enemas to clear the pouch and distal small bowel 
before pouchoscopies. Full bowel preparation is not required for pouchoscopies.   
2.3.3 Ileostomy and colostomy  
Bowel preparation is not needed for scoping through the ileostomy and in-fact may be 
relatively contraindicated is some cases due to the risk of increasing stoma output and 
causing dehydration. Bowel preparation for colostomy varies by site of colostomy and 
practice preference. For sigmoid colostomy, many physicians chose to give full bowel 
preparation. It is also preferable if the patients are on clear liquids for 1 day before the 
procedure, especially if they have a colostomy.  
2.3.4 Flexible sigmoidoscopy 
Usually, enemas given within 2 hours of examination are adequate for bowel preparation 
for flexible sigmoidoscopy.  Clear liquid diet for 1 day before procedure is optional. If 
patients are having diarrhea, then enemas are unnecessary. Many physicians chose not to 
give enemas to patients who have severe colitis, because of ongoing diarrhea and the 
potential for increased perforation risk.   
2.3.5 Decompressive colonoscopy for megacolon 
Decompressive colonoscopy is an exception when it comes to bowel preparation. 
Endoscopic decompression of the colon relieves acute pseudo-obstruction and megacolon in 
about 85% of patients but is associated with a perforation rate of about 2%. Because of the 
risk for colonic perforation, oral bowel preparation or enemas are avoided in these patients 
and decompressive colonoscopy is best done in unprepped bowel.  Patients are mostly NPO 
in these settings.  
2.3.6 Stricturing disease  
In our experience, many patients with ileal or colon strictures can successfully tolerate 
bowel preparation (including PEG). However, their symptoms need to be watched carefully 
and bowel preparation should be withheld if any significant nausea, vomiting or abdomen 
pain develops. Patients with high-grade strictures may not tolerate oral bowel preparation 
and may need enemas. Bowel preparation is contraindicated in patients with suspicion of 
bowel obstruction.   
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2 weeks before 
colonoscopy: 
Please let your primary care physician or the prescribing 
physician know if you are 
Taking  blood thinners or antiplatelet agents such as 
warfarin(Coumadin), enoxaparin (Lovenox), fondaparinux 
(Arixtra), clopidogrel (Plavix), ticlopidine (Ticlid), anagrelide 
(Agrylin),cilostazol (Pletal), pentoxyphylline (trental), 
dipyridamole (Persantine) with aspirin (Aggrenox) 
Over-the-counter medications like aspirin or other anti- 
inflammatory medications (motrin, advil, aleve etc) might need to 
be stopped as well 
Have diabetes and take insulin.  You may need to have your insulin 
adjusted the day before and the day of the procedure 
It is important to continue to take all other prescribed medications 
2-5 days before the 
procedure: 
If you tend to be constipated, maintain clear, liquid diet for two 
days prior to the exam.  
Do not take bulk-forming agents (such as Metamucil, Citrucel etc.) 
Do not take iron-containing preparations (such as multi-vitamins 
containing iron)  
Do not consume dairy products. 
Arrange for a driver to take you back home after the procedure 
Purchase your prescription 2 - 5 days before colonoscopy. Do not 
mix the solution until the before colonoscopy 
Evening of the exam:
Do not add sugar or flavorings containing sugar to the 
solution. Refrigerating the solution, adding lemon juice or Crystal Lite 
and rapidly drinking 8 ounce portions (instead of sipping) may help. 
At 6:00 p.m. the evening before the procedure, begin drinking 8 
ounces (240 ml, one cup) of the GoLYTELY every 15- 20 minutes 
until half of the solution is ingested. Continue drinking clear 
liquids until you go to bed.  
Do not eat solid foods for 24 hours before colonoscopy 
appointment.  
Do not take alcohol 
Do not take red-colored drinks, Jell-O or popsicles 
It is essential to drink at least 8 ounces of clear liquids (1 cup) every 
hour while awake to avoid dehydration. Clear liquids include: 
 - apple or white grape juice 
 - broth 
 - coffee or tea (without milk or creamer) 
 - clear carbonated beverages, such as ginger ale or  lemon-lime soda  
 - Gatorade or other sports drinks (not red) 
 - Kool-Aid or other flavored drinks (not red) 
 - plain Jell-O or other gelatins (not red) 
 - popsicles (not red) 
 - water 
Some people do experience nausea when drinking so much liquid, 
so the physician may prescribe an anti-nausea medication in case it 
is needed. Golytely now comes in several flavors to make it easier 
to drink. 
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Morning of the 
exam: 
Ask your doctor if you should take any of your medicines the 
morning of your  test. If so, take with sips of water only.  
If you have an afternoon appointment, begin drinking remaining 
GoLYTELY about 8 ounces every 10 minutes at 6:00 a.m. on the 
morning of the procedure, until finished at approximately 8:00 a.m.  
If your procedure is scheduled in early morning, you will need to 
get up in the night to finish the second half of GoLYTELY at least 2-
3 hours before the colonoscopy appointment or complete the entire 
GoLYTELY in the evening before the procedure.  
You should drink clear liquids at least 8 ounces of clear liquids 
every hour (no solids, alcohol or red colored drinks) until 2 hours 
before colonoscopy appointment. You may take your morning 
medications. 
If the eliminations do not become clear after the gallon is finished  
an enema may be needed 
After the exam: 
The colonoscopy generally takes 30-60 minutes  
You must have someone else drive you back home as sedation 
might take some time to wear off  
You can resume the solid diet on the same day after the 
procedure.You however should continue taking more liquids. After 
the colonoscopy, you are encouraged to drink  fluids to prevent 
dehydration. 
2.4 Patient Instructions  
Educating patients about bowel preparation instructions is critical for ensuring adequate 
bowel preparation and helps reduce the risk of preparation related adverse events. Patients 
on blood thinners, or who are diabetics, need additional instructions from their treating 
physicians to find the best approach in continuing or withholding some of their medications 
during bowel preparation.  
2.4.1 General patient instruction sheet  for split-dose PEG administration (with 
permission from Cleveland Clinic) 
Follow the schedule in the table below for your bowel preparation. You may need to get to 
the toilet right away. You will have many bowel movements through the day. They will 
become very watery. The bowels are clear or clean when there is only pale yellow fluid 
without flecks of stool.  
2.4.2 Key role of adequate hydration 
One of the key concepts to emphasize to patients is the need for adequate hydration during 
bowel preparation. Many patients mistakenly believe that taking 4 L of polyethylene glycol 
obviates the need for additional hydration, since they are already ingesting such a large 
volume of fluid. Given that bowel preparations induce diarrhea and, in some instances, 
nausea and decreased oral intake, all patients taking bowel preparations are at risk of 
dehydration.32 Hence, many safety issues associated with bowel preparation agents are 
related to dehydration and its complications. 
In general, patients should be advised to consume at least 64 oz (approximately 2 L) of clear 
fluid on the day before the colonoscopy. According to the American Society of 
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Anesthesiologists, clear liquids can be safely ingested up until 2 hours before receiving 
anesthesia.33 Patients should also be advised to keep drinking extra fluids after the 
procedure is completed to reduce the risk of dehydration and its complications 
3. Conclusion 
Adequate bowel preparation is essential before colonoscopy. Choosing an agent can be 
confusing, especially with so many agents available in the market today. Polyethylene 
glycol solutions are safe and effective, and are the preferred agents for cleansing the colon. 
Sodium phosphate can still be prescribed for patients who cannot tolerate polyethylene 
glycol solutions, provided they are not at risk of electrolyte or fluid imbalances. Enemas, 
bisacodyl, and metoclopramide are mainly used as adjuncts to polyethylene glycol but by 
themselves are inadequate for cleansing the entire colon. In this chapter, we have reviewed 
the advantages and disadvantages of available regimens, provided bowel preparation 
instructions for patients and emphasized the need to consider split–dose regimens as well as 
the need for adequate hydration before and after colonoscopy. 
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1. Introduction 
Many individuals are still hesitant to undergo colonoscopy despite numerous 
advertisements and campaigns about it. A few years back, a famous TV personality 
named Katie Kouric, had her colonoscopy broadcasted through live television because she 
wanted the public to see that there’s nothing scary or frightening about the procedure. 
Her husband died of colon cancer at a young age. Had he had a colonoscopy (Fig. 1), his 
cancer would have been diagnosed and treated early which could have saved or 
prolonged his life.  
 
 
Fig. 1. Colonoscopy.  
The test remains an uncomfortable, frightening, and embarrassing and anxiety producing 
situation, especially for people undergoing it for the first time, which can then lead to delays 
in screening and treatment. Though endoscopic procedures can be performed and tolerated 
without sedation, studies have shown that “16% to 56% of such procedures are terminated 
because of pain”.²² The goal of colonoscopy is to reach the cecum (the beginning of the large 
intestine). The scope is less likely to reach that destination, as it navigates the long and 
tortuous colon, without adequate sedation. Figure 2 shows the colon or large intestine and 
its location in the abdomen. 
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Many countries around the world commonly perform colonoscopy without sedation. ¹² In 
Japan, though endoscopic procedures are routinely carried out without sedation, many 
Japanese are now choosing this to ease the discomfort.³² Only 2%-7% would prefer this 





Fig. 2. The colon or large intestine 
The challenge and goal of sedation in colonoscopy is to effectively facilitate the procedure 
while relieving anxiety, pain or discomfort, providing amnesia, and preserving 
cardiopulmonary function of the individual, with minimal cognitive impairment post 
procedure. This may delay the individual’s discharge from the hospital. Sedation is now 
the standard of practice for endoscopic procedures in the U.S. and in many other 
countries. It is necessary to complete the procedure with ease and comfort.²6,¹9,²¹,²³,9,³²,³¹,³⁸ 
Currently used medications are: benzodiazepines (e.g., midazolam, diazepam), opioids 
(e.g., meperidine, sublimaze), and propofol. Ketamine and inhaled anesthetics (e.g. 
nitrous oxide) are rarely used because of their side effects and uneasiness of 
administration.²³,²² These drugs are used alone or in combination with another drug. 
Comparison studies have been done to determine which combination of drugs are better 
in minimizing cognitive impairment post procedure, but none have been found to be 
better than the other.²¹ The ideal amount of sedation for a patient undergoing colonoscopy 
has also not been established despite the many different techniques, medications and 
combinations thereof attempted.  
This chapter will discuss the different types of moderate sedation given, who will be 
administering it, and how individuals are monitored during the procedure. The goal is to 
inform the public of the different methods of making one comfortable during colonoscopy. 
Emphasis will be given to the fact that this procedure is short and safe, and usually does not 
require administration of heavy-duty anesthetics or sedatives. Monitoring is done 
frequently with particular attention to the airway, breathing (using pulse oximetry and 
capnography) and circulation i.e., heart rate and blood pressure. Knowledge of the 
availability of these medications will make the individual feel confident that he or she will 
be comfortable and cared for during his or her colonoscopy. 
 




Fig. 3. Confidence and satisfaction in colonoscopic procedures 
2. Safety and efficacy of currently used sedation drugs for colonoscopy 
Sedation is defined as the calming of mental excitement or abatement of physiologic 
functions with the administration of a drug,³¹ i.e. a drug-induced depression of the 
individual’s level of consciousness.⁴ As mentioned earlier, sedation is recommended in most 
endoscopic procedures to facilitate completion of the procedure, which in this case, would 
be colonoscopy.  
Four levels characterize sedation: minimal or light (anxiolysis) sedation, moderate sedation 
(formerly known as conscious sedation), deep sedation, and general anesthesia.² The most 
commonly used in colonoscopy is moderate sedation, where the patient continues to 
respond purposefully to verbal commands, with or without light touch stimulation. He is 
spontaneously breathing on his own and may be supported with minimal amounts of 
oxygen via a nasal cannula or sometimes a mask may be necessary. In deeply sedated states, 
patients may not be roused easily, and respond only after repeated or painful stimuli. They 
may also not have spontaneous respirations (breathing on their own) requiring assistance to 
maintain a patent airway. General anesthesia is normally reserved for surgical procedures 
wherein patients do not respond to any form of stimulation, are completely immobile and 
support of his or her cardiovascular functioning is required.⁴ Table 1 shows summary of the 
various levels of sedation and analgesia. Adapted from the American Society of 
Anesthesiologists Standards and Guidelines (2009).² 
Moderate anesthesia care (MAC) and/or moderate level of sedation (also formerly known 
as conscious sedation) is usually employed during colonoscopy. It allows for better patient 
cooperation and a quicker or shorter recovery time.²6 Individuals certified to administer the 
drugs and monitor the patient’s response(s), such as a gastroenterologist, a registered nurse, 
a certified registered nurse anesthetist, or an anesthesiologist, can safely administer this.³² 
However, there are some differences between MAC and moderate sedation. During 
moderate sedation, a physician personally administers or supervises a nurse to administer 
the sedative and/or analgesic drug. These individuals are qualified and certified to 
administer the sedation drugs maintaining the level of sedation to a “moderate” or lesser 
degree. They continually monitor and assess the effects of these drugs and level of sedation 
the patient is in throughout the duration of the procedure, are competent to recognize 
changes especially when the individual goes into a deeper level than originally intended 
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and, are able to manage the consequences and adjust additional doses of the medication to 



























































Table 1. Summary of the various levels of sedation and analgesia. Adapted from the 
American Society of Anesthesiologists, Standards and Guidelines, 2009. ² 
In moderate sedation, the provider assigned to observing and monitoring the patient as well 
as administering the sedation medications has other responsibilities and tasks that are 
interruptible and of short duration. The reverse is true for moderate anesthesia care or 
MAC, where the provider (usually an anesthesiologist or nurse anesthetist) is solely 
dedicated to the observation and monitoring of the patient and does not have any other 
procedure-related responsibilities. He must be prepared to convert to general anesthesia 
when the patient’s cardiorespiratory status is compromised. It is an essential component of 
his initial assessment to evaluate the patient’s actual or anticipated physiological problem 
that may compromise his cardiorespiratory status during the scheduled procedure. His 
ability to rescue a patient whose airway is compromised is a prerequisite to his ability to 
provide moderate anesthesia care. The administration of hypnotics, sedatives and 
analgesics, as well as other drugs commonly used for the induction and maintenance of 
general anesthesia is often, but not always, a part of monitored anesthesia care.⁴  
Since sedation is a continuum, it is impossible to predict how an individual will respond to 
the drugs. Some patients may require only small amounts of sedation, but MAC is often 
indicated because even small doses of these medications could precipitate adverse 
physiologic responses that would require acute clinical interventions and resuscitation. If a 
patient’s health status or condition, or medical/surgical history is likely to require sedation 
to a deeper level or even to a momentary period of general anesthesia, then MAC is the 
preferred method. Due to the strong possibility that a deep or deeper level of sedation may 
transition to general anesthesia, the skills and expertise of an anesthesia provider (e.g. 
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anesthesiologist or certified registered nurse anesthetist, CRNA) are essential to manage the 
effects of general anesthesia as well as the patient’s quick return to a lesser state of sedation. 
MAC also includes post-procedure responsibilities such as ensuring return to full 
consciousness, complete relief of pain, management of side effects or any adverse 
physiologic responses from the drugs administered during the procedure, as well as the 
diagnosis and treatment of some co-existing medical problems.² 
Since individuals vary in their responses to the sedation medication, and may be in different 
levels of sedation as well, while undergoing the same procedure, or may require different 
levels to complete the procedure;  it is imperative that clinicians administering the 
sedatives/analgesics and monitoring their effects have the necessary skills and knowledge 
in recognizing complications associated with sedation/analgesia, and be able to rescue or 
resuscitate the individual whose sedation status is deeper than originally intended.⁴,³⁷ They 
must have also undergone a course or class and be certified in cardiopulmonary 
resuscitation (CPR) as well as in Advanced Cardiac Life Support (ACLS).²º,¹6,³⁷,³  In patients 
with significantly sedation-related risk factors, i.e., severe obstructive pulmonary disease, 
sleep apnea, potentially difficult airway, congestive heart failure, and coronary artery 
disease, the presence of an anesthesiologist is highly recommended. It is also recommended 
for patients who may require a deeper level of sedation to achieve adequate procedure 
result, such as individuals who are on high doses of psychotropic medications, 
benzodiazepines, alcohol, and narcotics.⁴,²²,³ 
 
Class Description 
ASA I A normal healthy patient 
ASA II Patient has mild systemic disease which does not interfere with daily activities, such as high blood pressure that is under control 
ASA III 
Patient has a moderate or severe systemic disease that does not 
inhibit or limit daily activities such as diabetes with some 
systemic complications 
ASA IV 
Patient has a severe systemic disease that is a constant threat to 
life such as end-stage renal or liver failure, or congestive heart 
failure 
ASA V The patient is moribund and is not expected to survive  within 24 hours, with or without the procedure 
ASA VI The patient is declared brain-dead and his or her organs are being removed for donation purposes. 
E In addition to indicating the ASA status, a patient undergoing an emergency procedure is indicated by the suffix “E.” 
Table 2. Patient status classification according to the American Society of Anesthesiologists 
(ASA) 
Many studies have been performed regarding administration of these drugs during 
colonoscopy and were found to provide safe and effective sedation during the procedure, 
especially when titrated in small incremental doses. Though safe and effective, these drugs 
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and, are able to manage the consequences and adjust additional doses of the medication to 
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do carry potential problems or concerns that include cardiopulmonary events, such as 
hypotension, airway obstruction, hypoxia/hypoxemia, aspiration, apnea, arrhythmia, 
vasovagal episodes, and though uncommon, serious morbidity and death can also 
occur.²⁴,¹⁵,¹6 A review of data from the American Society for Gastrointestinal Endoscopy’s 
(ASGE) computer-based management system of 21,000 GI endoscopies in 1988 using Versed 
(Midazolam) and Valium (Diazepam) revealed the following: Overall complication rate was 
13.5 events per 1000 procedures and serious cardiopulmonary events were 5.4 per 1000. 
Death occurred in 0.3 per 1000.⁵ Another study evaluating the safety of the combination of 
meperidine (Demerol) with either midazolam (Versed) or diazepam (Valium) revealed no 
deaths.6 Results from two other studies showed a considerably lower incidence of 
cardiopulmonary complications using propofol as compared with the use of 
benzodiazepines during routine endoscopic procedure.³⁸,²⁵,²⁸  Because of these potential 
complications, endoscopy suites are equipped with the tools necessary to rescue the patient. 
These include: a suction machine, oxygen outlet or tank, a code cart with a defibrillator, a 
bag-valve mask, oral and nasal airways, a nasogastric tube, materials for respiratory 
intubation, and drugs required for cardiorespiratory resuscitation.²º 
3. Economics of sedation in endoscopy 
In the past, gastroenterologists have routinely administered the sedating agents to their 
patients as part of the colonoscopy service. However, in recent years, many endoscopists are 
employing the services of an anesthesiologist or a certified registered nurse anesthetist 
(CRNA) to administer the sedation. The influencing factors being, the increased use of 
propofol during this procedure, effective marketing by anesthesiologists, and by a decrease 
in reimbursements by insurers.⁴,³⁵  
The approach of individual countries towards administration of sedatives and analgesics 
during colonoscopy varies widely due to differences in health insurance reimbursements 
and budget restraints.⁴¹,²²  In the United States, Medicare reimbursements for use of an 
anesthesiologist during colonoscopy are not uniform across the nation. Some health insurers 
also question the separate billing of anesthesia service when generally; reimbursement fee 
for the colonoscopy includes administration of sedation under the supervision of the 
gastroenterologist.¹ 
Ideally, an anesthesiologist is present in all cases of colonoscopy to optimize sedation and 
analgesia. However, his presence during this short procedure for individuals who are at 
average-risk for developing sedation-related complications is debatable and not cost-
effective.¹ Normally, these patients are able to maintain their airway with minimal or no 
support so that the skills of an anesthesiologist is not necessary. Many studies have been 
done exploring the use of a registered nurse administering propofol and have found safety 
levels equivalent to those administered with benzodiazepines and narcotics.³²,³³,³º,³6 
4. Colonoscopy without sedation 
In some instances, few selected patients opt to undergo their colonoscopy without sedation. 
In the US, a survey found that only 2% to 7% of individuals were willing to do their 
colonoscopies without sedation.²9 Review of literature found no randomized control trials 
done to compare sedation versus no sedation during colonoscopy. Many argue that they 
want to watch the procedure and are fascinated by what’s inside the human body. Some are 
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unable to find an available designated driver and are unwilling to reschedule their 
appointment. Still some have stated that they have a lot of commitments and things to do 
that they cannot afford to skip a day to rest at home. In some rare instances, the individual 
went straight to work after his procedure. The type and level of monitoring should be 
tailored to each individual in these cases. Often, the individual is advised to bring a 
designated driver, in case he changes his mind and decides to receive sedation. Men, 
patients who are generally healthy and have no history of abdominal pain, individuals who 
are not anxious, and older patients may be better able to tolerate the colonoscopy without 
sedation. In situations like this, a smaller diameter endoscope (pediatric scope) is used and 
is better tolerated.  
5. Preprocedure assessment and monitoring 
A few weeks prior to the scheduled colonoscopy, the patient usually pays his endoscopist a 
visit to review his general state of health, medical and surgical histories, allergies, and 
regularly taken medications. Special instructions will be given to diabetics with regards to 
intake of their medications as well as diet. The appropriate bowel cleansing prep will be 
reviewed and instructions provided. The patient will also be informed that he will be 
receiving sedating medications to make the procedure more comfortable and tolerable. He is 
then advised to arrange for someone to drive him home because he will not be allowed to 
drive home, take the bus or taxi after the procedure due to the residual effects of the 
sedative; emphasizing the fact that these side effects do alter his reflexes and cognitive 
functioning. This usually wears off in about four to six hours; and, even after this time, the 
individual may still feel very tired and sleepy. Patients are discharged home and advised to 
take the day off and rest. They are normally allowed to eat light, non-spicy, and easily 
digestible foods to avoid nausea and vomiting which is often a side effect of sedatives and 
opioids. 
The use of combination regimen as well as patient characteristics influence the safety and 
choice of sedative regimens for this procedure. Therefore, general data is collected from 
every patient, recorded in his medical record and reviewed by both the endoscopist and the 
personnel providing the sedating medication (s), shortly before the colonoscopy is 
performed. These include: name, age (determined by date-of-birth), sex, general condition of 
health (as outlined in the ASA classification, Table 2), daily medications taken, allergies, 
medical and surgical histories, adverse reactions to sedatives and anesthetics, and problems 
(if any) post procedure or surgery. The following historical events should also be obtained 
from the patient: any significant abnormalities of major organ or organ systems, snoring or 
sleep apnea (using CPAP or BiPap), time and type of last meal taken, use of illicit drugs, and 
alcohol and tobacco use. Regarding the “time and type of last meal taken,” there are no 
absolute or ultimate guidelines regarding the stopping of oral intake prior to administration 
of sedatives. There are no supporting data showing a direct relationship between fasting 
time and risk of aspiration into the lungs. The ASA guidelines recommend that patients not 
have clear liquids two hours before the procedure and a light meal six hours before 
administration of any sedating medication. This would allow sufficient time for the stomach 
to adequately empty.⁴ According to the American College of Emergency Physicians, “recent 
food intake is not contraindicated for administering procedural sedation and analgesia, but 
should be considered in choosing the timing and target of sedation”.⁸ 
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do carry potential problems or concerns that include cardiopulmonary events, such as 
hypotension, airway obstruction, hypoxia/hypoxemia, aspiration, apnea, arrhythmia, 
vasovagal episodes, and though uncommon, serious morbidity and death can also 
occur.²⁴,¹⁵,¹6 A review of data from the American Society for Gastrointestinal Endoscopy’s 
(ASGE) computer-based management system of 21,000 GI endoscopies in 1988 using Versed 
(Midazolam) and Valium (Diazepam) revealed the following: Overall complication rate was 
13.5 events per 1000 procedures and serious cardiopulmonary events were 5.4 per 1000. 
Death occurred in 0.3 per 1000.⁵ Another study evaluating the safety of the combination of 
meperidine (Demerol) with either midazolam (Versed) or diazepam (Valium) revealed no 
deaths.6 Results from two other studies showed a considerably lower incidence of 
cardiopulmonary complications using propofol as compared with the use of 
benzodiazepines during routine endoscopic procedure.³⁸,²⁵,²⁸  Because of these potential 
complications, endoscopy suites are equipped with the tools necessary to rescue the patient. 
These include: a suction machine, oxygen outlet or tank, a code cart with a defibrillator, a 
bag-valve mask, oral and nasal airways, a nasogastric tube, materials for respiratory 
intubation, and drugs required for cardiorespiratory resuscitation.²º 
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employing the services of an anesthesiologist or a certified registered nurse anesthetist 
(CRNA) to administer the sedation. The influencing factors being, the increased use of 
propofol during this procedure, effective marketing by anesthesiologists, and by a decrease 
in reimbursements by insurers.⁴,³⁵  
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gastroenterologist.¹ 
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support so that the skills of an anesthesiologist is not necessary. Many studies have been 
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levels equivalent to those administered with benzodiazepines and narcotics.³²,³³,³º,³6 
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In the US, a survey found that only 2% to 7% of individuals were willing to do their 
colonoscopies without sedation.²9 Review of literature found no randomized control trials 
done to compare sedation versus no sedation during colonoscopy. Many argue that they 
want to watch the procedure and are fascinated by what’s inside the human body. Some are 
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unable to find an available designated driver and are unwilling to reschedule their 
appointment. Still some have stated that they have a lot of commitments and things to do 
that they cannot afford to skip a day to rest at home. In some rare instances, the individual 
went straight to work after his procedure. The type and level of monitoring should be 
tailored to each individual in these cases. Often, the individual is advised to bring a 
designated driver, in case he changes his mind and decides to receive sedation. Men, 
patients who are generally healthy and have no history of abdominal pain, individuals who 
are not anxious, and older patients may be better able to tolerate the colonoscopy without 
sedation. In situations like this, a smaller diameter endoscope (pediatric scope) is used and 
is better tolerated.  
5. Preprocedure assessment and monitoring 
A few weeks prior to the scheduled colonoscopy, the patient usually pays his endoscopist a 
visit to review his general state of health, medical and surgical histories, allergies, and 
regularly taken medications. Special instructions will be given to diabetics with regards to 
intake of their medications as well as diet. The appropriate bowel cleansing prep will be 
reviewed and instructions provided. The patient will also be informed that he will be 
receiving sedating medications to make the procedure more comfortable and tolerable. He is 
then advised to arrange for someone to drive him home because he will not be allowed to 
drive home, take the bus or taxi after the procedure due to the residual effects of the 
sedative; emphasizing the fact that these side effects do alter his reflexes and cognitive 
functioning. This usually wears off in about four to six hours; and, even after this time, the 
individual may still feel very tired and sleepy. Patients are discharged home and advised to 
take the day off and rest. They are normally allowed to eat light, non-spicy, and easily 
digestible foods to avoid nausea and vomiting which is often a side effect of sedatives and 
opioids. 
The use of combination regimen as well as patient characteristics influence the safety and 
choice of sedative regimens for this procedure. Therefore, general data is collected from 
every patient, recorded in his medical record and reviewed by both the endoscopist and the 
personnel providing the sedating medication (s), shortly before the colonoscopy is 
performed. These include: name, age (determined by date-of-birth), sex, general condition of 
health (as outlined in the ASA classification, Table 2), daily medications taken, allergies, 
medical and surgical histories, adverse reactions to sedatives and anesthetics, and problems 
(if any) post procedure or surgery. The following historical events should also be obtained 
from the patient: any significant abnormalities of major organ or organ systems, snoring or 
sleep apnea (using CPAP or BiPap), time and type of last meal taken, use of illicit drugs, and 
alcohol and tobacco use. Regarding the “time and type of last meal taken,” there are no 
absolute or ultimate guidelines regarding the stopping of oral intake prior to administration 
of sedatives. There are no supporting data showing a direct relationship between fasting 
time and risk of aspiration into the lungs. The ASA guidelines recommend that patients not 
have clear liquids two hours before the procedure and a light meal six hours before 
administration of any sedating medication. This would allow sufficient time for the stomach 
to adequately empty.⁴ According to the American College of Emergency Physicians, “recent 
food intake is not contraindicated for administering procedural sedation and analgesia, but 
should be considered in choosing the timing and target of sedation”.⁸ 
 
Endoscopic Procedures in Colon and Rectum 
 
66
Physical examination of the individual is obtained and recorded. These include, initial vital 
signs (temperature, heart rate, blood pressure, respiratory rate, and oxygen saturation), level 
of consciousness, examination of heart and lungs, and airway anatomy (using the 
Mallampati classification, Figure 4). The last one is important in situations where the 
individual may need resuscitative assistance such as: 1) individuals with a history of 
snoring, stridor, or sleep apnea and is using a CPAP or BiPAP machine, 2) neck 
abnormalities involving the neck and facial features (e.g. obese persons),  short neck, limited 
neck extension, neck mass, cervical spine disease or trauma to the neck, tracheal deviation, 
advanced rheumatoid arthritis, decreased hyoid-mental distance (<3cm in adults), 3) 
abnormalities of the mouth such as protruding incisors, small opening ( <3cm n adults), 
high arched palate, hypertrophy of the tonsils, nonvisible uvula (see class 4 of the 
Mallampati classification, Figure 4), edentulous, loose or capped teeth, macroglossia, 4) 
history of problems with sedation and anesthetics, 5) dysmorphic facial features such as 
trisomy and Pierre-Robin syndrome, and 6) jaw abnormalities such as trismus, significant 
malocclusion, micrognathia, and retrognathia. The ASA Task Force guideline states “that 
the presence of one or more sedation-related risk factors coupled with the potential for deep 
sedation will increase the likelihood of adverse sedation-related events.” Consultation with 
someone trained in managing these complex situations, usually an anesthesiologist or a 
certified registered nurse anesthetist should be considered.⁴ The presence of an 
anesthesiologist is also highly recommended for the following situations: 
 Significantly compromised individuals such as those with congestive heart failure, 
coronary artery disease, and severe obstructive pulmonary disease (COPD) on 
continuous oxygen therapy or using CPAP or BiPAP machines 
 Individuals with difficult airways (such as those described above) 
 Extremely obese individuals 
 ASA status classification of Class III, IV, and V 
 Increased risk of pulmonary aspiration 
 The individual is pregnant 
 If it appears that sedation (even with small doses) will make the patient unresponsive 
and airway will be compromised 
 General anesthesia is necessary to complete the procedure while maintaining patient 
safety and comfort 
 Unavailability of a trained practitioner to administer moderate sedation 
 Anticipated intolerance of standard sedation drugs (e.g. alcohol or substance abuse) 
 Adverse reactions to sedatives 
 Inadequate response to moderate sedation 
A Modified Aldrete score is also assigned (see post procedure monitoring). An 
intravenous access is established because sedation drugs are normally given 
intravenously. Fluids may or may not be routinely given depending on the institution’s 
procedural policies and regulations. For female patients, it is necessary to mention the 
possibility of being pregnant or is pregnant. If in doubt, a pregnancy test may be 
performed. Lactating mothers should also mention if they are breastfeeding as most of the 
medication is excreted in breast milk.  
Shortly before the procedure starts, the provider of the sedating medications will discuss 
with the patient the type of sedating medications to be given; its benefits, risks and 
complications, limitations and other alternatives. The endoscopist will also review the 
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procedure with the patient. He will then sign the consent form allowing the endoscopist to 
perform the procedure and to be given sedating medications (if agreeing to sedation). The 
anticipated level of sedation should be congruent with the expected level of sedation by the 
individual as much as possible. The endoscopist will also review the colonoscopy 
procedure, the benefits, risks and complications to patients who are not receiving sedation. 
Preparation is the same as for sedation in the event that an emergency arises or the patient 
requests medication during the procedure. 
 
 
Fig. 4. Mallampati classification of airway management. 
6. Sedation and monitoring during colonoscopy 
According to the recommendations outlined by The Joint Commission and the Association 
of Anesthesiologists, hospital-based endoscopy suites consists of the following personnel: a 
physician endoscopist, an assisting nurse, and an additional nurse solely administering 
sedatives and monitoring the patient.¹⁴ However, with the advent and increased use of 
propofol, there has been a demand for the presence of an anesthesiologist or certified 
registered nurse anesthesiologist. This is partly due to the widespread perception that the 
drug carries major complication risks and statements emphasized by the information on the 
package insert of the drug itself, recommending that only personnel trained in the 
administration of general anesthesia administer this drug. The ASA guidelines also outlined 
numerous precautions regarding the administration of propofol thereby, increasing fears of 
non-anesthetists. It is also the perception that administration of benzodiazepines and opiates 
only induce moderate level of sedation and that propofol brings the patient into a deep level 
sedation.²º Several studies though have proved that propofol can be safely administered by 
non-anesthesiologists.¹¹,³²,¹⁵,²9 
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Only 7.7% of gastroenterologists in the US administer propofol themselves without the 
assistance or presence of an anesthesiologist or nurse anesthetist (CRNA), and 68% have 
expressed interest in incorporating it in their practice given proper training and adequately 
trained staff.9 The reason for the reluctancy among endoscopists to administer propofol 
themselves, are medico legal implications of the off-label use of propofol, the potential risks 
and complications, local institutional policy, and state regulatory restrictions.⁴ Hence, 
propofol is usually administered by an anesthesiologist (or by a certified registered nurse 
anesthetist [CRNA]) which is often not cost-effective in ambulatory gastrointestinal (GI) 
suites .¹² In some countries, like Switzerland, 34% of gastroenterologists polled administer 
propofol themselves.¹⁵  
During the procedure, the patient is hooked up to a monitor that measures and displays the 
heart rate, blood pressure, and oxygen saturation (Figure 5) and in some cases, carbon 
dioxide levels (capnography). Some have also used transcutaneous carbon dioxide 
measurement or bispectral index monitoring (BIS). The latter is a quantitative assessment of 
cortical activity that has been used to monitor sedation and adjust sedation levels (Kissin, I., 
2000). These are monitored by a licensed personnel (usually the person providing the 
sedation) every 3-5minutes during the procedure and with each incremental dose of the 
sedative. Monitoring may detect changes in the individual’s blood pressure, heart rate, 
cardiac electrical activity, ventilatory, and neurologic status that might signal a clinically 
significant compromise of the patient’s health status or that the patient has progressed to a 
deeper level of sedation than originally intended. Oxygen is usually given as an adjunct via 
a nasal cannula or mask as all of the sedation agents depress the respiratory system. The 
ASA guidelines recommend that patients receiving sedation medications receive continuous 
electrocardiogram (ECG) monitoring, especially if they have significant cardiovascular 
disease or arrhythmias.²º Parameters outlined in the Modified Aldrete scoring system, 
which includes the above mentioned items plus activity and consciousness are also 
monitored and recorded. 
 
 
Fig. 5. Sample of monitoring equipment used 
In most institutions, an intravenous access is started and IV fluids are given prior and 
during the procedure. This helps hydrate the patient, provide an avenue for the 
administration of sedating drugs, and as a rescue means should the patient become 
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hypotensive (ASGE, 2008). Should the patient’s condition get compromised or deteriorate at 
any given time during the procedure, the colonoscopy is halted and resuscitative measures 
are instituted. He may need to be transferred to the Critical Care Unit or the Emergency 
Department for further management. 
6.1 Post procedure monitoring 
Upon completion of the colonoscopy, the patient is kept in the room and monitored for a 
few more minutes until he is rousable and able to maintain his airway independently. 
Shortly thereafter, he is disconnected from all the monitoring equipment and brought to the 
recovery or discharge area to allow the effects of the sedatives to wear off. Here, the same 
parameters monitored during the procedure are monitored and recorded every 10-15 
minutes for about half-an-hour to an hour, without the continuous cardiac monitoring 
(ECG) (unless warranted) and the carbon dioxide monitoring, until the patient is at or close 
to his or her baseline cognitive functioning level as possible, and is ready for discharge to 
home. Blood sugar levels of diabetics will also be checked and intervention given as 
necessary. 
At this time, the endoscopist will come to discuss his findings during the procedure, any 
interventions done (i.e. biopsies taken), and discharge and follow-up instructions will be 
given. The patient’s designated driver is encouraged to be present because he (the patient) 
may not remember what the endoscopist has said as a result of the amnesic properties of the 
sedatives, especially with benzodiazepines (not so with propofol), unless the patient 
requests otherwise. The patient is discharged when he or she has met discharge criteria as 
outlined by the Modified Aldrete or Aldrete and Kroulik scoring system (Tables 3 and 3.a) 
or whichever discharge scoring system the institution is using and has returned to his 
baseline (or close to it) level of cognitive and physiological functioning as possible.  
Ideally, the recovery or discharge area should allow rapid recovery of the sedated 
individual, with minimal or without residual physiologic, cognitive or psychomotor 
impairments. Several discharge criteria have been formulated to facilitate and guide 
clinicians to objectively asses the clinical status of the sedated patient and be able to 
discharge him home. The most commonly used is the Modified Aldrete or Aldrete and 
Kroulik scoring systems (Table 3 and 3.a).³9 The preferred method is the Modified Aldrete 
scoring system as most institutions do not use arterial pressure monitoring for endoscopy 
procedures, especially in an outpatient setting. This scoring is also used pre-, inta and post 
procedure. During the procedure, if the patient is maintained at the moderate sedation level, 
his score should be a 9 or a 10 or whatever his baseline score was at the start. Over sedation 
is defined by a score of less than 9 and corrective action should be initiated. All post 
sedation patients should have their vital signs back to within 10% of their baseline score or 
be admitted to the hospital for further evaluation especially if corrective/resuscitative 
actions have failed to improve his score or condition.  
Post anesthesia discharge scoring system (PADSS) has been developed for post-anesthesia 
care units in Canada. This allows the health care providers to monitor the patient’s 
readiness to be discharged home. The average length of time the sedated patient stays in the 
discharge or recovery area is half-an-hour to an-hour depending on the kind and amount of 
sedation drugs received during the procedure. Patients who receive propofol generally 
recover quicker and are discharged home in a much shorter time than those who receive 
benzodiazepines or in combination thereof.²º Prompt and safe discharge of the patients 
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actions have failed to improve his score or condition.  
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sedation drugs received during the procedure. Patients who receive propofol generally 
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reduces the amount of time they stay in the discharge area and contributes to cost reduction 
and unit efficiency.⁷ 
 
Modified Aldrete Scoring 
Criteria Ability Score 
Activity 









Able to cough and breathe deeply freely 






Blood pressure within 20mm Hg of  pre-sedation level 
Blood pressure within 20-50mm Hg of pre-sedation level 












Able to maintain O2 saturation >92% on room air 
Needs O2 to maintain O2 saturation >90% 




Table 3. Modified Aldrete Scoring System 
 
Assessment Item                 Condition                                                        Grade 
                                               Moves 4 extremities                                               2 
Muscle Activity                     Moves 2 extremities                                               1 
                                               Moves 0 extremities                                               0 
                                                   Deep, Cough                                                           2 
Breathing                              Limited, Dyspnea                                                   1 
                                                  Apnea                                                                       0 
                                                Fully awake                                                             2 
Consciousness                     Awakens when called                                             1 
                                             Does not respond to call                                         0 
                                             + of 20% of pre-anesthesia level                             2 
Circulation (AP)*                 + 20% to 49% of pre-anesthesia 
                                                level                                                                         1 
                                             + 50% of pre-anesthesia level                                 0 
                                             Maintains SpO2 >92% in ambient air                     2 
SpO2**                                  Maintains SpO2 > 90% with O2                             1 
                                             Maintains SpO2 <90% with O2                               0 
*AP = arterial pressure  
** = peripheral oxygen saturation 
Table 3a. Aldrete and Kroulik Index 
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7. Commonly used sedation agents 
Colonoscopy procedures are usually done under moderate level of sedation or moderate 
anesthesia care (MAC). To achieve this, general practice guidelines call for the careful 
titration of the chosen sedative using incremental doses. The most commonly used agents 
are benzodiazepines, alone or in combination with an analgesic, and propofol, alone or also 
in combination with another agent.²¹,²6,²²  The choice of sedating agent is largely dependent 
on the provider based on what he thinks and feels is the best in maximizing patient comfort 
at the same time, minimizing risks and complications. A US survey noted that over 85% of 
endoscopists use or prefer to use midazolam over diazepam. Only 10% have indicated 
preference for using diazepam.9  
7.1 Benzodiazepines 
The two most commonly used benzodiazepines are midazolam (Versed) and diazepam 
(Valium). Midazolam (Versed) is also classified as an anesthetic adjunct and as a short or 
intermediate acting hypnotic. It depresses subcortical levels in the Central Nervous System, 
may potentiate -aminobutyric acid (GABA), and may act on the limbic system and reticular 
formation. It is used for preoperative sedation, anxiety, intubation procedures, induction of 
general anesthesia, and for diagnostic endoscopic procedures. It can also be used for 
refractory status epilepticus. For moderate sedation or conscious  
sedation during endoscopic procedures such as colonoscopy, midazolam can be used alone 
or in combination with a narcotic (e.g. an analgesic like meperidine or fentanyl). It is 
administered immediately prior to the procedure and supplemented by small incremental 
doses throughout until the desired effect is achieved to complete the procedure.²¹ 
Usual dosing for a healthy adult below 60 years of age range from 1mg to 2.5mg titrated 
slowly (within 2 minutes). Allow a 2-3 minute interval or more before administering any 
additional doses, and after each incremental dose to fully evaluate the desired sedative 
effect. A total dose greater than 5mg is usually not necessary and patients given an 
additional narcotic may only require 30% less of this drug, because of the cumulative CNS 
depressant effect (Product Info midazolam hcl injection, 2005). Patients 60 years and older, 
chronically ill, debilitated or with renal or hepatic insufficiency will require less, 1mg to 
1.5mg titrated slowly intravenously (maximum infusion rate is 0.75mg/min). Again, allow 2 
or more minutes before each additional dose to evaluate the desired sedative effect. A total 
dose of greater than 3.5mg is not necessary and individuals will normally require 50% less 
than what a normal healthy adult would receive especially if a narcotic were also added. An 
elderly patient should not receive a dose of more than 1.5mg. The peak effect of the drug 
may take longer and the danger of apnea or hypoventilation is greater. Metabolites of 
midazolam can accumulate in patients with renal and hepatic failure and may prolong the 
sedative effect. Administration of midazolam is contraindicated in patients with 
hypersensitivity to any component of the drug, hypersensitivity to midazolam, acute 
narrow-angle glaucoma, untreated open-angle glaucoma, pregnancy, and status 
asthmaticus.³²  
Midazolam is 97% protein bound; has a half-life of 1.8-6.4 hours; metabolized in the liver; 
excreted in the urine; and crosses the placenta and blood-brain barriers. Given 
intravenously, it has an onset of 1-5min, for a duration of 1-3 hours. Side effects of the drug 
include: headache, anxiety, insomnia, retrograde amnesia, euphoria, confusion, agitation, 
paresthesia, slurred speech, agitation, chills, arrhythmias, nausea, vomiting, hiccups, 
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reduces the amount of time they stay in the discharge area and contributes to cost reduction 
and unit efficiency.⁷ 
 
Modified Aldrete Scoring 
Criteria Ability Score 
Activity 









Able to cough and breathe deeply freely 






Blood pressure within 20mm Hg of  pre-sedation level 
Blood pressure within 20-50mm Hg of pre-sedation level 












Able to maintain O2 saturation >92% on room air 
Needs O2 to maintain O2 saturation >90% 




Table 3. Modified Aldrete Scoring System 
 
Assessment Item                 Condition                                                        Grade 
                                               Moves 4 extremities                                               2 
Muscle Activity                     Moves 2 extremities                                               1 
                                               Moves 0 extremities                                               0 
                                                   Deep, Cough                                                           2 
Breathing                              Limited, Dyspnea                                                   1 
                                                  Apnea                                                                       0 
                                                Fully awake                                                             2 
Consciousness                     Awakens when called                                             1 
                                             Does not respond to call                                         0 
                                             + of 20% of pre-anesthesia level                             2 
Circulation (AP)*                 + 20% to 49% of pre-anesthesia 
                                                level                                                                         1 
                                             + 50% of pre-anesthesia level                                 0 
                                             Maintains SpO2 >92% in ambient air                     2 
SpO2**                                  Maintains SpO2 > 90% with O2                             1 
                                             Maintains SpO2 <90% with O2                               0 
*AP = arterial pressure  
** = peripheral oxygen saturation 
Table 3a. Aldrete and Kroulik Index 
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7. Commonly used sedation agents 
Colonoscopy procedures are usually done under moderate level of sedation or moderate 
anesthesia care (MAC). To achieve this, general practice guidelines call for the careful 
titration of the chosen sedative using incremental doses. The most commonly used agents 
are benzodiazepines, alone or in combination with an analgesic, and propofol, alone or also 
in combination with another agent.²¹,²6,²²  The choice of sedating agent is largely dependent 
on the provider based on what he thinks and feels is the best in maximizing patient comfort 
at the same time, minimizing risks and complications. A US survey noted that over 85% of 
endoscopists use or prefer to use midazolam over diazepam. Only 10% have indicated 
preference for using diazepam.9  
7.1 Benzodiazepines 
The two most commonly used benzodiazepines are midazolam (Versed) and diazepam 
(Valium). Midazolam (Versed) is also classified as an anesthetic adjunct and as a short or 
intermediate acting hypnotic. It depresses subcortical levels in the Central Nervous System, 
may potentiate -aminobutyric acid (GABA), and may act on the limbic system and reticular 
formation. It is used for preoperative sedation, anxiety, intubation procedures, induction of 
general anesthesia, and for diagnostic endoscopic procedures. It can also be used for 
refractory status epilepticus. For moderate sedation or conscious  
sedation during endoscopic procedures such as colonoscopy, midazolam can be used alone 
or in combination with a narcotic (e.g. an analgesic like meperidine or fentanyl). It is 
administered immediately prior to the procedure and supplemented by small incremental 
doses throughout until the desired effect is achieved to complete the procedure.²¹ 
Usual dosing for a healthy adult below 60 years of age range from 1mg to 2.5mg titrated 
slowly (within 2 minutes). Allow a 2-3 minute interval or more before administering any 
additional doses, and after each incremental dose to fully evaluate the desired sedative 
effect. A total dose greater than 5mg is usually not necessary and patients given an 
additional narcotic may only require 30% less of this drug, because of the cumulative CNS 
depressant effect (Product Info midazolam hcl injection, 2005). Patients 60 years and older, 
chronically ill, debilitated or with renal or hepatic insufficiency will require less, 1mg to 
1.5mg titrated slowly intravenously (maximum infusion rate is 0.75mg/min). Again, allow 2 
or more minutes before each additional dose to evaluate the desired sedative effect. A total 
dose of greater than 3.5mg is not necessary and individuals will normally require 50% less 
than what a normal healthy adult would receive especially if a narcotic were also added. An 
elderly patient should not receive a dose of more than 1.5mg. The peak effect of the drug 
may take longer and the danger of apnea or hypoventilation is greater. Metabolites of 
midazolam can accumulate in patients with renal and hepatic failure and may prolong the 
sedative effect. Administration of midazolam is contraindicated in patients with 
hypersensitivity to any component of the drug, hypersensitivity to midazolam, acute 
narrow-angle glaucoma, untreated open-angle glaucoma, pregnancy, and status 
asthmaticus.³²  
Midazolam is 97% protein bound; has a half-life of 1.8-6.4 hours; metabolized in the liver; 
excreted in the urine; and crosses the placenta and blood-brain barriers. Given 
intravenously, it has an onset of 1-5min, for a duration of 1-3 hours. Side effects of the drug 
include: headache, anxiety, insomnia, retrograde amnesia, euphoria, confusion, agitation, 
paresthesia, slurred speech, agitation, chills, arrhythmias, nausea, vomiting, hiccups, 
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increased salivation, urticaria, swelling and/or itchiness at injection site, and coughing. 
Serious adverse effects of the drug include: apnea, cardio-respiratory arrest (occurs usually 
in combination with a narcotic), oxygen desaturation, hypotension, respiratory depression, 
respiratory obstruction, bronchospasm and laryngospasm. Unopened vials are stored at 
room temperature (between 68-77 degrees Fahrenheit or 20-25 degrees Celsius) and are 
stable up to 36 days. Protect from light.³² Over sedation can be reversed with the 
administration of 0.2 mg IV flumazenil (Romazicon, Anexate). 
Diazepam (Valium) works similarly as midazolam. It is a member of the following classes: 
antianxiety, anticonvulsant, benzodiazepine, and long-acting skeletal muscle relaxant. It 
potentiates the actions of -aminobutyric acid (GABA), especially in the limbic system and 
reticular formation; enhances presympathetic inhibition, and inhibits spinal polysynaptic 
afferent paths. It is used for anxiety, acute alcohol withdrawal, as an adjunct in seizure 
disorders; as a relaxant both preoperatively and general skeletal muscle relaxation (adjunct 
for skeletal muscle spasm). Given rectally, it is used in acute repetitive (refractory) seizures. 
Other uses of diazepam are: for agitation, benzodiazepine withdrawal, chloroquine 
overdose, insomnia, and as seizure prophylaxis.³²  For sedation during endoscopic 
procedures, a dose of 10 mg or less is given intravenously prior to the procedure for a 
maximum dose of 20 mg. Patients 60 years and older, chronically ill, debilitated or with 
hepatic insufficiency will require less. There are no specific dose adjustments in patients 
with renal insufficiency. Due to the irritating nature of the drug, administration must be 
done slowly, no faster than 5mg/min., and if given through IV infusion tubing, give as 
close to the IV insertion site as possible. Do not inject into small veins (irritating and may 
cause phlebitis) or through intravenous sets made of polyvinyl chloride (PVC). Diazepam 
binds to polyvinyl chloride.³² 
Contraindications to its administration are severe hepatic insufficiency, hypersensitivity to 
diazepam, myasthenia gravis, acute narrow-angle glaucoma, severe respiratory 
insufficiency, sleep apnea, and children less than 6 months of age. Diazepam is 99% protein 
bound (and significantly greater in males than in females), metabolized extensively in the 
liver and excreted in the urine. It is excreted in breast milk, crosses the placenta and blood-
brain barriers. It has a half-life of 30-60 hours. Given intravenously, it has an immediate 
effect and has a duration of about 15 minutes to an hour. Side effects are similar to 
midazolam and include: dizziness, drowsiness, confusion, headache, anxiety, tremors, 
stimulation, fatigue, depression, insomnia, hallucinations, ataxia, hypotension, ECG changes 
and tachycardia. Some, especially for prolonged users, experience blurred vision, tinnitus, 
mydriasis, nystagmus, constipation, dry mouth, nausea, vomiting, diarrhea, anorexia, 
neutropenia, rash, dermatitis, and itching. Injectable diazepam can be stored at room 
temperature and has been found to maintain stability up to 5 months; otherwise, store at 
temperatures 25 degree Celsius (77̊ F) or lower to prevent deterioration. 
Both diazepam and midazolam are similar in producing effective sedation prior to short 
surgical as well as endoscopic procedures. However, midazolam produced a greater degree 
of amnesia, lesser pain on injection, and lesser phlebitis at injection site than diazepam. It 
also produced a greater respiratory depression than diazepam during the first 45minutes of 
administration, though the latter sustained the effects longer than midazolam after an hour 
of administration. Midazolam was also more acceptable to patients than those given 
diazepam. Hence, midazolam is now the agent of choice when amnesia and adequate 
sedation is required. One disadvantage, though, noted with the administration of 
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benzodiazepines is that since they are fat-soluble (particularly diazepam), repeated dose 
results in accumulation of the drug in the adipose tissues which is subsequently released 
into the bloodstream resulting in prolonged effects. Hence, the most common reasons for 
missing work were feeling weak and drowsy or having abdominal cramping and bloating.²²  
Over sedation can be reversed with the administration of 0.2mg IV flumazenil (Romazicon, 
Anexate). 
7.2 Opiates 
The sedative and amnesic effects of benzodiazepines often times do not provide adequate 
comfort for patients undergoing endoscopic procedures, especially if the procedure lasts 
longer than half-an-hour. For this reason, opiates are often added to achieve optimum 
sedation and analgesia. Very few studies have been done to evaluate the efficacy of adding 
an opiate prior to colonoscopy and authors have casted doubt on its benefit.⁸,¹º,¹⁷ The two 
commonly used opiates are meperidine (Demerol) and fentanyl.  
Meperidine (Demerol) is an analgesic, anesthetic adjunct, and is an opioid. It is indicated as 
an anesthetic adjunct, for obstetrical pain, and as premedication for a procedure. It 
depresses pain impulses at the spinal cord level by interacting with opioid receptors. For 
endoscopic procedures, meperidine is dosed as follows: initial bolus of 25mg (given slowly) 
and subsequent incremental doses of 25mg every 2-3 minutes until the desired effect is 
achieved. Colonoscopy is usually started two to three minutes after the initial bolus of 
meperidine and midazolam and titration delivery was given every three minutes thereafter 
with meperidine 25mg and midazolam 1mg until the desired sedation effect was achieved, 
i.e. ptosis, slurred speech, and sleep. See Table 2 for dosing guidelines. 
Meperidine is readily absorbed and crosses the blood-brain and placental barriers. It is 65-
80% protein bound, metabolized in the liver and excreted in the kidneys. It has an 
elimination half-life of 3.2-3.7 hours. It is contraindicated in individuals with 
hypersensitivity to meperidine and those who are taking MAOI (monoamine oxidase 
inhibitor) drugs. Use with caution in individuals with low blood volume, receiving 
concomitant CNS depressants (reduce dosage), head injury, impaired respiratory function, 
acute abdominal conditions, Addison’s disease (reduce dosage), elderly, debilitated, 
hypothyroidism, prostatic hypertrophy and urethral strictures, seizures (may induce more), 
severe hepatic and renal impairment, cardiac dysrhythmias such as SVTs and A-flutter. Side 
effects include: CNS: drowsiness, dizziness, confusion, headache, sedation, euphoria, 
increased intracranial pressure, seizures and serotonin syndrome; CV: palpitations, 
bradycardia, hypotension and orthostatic hypotension, tachycardia; EENT: tinnitus, blurred 
vision, miosis, diplopia, depressed corneal reflex; GI: nausea, vomiting, anorexia, 
constipation, cramps, biliary spasm, and paralytic ileus; GU: urinary retention, dysuria; 
Integ: rash, urticarial, bruising, flushing, diaphoresis, xerostomia and pruritus. Adverse 
effects include respiratory depression, cardiac arrest and anaphylaxis. Use judiciously when 
used in conjunction with benzodiazepines because of its added CNS and respiratory 
depressant effects.³² 
The other opioid of choice is fentanyl which shares the same classification as meperidine: 
analgesic, anesthetic adjunct, and opioid. It acts by inhibiting the ascending pain pathways 
in the CNS (central nervous system), increases pain threshold, and alters pain perception by 
binding to opioid receptors. It is used to control moderate to severe pain, as an adjunct to 
general and regional anesthesia, and premedication for procedures requiring conscious 
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increased salivation, urticaria, swelling and/or itchiness at injection site, and coughing. 
Serious adverse effects of the drug include: apnea, cardio-respiratory arrest (occurs usually 
in combination with a narcotic), oxygen desaturation, hypotension, respiratory depression, 
respiratory obstruction, bronchospasm and laryngospasm. Unopened vials are stored at 
room temperature (between 68-77 degrees Fahrenheit or 20-25 degrees Celsius) and are 
stable up to 36 days. Protect from light.³² Over sedation can be reversed with the 
administration of 0.2 mg IV flumazenil (Romazicon, Anexate). 
Diazepam (Valium) works similarly as midazolam. It is a member of the following classes: 
antianxiety, anticonvulsant, benzodiazepine, and long-acting skeletal muscle relaxant. It 
potentiates the actions of -aminobutyric acid (GABA), especially in the limbic system and 
reticular formation; enhances presympathetic inhibition, and inhibits spinal polysynaptic 
afferent paths. It is used for anxiety, acute alcohol withdrawal, as an adjunct in seizure 
disorders; as a relaxant both preoperatively and general skeletal muscle relaxation (adjunct 
for skeletal muscle spasm). Given rectally, it is used in acute repetitive (refractory) seizures. 
Other uses of diazepam are: for agitation, benzodiazepine withdrawal, chloroquine 
overdose, insomnia, and as seizure prophylaxis.³²  For sedation during endoscopic 
procedures, a dose of 10 mg or less is given intravenously prior to the procedure for a 
maximum dose of 20 mg. Patients 60 years and older, chronically ill, debilitated or with 
hepatic insufficiency will require less. There are no specific dose adjustments in patients 
with renal insufficiency. Due to the irritating nature of the drug, administration must be 
done slowly, no faster than 5mg/min., and if given through IV infusion tubing, give as 
close to the IV insertion site as possible. Do not inject into small veins (irritating and may 
cause phlebitis) or through intravenous sets made of polyvinyl chloride (PVC). Diazepam 
binds to polyvinyl chloride.³² 
Contraindications to its administration are severe hepatic insufficiency, hypersensitivity to 
diazepam, myasthenia gravis, acute narrow-angle glaucoma, severe respiratory 
insufficiency, sleep apnea, and children less than 6 months of age. Diazepam is 99% protein 
bound (and significantly greater in males than in females), metabolized extensively in the 
liver and excreted in the urine. It is excreted in breast milk, crosses the placenta and blood-
brain barriers. It has a half-life of 30-60 hours. Given intravenously, it has an immediate 
effect and has a duration of about 15 minutes to an hour. Side effects are similar to 
midazolam and include: dizziness, drowsiness, confusion, headache, anxiety, tremors, 
stimulation, fatigue, depression, insomnia, hallucinations, ataxia, hypotension, ECG changes 
and tachycardia. Some, especially for prolonged users, experience blurred vision, tinnitus, 
mydriasis, nystagmus, constipation, dry mouth, nausea, vomiting, diarrhea, anorexia, 
neutropenia, rash, dermatitis, and itching. Injectable diazepam can be stored at room 
temperature and has been found to maintain stability up to 5 months; otherwise, store at 
temperatures 25 degree Celsius (77̊ F) or lower to prevent deterioration. 
Both diazepam and midazolam are similar in producing effective sedation prior to short 
surgical as well as endoscopic procedures. However, midazolam produced a greater degree 
of amnesia, lesser pain on injection, and lesser phlebitis at injection site than diazepam. It 
also produced a greater respiratory depression than diazepam during the first 45minutes of 
administration, though the latter sustained the effects longer than midazolam after an hour 
of administration. Midazolam was also more acceptable to patients than those given 
diazepam. Hence, midazolam is now the agent of choice when amnesia and adequate 
sedation is required. One disadvantage, though, noted with the administration of 
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benzodiazepines is that since they are fat-soluble (particularly diazepam), repeated dose 
results in accumulation of the drug in the adipose tissues which is subsequently released 
into the bloodstream resulting in prolonged effects. Hence, the most common reasons for 
missing work were feeling weak and drowsy or having abdominal cramping and bloating.²²  
Over sedation can be reversed with the administration of 0.2mg IV flumazenil (Romazicon, 
Anexate). 
7.2 Opiates 
The sedative and amnesic effects of benzodiazepines often times do not provide adequate 
comfort for patients undergoing endoscopic procedures, especially if the procedure lasts 
longer than half-an-hour. For this reason, opiates are often added to achieve optimum 
sedation and analgesia. Very few studies have been done to evaluate the efficacy of adding 
an opiate prior to colonoscopy and authors have casted doubt on its benefit.⁸,¹º,¹⁷ The two 
commonly used opiates are meperidine (Demerol) and fentanyl.  
Meperidine (Demerol) is an analgesic, anesthetic adjunct, and is an opioid. It is indicated as 
an anesthetic adjunct, for obstetrical pain, and as premedication for a procedure. It 
depresses pain impulses at the spinal cord level by interacting with opioid receptors. For 
endoscopic procedures, meperidine is dosed as follows: initial bolus of 25mg (given slowly) 
and subsequent incremental doses of 25mg every 2-3 minutes until the desired effect is 
achieved. Colonoscopy is usually started two to three minutes after the initial bolus of 
meperidine and midazolam and titration delivery was given every three minutes thereafter 
with meperidine 25mg and midazolam 1mg until the desired sedation effect was achieved, 
i.e. ptosis, slurred speech, and sleep. See Table 2 for dosing guidelines. 
Meperidine is readily absorbed and crosses the blood-brain and placental barriers. It is 65-
80% protein bound, metabolized in the liver and excreted in the kidneys. It has an 
elimination half-life of 3.2-3.7 hours. It is contraindicated in individuals with 
hypersensitivity to meperidine and those who are taking MAOI (monoamine oxidase 
inhibitor) drugs. Use with caution in individuals with low blood volume, receiving 
concomitant CNS depressants (reduce dosage), head injury, impaired respiratory function, 
acute abdominal conditions, Addison’s disease (reduce dosage), elderly, debilitated, 
hypothyroidism, prostatic hypertrophy and urethral strictures, seizures (may induce more), 
severe hepatic and renal impairment, cardiac dysrhythmias such as SVTs and A-flutter. Side 
effects include: CNS: drowsiness, dizziness, confusion, headache, sedation, euphoria, 
increased intracranial pressure, seizures and serotonin syndrome; CV: palpitations, 
bradycardia, hypotension and orthostatic hypotension, tachycardia; EENT: tinnitus, blurred 
vision, miosis, diplopia, depressed corneal reflex; GI: nausea, vomiting, anorexia, 
constipation, cramps, biliary spasm, and paralytic ileus; GU: urinary retention, dysuria; 
Integ: rash, urticarial, bruising, flushing, diaphoresis, xerostomia and pruritus. Adverse 
effects include respiratory depression, cardiac arrest and anaphylaxis. Use judiciously when 
used in conjunction with benzodiazepines because of its added CNS and respiratory 
depressant effects.³² 
The other opioid of choice is fentanyl which shares the same classification as meperidine: 
analgesic, anesthetic adjunct, and opioid. It acts by inhibiting the ascending pain pathways 
in the CNS (central nervous system), increases pain threshold, and alters pain perception by 
binding to opioid receptors. It is used to control moderate to severe pain, as an adjunct to 
general and regional anesthesia, and premedication for procedures requiring conscious 
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sedation, such as colonoscopy. Compared to meperidine, fentanyl has a more rapid onset of 
action and clearance. It also has a lesser incidence of nausea than meperidine. 
For procedural sedation, the suggested doses are 0.5 to 1.5mcg/kg intravenously and 
repeated every 1 to 3 minutes until the desired sedative effects is achieved. Administer 
slowly to prevent rigidity. It is metabolized by the liver, excreted in the kidneys and breast 
milk and crosses the placenta. Given intravenously, its onset is immediate, within a minute, 
peaking in 3-5 minutes for ½-1 hour. It has a half-life of 1 ½-6 hours and is 80% bound to 
plasma proteins. Side effects are similar to meperidine and include: dizziness, delirium, 
bradycardia, hypo/hypertension, blurred vision, miosis, nausea, vomiting, constipation, 
urinary retention, rash, diaphoresis, muscle rigidity, cardio-respiratory depression and/or 
arrest, and laryngospasm. It is contraindicated in individuals with myasthenia gravis and 
those with hypersensitivity to opiates, bronchial asthma, paralytic ileus, situations of 
significant respiratory distress.³² 
Opioids and benzodiazepines combined work synergistically. Antagonists of these 
medications are naloxone (Narcan) for opiates (typical dose is 40-400mcg IV) and flumazenil 
(Romazicon) for benzodiazepines (typical dose is 40-400mcg IV). These drugs should be 
readily available in every GI suite to rescue a patient who has been given too much sedative 
and whose cardiorespiratory status is compromised. 
7.3 General anesthetic 
The only drug used in colonoscopy in this category is propofol (Diprivan). It produces a 
dose-dependent CNS depression by activating the GABA receptors. Its principal uses are for 
the induction and maintenance of anesthesia and sedation in mechanically ventilated 
patients. It also potentiates the effects on the central nervous system of analgesics and 
sedatives such as benzodiazepines and barbiturates. It has a rapid onset of sedation, but also 
marked cardio-respiratory depressant properties. These side effects usually rapidly 
diminish or reverse with reduction of dose or stopping of administration or infusion of 
propofol. There has been an increase in its use in endoscopic procedures because of its rapid 
onset and faster recovery to alertness properties with minimal residual sedative effects, 
which makes it an attractive alternative to the longer half-life benzodiazepines.²²,¹¹ Do not 
use within 10 days of intake of monoamine oxidase inhibitors (MAOI). This drug potentiates 
CNS depression in individuals taking antipsychotic drugs, opioids, skeletal muscle 
relaxants, St. John’s wort and alcohol.³²  
Propofol may be used alone or in combination with other agents such an opioid or 
benzodiazepine. When used alone, higher doses are often required to achieve the desired 
sedation level which increases the risks of dose-related side effects such as hypotension, 
respiratory depression, and bradycardia. In combination with other agents, the clinician can 
adjust the dosages which usually results in administration of smaller dosages of each of the 
agents to achieve moderate sedation level. If necessary, the effects of the opioid and 
benzodiazepine can be reversed with naloxone and flumazenil. Propofol does not have an 
antidote or reversal agent as its half-life is short and the effects wear off as soon as the 
infusion of the drug is stopped.9  
Though theoretically, propofol in combination with an opioid or benzodiazepine will 
decrease the rapid recovery benefit seen with administration of propofol alone, a 
randomized control trial proved otherwise. The results showed a shorter recovery time with 
the combination regimen than the propofol alone.³⁵  
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The drug is highly lipophilic. There are two preparations that exist on the market. One is 
prepared as an oil/water emulsion (Diprivan) consisting of 1% propofol, 10% soybean oil, 
2.25% glycerol, 1.2% egg lecithin and the antimicrobial agent, EDTA. This preparation is 
contraindicated in individuals with propofol, soy or egg hypersensitivities or allergies. The 
other generic preparation has bisulfites (sodium metabisulfite) as the antimicrobial agent 
and is therefore, contraindicated in individuals with hypersensitivity or allergy to 
bisulfites.⁴,³²  
Propofol is notorious for being painful at the injection site, often described as a burning 
sensation. Several approaches have been employed to minimize this discomfort. One is the 
administration of 1-2 ml of 1% lidocaine prior to injecting propofol or mixing lidocaine and 
propofol in the same syringe. Another approach is diluting propofol in a 5% glucose 
solution. A study found that there was less pain at the injection site in individuals given the 
generic propofol (bisulfite-containing propofol) than those given Diprivan.³²  
Propofol is a category B drug and should be used with caution in lactating mothers as it is 
excreted in breast milk. It is 98% plasma-protein bound, is metabolized primarily in the 
liver, and excreted in the kidneys. Usual time from injection to onset of sedation is anywhere 
from 13-30 seconds and the duration is about 4-8 minutes.⁴ Table 4 shows a summary of 
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sedation, such as colonoscopy. Compared to meperidine, fentanyl has a more rapid onset of 
action and clearance. It also has a lesser incidence of nausea than meperidine. 
For procedural sedation, the suggested doses are 0.5 to 1.5mcg/kg intravenously and 
repeated every 1 to 3 minutes until the desired sedative effects is achieved. Administer 
slowly to prevent rigidity. It is metabolized by the liver, excreted in the kidneys and breast 
milk and crosses the placenta. Given intravenously, its onset is immediate, within a minute, 
peaking in 3-5 minutes for ½-1 hour. It has a half-life of 1 ½-6 hours and is 80% bound to 
plasma proteins. Side effects are similar to meperidine and include: dizziness, delirium, 
bradycardia, hypo/hypertension, blurred vision, miosis, nausea, vomiting, constipation, 
urinary retention, rash, diaphoresis, muscle rigidity, cardio-respiratory depression and/or 
arrest, and laryngospasm. It is contraindicated in individuals with myasthenia gravis and 
those with hypersensitivity to opiates, bronchial asthma, paralytic ileus, situations of 
significant respiratory distress.³² 
Opioids and benzodiazepines combined work synergistically. Antagonists of these 
medications are naloxone (Narcan) for opiates (typical dose is 40-400mcg IV) and flumazenil 
(Romazicon) for benzodiazepines (typical dose is 40-400mcg IV). These drugs should be 
readily available in every GI suite to rescue a patient who has been given too much sedative 
and whose cardiorespiratory status is compromised. 
7.3 General anesthetic 
The only drug used in colonoscopy in this category is propofol (Diprivan). It produces a 
dose-dependent CNS depression by activating the GABA receptors. Its principal uses are for 
the induction and maintenance of anesthesia and sedation in mechanically ventilated 
patients. It also potentiates the effects on the central nervous system of analgesics and 
sedatives such as benzodiazepines and barbiturates. It has a rapid onset of sedation, but also 
marked cardio-respiratory depressant properties. These side effects usually rapidly 
diminish or reverse with reduction of dose or stopping of administration or infusion of 
propofol. There has been an increase in its use in endoscopic procedures because of its rapid 
onset and faster recovery to alertness properties with minimal residual sedative effects, 
which makes it an attractive alternative to the longer half-life benzodiazepines.²²,¹¹ Do not 
use within 10 days of intake of monoamine oxidase inhibitors (MAOI). This drug potentiates 
CNS depression in individuals taking antipsychotic drugs, opioids, skeletal muscle 
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infusion of the drug is stopped.9  
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The drug is highly lipophilic. There are two preparations that exist on the market. One is 
prepared as an oil/water emulsion (Diprivan) consisting of 1% propofol, 10% soybean oil, 
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and is therefore, contraindicated in individuals with hypersensitivity or allergy to 
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propofol in the same syringe. Another approach is diluting propofol in a 5% glucose 
solution. A study found that there was less pain at the injection site in individuals given the 
generic propofol (bisulfite-containing propofol) than those given Diprivan.³²  
Propofol is a category B drug and should be used with caution in lactating mothers as it is 
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liver, and excreted in the kidneys. Usual time from injection to onset of sedation is anywhere 
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action of the combined benzodiazepine and opiate and the result may be a deeper level of 
sedation. Adjuncts are employed when the first-line of sedatives fail to produce the desired 
level of sedation. 
Diphenhydramine, better known as Benadryl, acts on the GI tract, blood vessels, and 
respiratory system by competing with histamine for H-1 receptor sites, thereby decreasing 
histamine’s actions. It is usually used for allergy symptoms, rhinitis, motion sickness, 
nonproductive cough, antiparkinsonism, insomnia in children, infant colic, and for 
nighttime sedation. Effects are heightened in individuals taking MAOIs. Side effects include 
dizziness, drowsiness, anxiety, fatigue, euphoria, confusion, seizures, blurred vision, 
hypotension, blurred vision, urinary retention, hemolytic anemia, thrombocytopenia, 
agranulocytosis, chest tightness, wheezing, and anaphylaxis. Dose is 10-50mg IV. It is 
metabolized in the liver and excreted by the kidneys. It crosses the placenta and is excreted 
in breast milk. Its onset is immediate when given IV and the duration is 4-7 hours.³² 
Promethazine (Phenergan) acts the same way as diphenhydramine. Its uses are also similar to 
diphenhydramine. In addition, it is also used to counteract nausea and for preoperative and 
postoperative sedation. Side effects are the same as diphenhydramine with the addition of 
neuroleptic syndrome, neuritis and paresthesia, Dose is 12.5mg-50mg IV. Its onset is 3-5 
minutes with duration of 4-12 hours. It is metabolized in the liver and excreted in the 
kidneys and GI tract.³² 
Dropeidol (Inapsine) is a neuroleptic agent acting on the subcortical level producing sleep 
and tranquilization. It is used as premedication prior to surgery and induction and 
maintenance of general anesthesia. It is also used as an antiemetic postoperatively. It is also 
sometimes used for anxiety and for difficult to sedate individuals undergoing therapeutic 
endoscopy. However, this drug carries a black box warning from the Food and Drug 
Administration (FDA) warning users that it can prolong the QT interval and should be 
avoided in individuals with congestive heart failure (CHF), bradycardia, on diuretics, has 
cardiac hypertrophy, hypokalemia, hypomagnesemia, and are on drugs that normally 
prolong the QT interval. It is contraindicated in males whose QT intervals are >440msec. or 
for females whose QT intervals are > 450msec. Individuals over the age of 65, history of 
alcohol abuse, and use of benzodiazepines and opiates are also at risk. Side effects include 
seizures, neuroleptic malignant syndrome, torsade de pointes, prolonged QT interval, 
tachycardia, hypotension, hallucination, depression, extra pyramidal symptoms (EPS), 
laryngospasm, bronchospasm, chills, and sweating. Initial dose should start at 1.25mg IV. 
May give an additional 1.25mg IV dose to max of 2.5mg. Its onset is 3-5 min, peaking in ½ 
an hour and duration of 3-6 hours. It is metabolized in the liver, excreted in the urine and 
crosses the placenta. It has a half-life of 2-3 hours.³²  
The long duration of actions of these adjuncts make it a less ideal drug for use in short 
procedures such as colonoscopy. Recovery will take a longer time and will not be cost 
effective for the GI unit. 
9. Conclusion 
Colonoscopy remains the gold standard in diagnosing gastrointestinal disorders. The test 
itself along with the preparation is anxiety provoking and frightening for most people. In 
many countries around the world, colonoscopy is commonly performed without sedation. 
The discomfort hampers completion of the test; hence, sedation is now the standard practice 
in endoscopic procedures, particularly colonoscopy. Benzodiazepines, opiates, and propofol 
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are the commonly used sedating agents. Alone or in combination, many of these agents 
have been employed to maximize patient comfort and patient and physician satisfaction, but 
none have proved ideal. The widespread variation in sedation practices are also influenced 
by physician experience and expertise, financial and regulatory constraints, patient 
expectations and satisfaction, and lack of consensus on the ideal sedating agent for 
colonoscopy. More controlled clinical trials are needed to evaluate the safety and efficacy of 
the ideal sedating agent (s). 
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where food enters the mouth, continuing through the pharynx, oesophagus, stomach and 
intestines to the rectum and anus, where faeces pass out. The primary purpose of the 
gastrointestinal system is to break down food into nutrients, which together with water can 
be absorbed to feed the body cells. In the case of gastrointestinal disease or disorders, these 
functions of the gastrointestinal tract are not achieved successfully, discussed in the 
subsequent sections of this chapter. The innermost layer of the gastrointestinal system is the 
mucosa, which is lined with specialised epithelial cells, supported by an underlying 
connective tissue layer called the lamina propria, where infiltrating leucocytes, in particular, 
myeloid linage leucocytes are often seen. 
2. The natural history of ulcerative colitis 
Ulcerative colitis (UC) is one of the two major phenotypes of the idiopathic inflammatory 
bowel diseases (IBD) of the intestine; the other major phenotype is Crohn’s disease (CD). UC 
and CD are both debilitating chronic disorders that afflict millions of individuals 
throughout the world with symptoms which impair function and quality of life. However, 
whereas UC is confined to the colon and the rectum, CD may affect any part of the gut from 
the mouth to the perianal (1,2). A multitude of clinical manifestations represent the 
expressions of IBD. These include diarrhoea, rectal bleeding, abdominal discomfort, fever, 
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by diverse environmental factors (2). From here on, we shall focus only on UC. The severity 
of UC is often presented by clinical activity index (CAI). Another, but complementary 
parameter is endoscopic activity index, not used in this chapter. 
3. Colonoscope, the gastroenterologist’s eye and arms in modern times 
Colonoscopy is a revolutionary development in gastroenterology, now days like both arm 
and eyes for specialist gastroenterologists that can reach the inside of the large and distal 
segment of the small intestine. Introduced in the late 1960s (3), the term, colonoscopy refers 
to the endoscopic examination of the bowel with a charge-coupled device (CCD) camera or a 
fiber optic camera on a flexible tube passed through the rectal opening. As the name implies, 
colonoscopy allows a visual diagnosis of intestinal wall lesions like inflammation, 
ulceration, polyps and provides the opportunity for biopsy or removal of suspected 
cancerous lesions. Colonoscopy can remove polyps as small as one millimetre or less. Once 
polyps are removed, they can be studied with the aid of a microscope to determine if they 
are precancerous or not. Retrograde colonoscopy of the entire colon, and endoscopic 
excision of polyps from anywhere in the colon, began in 1969 (4). Momentous advances 
have occurred over the past two decades, and the two procedures are now widely accepted 
and practiced. Development and perfection of the methodology were, at first, fraught with 
many difficulties, both procedural and technical, which had to be overcome. Significant 
opposition was engendered in the early years by some who claimed that the methods were 
both unnecessary and unduly dangerous. Time has proven otherwise. Progress came about 
as the result of a steady stream of publications from a number of centres documenting the 
successful and safe application of the methodology.  
More advanced versions include virtual colonoscopy, which uses 2D and 3D imagery 
reconstructed from computed tomography (CT) scans or from nuclear magnetic resonance 
(MR) scans, is also possible, as a totally non-invasive medical test. However, unlike standard 
colonoscopy, virtual colonoscopy does not allow for therapeutic maneuvers such as 
polyp/tumour removal or biopsy nor visualization of lesions smaller than 5 millimeters. If a 
growth or polyp is detected by using CT colonography, a standard colonoscopy would still 
need to be performed. Further, colonoscopy is similar to, but not the same as, 
sigmoidoscopy, the difference being related to which parts of the colon each can examine. A 
colonoscopy allows an examination of the entire colon (measuring more than 1.5m in 
length). A sigmoidoscopy allows an examination of only the final 60cm of the colon. A 
sigmoidoscopy is often used as a screening procedure for a full colonoscopy to be followed 
in many instances in conjunction with a faecal occult blood test, which can detect the 
formation of cancerous cells throughout the colon. At other times, a sigmoidoscopy is 
preferred to a full colonoscopy in patients having an active flare of ulcerative colitis (UC) or 
Crohn's disease (CD) to avoid a perforation of the colon. Additionally, surgeons use the 
term pouchoscopy to refer to a colonoscopy of the ileo-anal pouch. Conditions that call for 
diagnostic colonoscopy include gastrointestinal haemorrhage, unexplained changes in 
bowel habit and suspicion of malignancy. Colonoscopies are often used to diagnose colon 
cancer, but are also frequently used to diagnose and assess inflammatory bowel disease 
(IBD). In older patients (sometimes even younger ones) an unexplained drop in haematocrit 
(one sign of anaemia) is an indication that calls for a colonoscopy, usually along with an 
oesophagogastroduodenoscopy, even if no obvious blood has been seen in the stool (faeces). 
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Due to the high mortality associated with colon cancer and the high effectiveness and low 
risks associated with colonoscopy, it is now becoming a routine screening test for people 50 
years of age or older. Subsequent re-screenings are then scheduled based on the initial 
results found, with a five or ten-year recall being common for colonoscopies that produce 
normal results (5). Patients with a family history of colon cancer are often first screened 
during their teenage years. A recent study found that among people who have had an initial 
colonoscopy that found no polyps, the risk of developing colorectal cancer within five years 
is extremely low. Therefore, there is no need for those people to have another colonoscopy 
sooner than five years after the first screening (6). In this chapter, the authors endeavour to 
describe the potential diagnostic power of colonoscopy potentially to identify patients with 
an active flare of UC who are most likely to respond to selective, but therapeutic removal of 
circulating myeloid linage leucocytes (granulocytes and monocytes/macrophages) by 
extracorporeal adsorption, as a new and non-pharmacologic treatment intervention for 
patients with IBD, better known as GMA, which stands for granulocyte and monocyte 
adsorption (7). 
4. Colonoscopy in inflammatory bowel diseases 
Figure 1 shows colonoscopy photographs from the surface of the colonic mucosa of healthy 
human subjects or patients with UC following full remission in association with GMA 
therapy. The mucosa is the surface through, which nutrients and water from the food in the 
intestine are absorbed into the blood stream. Accordingly, healthy mucosa is typically well 
vascularised for adequate absorption. Colonoscopy has a unique position in viewing and 




Most symptoms of UC are due to the ulceration and the loss of the mucosal layer covering 
the inner wall of the large intestine (colon and the rectum). As the mucosal layer is involved 
in the absorption of nutrients and water from the gut, during severely active UC, absorption 
of nutrients and water is seriously impaired. In Figure 2, typical colonoscopy photographs 
from the surface of the colon or the rectum of patients with severe and fulminant UC are 
seen. There is extensive and deep ulcers together with near total loss of the mucosal tissue. 
This condition is debilitating, the patients may suffer from weight loss, and impaired quality 
of life. For example unabsorbed food and water will pass as watery diarrhoea, or bloody 
diarrhoea due to bleeding. Such patients are not likely to respond to any drug based 
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medication or even to therapeutic depletion of myeloid leucocytes by GMA, they have 
fulminant (disease persists in the presence of optimal medication) UC and often must opt 
for surgery known as colectomy. Needless to say that only an initial diagnostic colonoscopy 
can identify such patients as non-responders to drug based interventions so that the patient 
can opt for colectomy at an early stage. This should significantly shorten morbidity time and 
save medical cost.  
 
 
Fig. 2.    
5. Therapeutic options for patients with ulcerative colitis 
Despite the recognition of a genetic background together with environmental factors, which 
at present are thought to translate into an inappropriate inflammatory response in patients 
with UC (2, 8-10), currently our understanding on the immunopathogenesis of UC is 
inadequate. Hence, up to now drug therapy of UC has been empirical rather than based on 
sound understanding of disease aetiology. Accordingly, while drug therapy initially 
appears successful in the majority of patients, it comes at the cost of significant side effects 
(11,12). Further, up to now, first line medications for exacerbation of UC include 5-
aminosalicylic acid (5-ASA) or sulphasalazine in combination with a corticosteroid with 
consideration of azathioprine (or 6-mercaptopurine) and nutritional support for some 
patients (2,14-18). Treatment failure in patients with severe disease has often been an 
indication for colectomy in up to 40% of steroid refractory patients (2,19, 20) although in 
recent years, cyclosporin A (CsA) has been introduced for corticosteroid refractory UC 
(18,21). Despite being moderately effective in this clinical setting in reducing colectomy 
rates, there remain serious concerns over long-term efficacy and toxicity of CsA (22). 
However, this is not to say that drug has no place in the treatment of UC. In fact, no one can 
deny the role of medicines in the elimination of most disease that our ancestors were left 
defenseless against. However, even in today’s era of modern medicine, it is essential to bear 
in mind that drug therapy by its very nature, involves adding a foreign substance to the 
body system and although initially effective, may lead to the disease becoming drug 
dependent or refractory. Additionally, many drugs are associated with toxic side effects 
which can add to the disease complexity. Hence, a therapeutic strategy based on a non-drug 
intervention, a correction or support of body’s natural processes like GMA (which takes 
away from the body instead of adding to it), if effective, should have advantages over drugs, 
long term adverse side effects and refractoriness are unlikely (23, 24). 
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6. Myeloid leucocytes, cytokines and ulcerative colitis 
It is now known that UC is exacerbated by inflammatory cytokines like tumour necrosis 
factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8 and others (25). Accordingly, anti-cytokine 
antibodies, notably anti-TNF antibodies like infliximab (IFX) are being used and new 
antibodies are being developed for the treatment of IBD (26). Indeed, the efficacy of anti-
TNF, notably IFX, in patients with CD (27) as well as in UC (26) has validated the role of this 
cytokine in the immunopathogenesis of IBD. However, the enthusiasm towards biologicals 
is increasingly being dampened by concerns about their long-term efficacy and in particular, 
the safety profiles (28,29). However, patients with active IBD harbour elevated and activated 
myeloid linage leucocytes (granulocytes and monocytes) in the presence of compromised 
lymphocytes (1,30-33). Further, histologic examinations of mucosal biopsies from patients 
with active IBD reveals a spectrum of pathologic manifestations among which an abundance 
of neutrophils accounts not only for the morphologic lesions in IBD, but also for the 
prevailing patterns of mucosal inflammation (2,34,35). When activated, myeloid leucocytes 
produce an array of pleiotropic cytokines like TNF-α, IL-1β, IL-6, IL-12, IL-23, which are 
strongly pro-inflammatory (25,36). Therefore, targeting leucocytes as key players in the 
exacerbation of IBD is what lies behind extracorporeal granulocyte monocyte/macrophage 
adsorption (GMA) with the Adacolumn (7). Likewise, neutrophils in patients with IBD show 
activation behaviour (30) and prolonged survival time (37). Factors that are known to 
promote neutrophil survival in IBD include inflammatory cytokines (38) and paradoxically 
corticosteroids (39), which are commonly used to treat IBD patients. Myeloid leucocytes, like 
the CD14(+)CD16(+) monocytes are major sources of TNF-α (40,41), and it could be valid to 
say that selective depletion of myeloid leucocytes by GMA should alleviate inflammation 
and promote remission or at least enhance the efficacy of pharmacologics. However, clinical 
studies in patients with UC have reported unmatched efficacy outcomes, ranging from an 
85% (42) to a statistically insignificant level (43), indicating that certain subpopulations of 
patients benefit from GMA while others not so, suggesting that patients’ baseline 
demographic variables determine clinical response to this non-pharmacologic mode of 
therapy (23,24). 
7. Therapeutic leucocytapheresis in ulcerative colitis – logics and 
mechanisms 
For an extracorporeal intervention to be a novel non-drug therapeutic option, it should be 
able to selectively deplete leucocytes, which in patients with UC are thought to contribute 
to the disease pathogenesis. For example, we have already said that patients with active 
IBD are found to have compromised lymphocytes (31-33). With this in mind, certain sub-
populations of lymphocytes like the CD4(+)CD25(+) phenotype, known as the regulatory 
T cells (Treg) have essential immunoregulatory roles and therefore, are indispensable to 
the host (44-49). Based on these understandings, the Adacolumn leucocytapheresis system 
is designed to spare lymphocytes. It is filled with specially designed cellulose acetate 
beads of 2mm in diameter as the column leucocytapheresis carriers that are bathed in 
physiologic saline (50). The carriers remove from blood in the column most of the 
granulocytes, monocytes/macrophages together with some platelets (7,51). Surprisingly, 
the procedure has been associated with a sustained increase in absolute lymphocyte 
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counts in the post treatment phase (32,33,50) including the regulatory phenotype, 
CD4(+)CD25(+) Treg (7,49,50). The Adacolumn is an adsorptive type and 
leucocytapheresis with this column is often abbreviated as GMA. The mechanisms for 
sparing lymphocytes are briefly described here. Patients with immune dysfunction may 
have immune complexes (IC) in their plasma (7,51,52). Cellulose acetate adsorbs 
immunoglobulin G (IgG) and IC from the plasma (52,53). Upon adsorption, the binding 
sites on IgG and IC become available for the Fcγ receptors (FcγRs) on myelocytes (7,51-
53). Further, cellulose acetate with adsorbed IgG and IC generates complement activation 
fragments including C3a and C5a (7,52,53). The opsonins C3b/C3bi and others derived 
from the activation fragments also adsorb onto the carriers and serve as binding sites for 
the leucocyte complement receptors, CR1, CR2, CR3 (Mac-1, CD11b/CD18). Hence, 
leucocyte adsorption to the GMA carriers in the Adacolumn is governed by the opsonins, 
FcγRs and the leucocytes complement receptors (7,53). The expressions of these sets of 
receptors are common features of myeloid linage leucocytes. Lymphocytes are not known 
to express complement receptors except on small subsets of B, T and natural killer (NK) 
cells. Similarly, FcγRs are not widely expressed on lymphocytes except on small 
populations of CD19+B cells and CD56+NK cells (7,51). These basic phenomena proceed 
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8. Colonoscopic features of typical responders to GMA 
Clinical experience has shown that GMA in patients with steroid dependent or steroid 
refractory UC was associated with significant efficacy as assessed by measuring the fall in 
UC clinical activity index (CAI) and tapering or discontinuation of steroids, while in steroid 
naïve patients, GMA spared patients from exposure to steroids (23,24). Therefore, published 
data (23,24,32,34,55) suggest that steroid naive patients respond particularly well. 
Characteristically they respond faster with fewer GMA sessions and have a high cumulative 
rate of remission. Thus, the remission rate in steroid naïve patients reported by Suzuki et al. 
(32) was an 85%. Similarly, Tanaka et al. (34) treated a cohort of 45 patients, 26 steroid naive 
and 19 steroid dependent. Each patient could receive up to a maximum of 11 GMA sessions 
(or until CAI decreased to 4 or less). At week 12, the response rate (CAI ≤4) in steroid naïve 
subgroup was 22 of 26 patients (84.6%) and in steroid dependent sub-group was 11 of 19 
(57.9%). Colonoscopy revealed that most non-responders in both groups had deep colonic 
ulcers and extensive loss of the mucosal tissue. Further, this is the only study that looked at 
the impact of GMA on leucocyte level in the colonic mucosa. Biopsies taken during 
colonoscopy revealed massive infiltration of the colonic mucosa by neutrophils and GMA 
was associated with a striking reduction of neutrophils in the mucosa (Figure 5). Tanaka’s 
colonoscopic observations (23,34) echo those of Suzuki et al. a few years earlier (32), who 
also reported that the only 3 non-responders in their cohort of 20 steroid naïve patients had 
deep colonic ulcers. In a very thorough study by Suzuki et al. (56), the authors aimed at 
determining the responders to GMA. Their major findings are as follows. Seven days after 
the last GMA session, 20 of 28 patients (71.4%) achieved clinical remission including all 8 
patients who had their first UC episode. The mean duration of UC in the 8 first episode 
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cases was just 3.4 months compared with 40.2 months for all 28 patients and 65.4 months for 
the 8 patients who did not respond at al. The response to GMA seemed to be independent of 
baseline CAI. The authors concluded that first UC episode and short disease duration might 
be good predictors of response to GMA in that clinical setting. Further, they stated that 
GMA could be an effective first line medication for steroid naïve patients (23,32,56).  
9. The impact of GMA on mucosal leucocytes 
It is of particular interest to see if GMA, in fact does impact the mucosal level of infiltrating 
myeloid leucocytes. As stated above, colonic biopsies were taken from active disease sites 
before and after GMA induced remission in patients with active UC. Figure 5 shows 
representative histology photographs from a GMA responder patient. The specimen taken 
at baseline shows the colonic mucosa is infiltrated by a vast number of inflammatory 
leucocytes, primarily granulocytes and monocytes/macrophages; the density of the 
infiltrating cells was strongest in or around the glandular lumen (crypt abscesses). The 
specimen taken when the patient had achieved remission shows very striking reduction in 
inflammatory cell infiltrate. Surprisingly, the density of leucocytes was reported to be 
stronger in steroid naïve patients vs patients on steroids, suggesting that corticosteroids 
have inhibitory effects on neutrophils (23). 
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10. Colonoscopic features of non-responders to GMA 
As reviewed above, several studies have reported that any patient with a fair level of colonic 
mucosa is a potential responder to GMA. In contrast, Figure 2 (above) shows deep and 
extensive colonic lesions with virtually no mucosal tissue left at the lesion sites in two 
typical GMA non-responder patients. Such patients are unlikely to respond to any 
medication except colectomy. Even patients with a near equal CAI score had very different 
mucosal damage status, indicating that CAI per se does not reflect the full extent of mucosal 
damage in patients with UC. Figure 6 shows colonoscopy photographs from the colonic 
mucosa of a 60-year-old steroid dependent patient who showed partial response to GMA. 
At baseline, the major colonoscopic findings seen are strong inflammation with multiple 
polyp-like protrusions in the mucosa. Following a course of GMA therapy, inflammation 
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has alleviated, but multiple polyps are exposed and apparently seem not to be affected by 
GMA, but the mucosa appears to be regenerating once again, suggesting a fair level of 
mucosal tissue was left prior to the initiation of GMA therapy. Based on CAI, this patient 
might be in clinical remission, but has not achieved endoscopic (colonoscopic) remission, 
which could require a long observation time.  
A small minority of patients without deep colonic lesions or extensive loss of the mucosal 
tissue do not respond to GMA as well. Colonoscopy photographs from such patients are 
presented in Figure 7, showing inflammation, but without extensive ulcers (entry CAI, 15). 
These cases are likely to have a long history of multiple drug therapy. However, no patient 
with the entry colonoscopy features seen in Figure 2 did show any significant fall in CAI score. 
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11. Colonoscopic features of patients who are most likely to respond to GMA 
From the plethora of published clinical observations, it appears that drug naïve patients 
with superficial lesions, usually first episode cases are the best responders to GMA, respond 
soon after a few GMA sessions and can be spared from multiple drug therapy. Typical 
colonoscopic features in these patients are seen in Figure 8. Accordingly, GMA should have 
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12. Concluding remarks 
The gastrointestinal system is often affected by diseases which can impair its function and 
the individual’s well being. The colonoscope may be regarded as the gastroenterologist’s 
eyes and arms. Within limits, surgery can be achieved by the application of colonoscope like 
removing suspected cancerous lesions and excision of polyps which grow inside the large 
intestine in many individuals and can cause morbidity. Further, the large intestine is the 
main organ where IBD, in particular UC develops as a very debilitating health disorder. UC 
patients present with diverse clinical and endoscopic disease severity levels, and therefore, 
their clinical response to medical interventions can be complete remission, partial response 
or no response at all. Therefore, without colonoscopic evaluations of patients’ relevant 
demographic variables, medical resources will be wasted together with prolonged 
morbidity time for many patients. Further, patients with UC have activated myeloid 
leucocytes, which infiltrate the colonic mucosa in vast numbers and potentially can 
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exacerbate the inflammation and perpetuate the disease. Accordingly, efficient depletion of 
myeloid leucocytes by GMA, which reduces the mucosal concentrations of myeloid 
leucocytes, should benefit patients with UC. In spite of this view, clinical efficacy outcomes 
are both encouraging as well as disappointing; the answer might lie in the patients’ disease 
status at entry. By the power of colonoscopy over a decade in patients with UC we have 
learnt that all patients with the first UC episode and short duration of disease readily 
respond to GMA and can be spared from multiple drug therapy. Similarly, most steroid 
naïve or dependent patients who have a fair level of intact mucosal tissue are potential 
responders to GMA. Patients with extensive loss of the mucosal tissue and those with a long 
history of exposure to multiple drugs like corticosteroids are unlikely to respond to GMA. 
Further, one of the most favoured features of Adacolumn GMA is its safety profile. Serious 
side effects are very rare. This is in sharp contrast to multiple severe side effects associated 
with most conventional pharmacologicals and new biologics. Our view is that in patients 
with UC, there is an evolving scope for therapeutic opportunity based on taking away the 
sources of inflammatory cytokines.  
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1. Introduction 
Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. Early 
detection and removal of CRC or its precursor lesions by population screening can reduce 
mortality.[1] 
An increasingly popular screening test for colorectal cancer is computed tomographic (CT) 
colonography, also called virtual colonoscopy (VC). It is a powerful technique for 
population screening of asymtomatic adults. It has potential advantages over conventional 
colonoscopy (CC) as it is less invasive, less time-consuming and less expensive. Moreover, 
no sedation is needed.[2] Its main disadvantages to CC are the exposure of individuals to 
ionizing radiation and the lack of ability to take tissue samples or to remove polyps during 
the procedure.[2-6] 
CT colonography was first described in 1994 as a radiographic technique in which thin-
section images of pneumocolon could be reconstructed by sophisticated software into high-
resolution 2D- and 3D images.[7,8] Over time, improvements in hardware and software 
have allowed faster scanning, reduced exposure to radiation, and better imaging. Newer 
modes of imaging (called fly-through) can produce results that resemble endoscopic images 
and permit sophisticated characterization of detected lesions.[7,9-11] 
The ability of VC to detect colorectal polyps has been tested in a multitude of studies. VC 
appeared to be promising in high risk populations, with a reported sensitivity greater than 
90% for polyps ≥10 mm. [12-14] To achieve such results, adequate bowel cleaning or fecal 
tagging and reader experience are essential.  
This chapter summarizes the main indications, the current techniques in patient 
preparation, data acquisition and data analysis as well as imaging features for common 
benign and malignant colorectal lesions. 
2. Indications 
CT colonography is used to examine the colon and rectum, and detect abnormalities such as 
polyps and cancer. There are several clinical indications for CT colonography. They include 
evaluation of the colon after an incomplete or unsuccessful CC examination and evaluation 
of the colon proximal to an obstructing neoplasm.[2,15-19] An incomplete CC examination is 
defined as a failure to intubate the caecum. Incomplete CC may be the result of poor bowel 
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preparation, redundant colon, and patient intolerance to the procedure, spasm, or colonic 
obstruction caused by a neoplastic or non-neoplastic stenosis. The CT colonography 
examination can be performed on the same day directly after CC and without additional 
bowel preparation.[2,20] In cases of an obstructing cancer (Figure 1), CT colonography offers 
information about the pre-stenotic colon, local tumor invasion, lymph nodes, and distant 






Fig. 1. Incomplete colonoscopy because of a stenotic cancer of the rectum. (A) 2D sagittal CT 
colonographic image shows circular wall thickening in the rectum (arrowheads). (B) 3D CT 
colonographic image shows an irregular, circular, stenotic filling defect. 
Another indication for CT colonography is  the evaluation of patients with contraindications 
to CC or who refuse other screening options.[2,3] This includes patients in need of 
anticoagulation, past history of difficult or incomplete colonoscopy, and patients who 
cannot be sedated due to medical conditions. Furthermore, in cases of advanced patient age, 
and in frail or immobile patients, CT colonography can be safely performed to exclude 
neoplastic or stenotic conditions.[2,3,24,25] 
At chronic stages of inflammatory bowel disease, CT colonography can provide information 
on the extent of disease and about stenosis and prestenotic regions, as well as the 
extracolonic extent and complications of the disease.[2,26-29]. 
3. Contraindications 
Contraindications to CT colonography include acute abdominal pain, recent abdominal or 
pelvic surgery, abdominal wall hernia with entrapment of colonic loops, and acute 
inflammatory conditions, such as acute diverticulitis, acute active stage of ulcerative colitis 
or Crohn’s disease, and toxic megacolon. In these conditions, insufflations of the colon can 
lead to perforation and widespread peritonitis.[2,30-32]. In addition, weight and girth 
limitations of the scanner, artifacts from metal prosthesis, pregnancy, and patients with 
claustrophobia are general CT contraindications.[2]  
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4. CT colonography technique 
4.1 Patient preparation 
For optimal image quality, the colon should be clean, dry, and completely distended. 
Residual stool and fluid may lead to a false-negative or false positive diagnosis. A well-
prepared colon will facilitate lesion detection and minimize false-positive findings, whereas 
residual matter in the lumen (e.g., stool, fluid) may stimulate or obscure colonic 
lesions.[2,12] 
There are three commercially available bowel preparations; these include cathartics such as 
magnesium citrate (LoSo Preparation, EZ-Em Inc, Westbury, NY, USA) and phosphosoda 
(Fleet Pharmaceuticals, Lynchburg, VA, USA) and colonic lavage solutions such as 
polyethylene glycol (PEG). Magnesium citrate and phosphosoda are adequate for CT 
colonography.[2] The polyethylene glycol preparation frequently leaves a large amount of 
residual fluid in the colon.[3,33] While this preparation is adequate for CC, large amounts of 
residual fluid will limit CT colonography. At CC, residual fluid can be endoscopically 
aspirated from the colon. With CT colonography, the examination is typically limited to 
only two acquisitions (which are supine and prone). While supine and prone imaging allow 
for fluid redistribution, this does not ensure full mucosal evaluation if a large amount of 
fluid is present. Thus, for CT colonography, the preparation that provides the least amount 
of residual fluid will theoretically allow the evaluation of the entire mucosal surface.[2,3] 
Phosposoda is contraindicated in patients with known renal failure, preexisting electrolyte 
abnormalities, congestive heart failure, ascites, or ileus. [2,34] In these circumstances,  
PEG can be used as an alternative, as it does not result in fluid shifts and electrolyte 
imbalances. [3,35] 
The Fleet Kit consists of a clear fluid diet the day before the examination, as well as a single 
45-mL dose of phosphosoda and four bisacodyl tablets the day before the examination. In 
addition, patients receive a bisacodyl suppository the morning of the examination. The LoSo 
preparation consists of magnesium citrate and four bisacodyl tablets the day before the 
examination and a bisacodyl suppository the morning of the examination.[3] 
The addition of oral contrast agents will tag residual stool or fluid (Figure 2). Oral contrast 
agents for stool and fluid tagging consist of meglumine diatrizoate (Gastrografin, Schering 
AG, Berlin, Germany) and a barium sulfate suspension (Tagitol, E-Z-EM, Lake Success, NY, 
USA).[6] 
The resulting higher attenuation of fecal and fluid residues simplifies their distinction from 
colonic abnormality. Whereas some authors prefer tagging with barium only, others have 
reported good results with iodine or a combination of both to achieve fecal and fluid 
tagging.[2,36-38] 
4.2 Bowel distention 
Optimal colonic distention is a fundamental prerequisite for CT colonography data 
evaluation that allows intraluminal evaluation of the large bowel. Underdistended or 
collapsed segments may hide intraluminal lesions.[2] 
Immediately before data acquisition, the patient should evacuate any residual fluid from the 
rectum. For colonic insufflations, either room air or carbon dioxide (CO2) can be used. The 
easiest and cheapest method is manual room air distention via a handheld plastic bulb 
insufflators. Proponents of CO2 use argue that  its readily absorbance from the colon causes 
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collapsed segments may hide intraluminal lesions.[2] 
Immediately before data acquisition, the patient should evacuate any residual fluid from the 
rectum. For colonic insufflations, either room air or carbon dioxide (CO2) can be used. The 
easiest and cheapest method is manual room air distention via a handheld plastic bulb 
insufflators. Proponents of CO2 use argue that  its readily absorbance from the colon causes 
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less cramping after the procedure than does room air insufflations. [3,39] Bowel distention is 
performed in the left decubitus or supine position with a thin, flexible rubber catheter 
placed in the rectum (e.g., thin plastic or rubber 14F rectal tube, small gauge Foley 
catheter).[2,40] During the gas insufflation, gentle insufflation is continuous until the patient 
feels uncomfortable or bloated. Patients are encouraged to keep the gas (room air or CO2) in 
as much as possible. The patient is asked to let the technologist know when they begin to 
feel uncomfortable. Generally this signals that the colon is well distended. If the ileocecal 
section is incompetent, more gas will be required for optimal distention.[2,3] 
 
 
Fig. 2. Fecal tagging with orally ingested barium: 2D sagittal CT colonographic image shows 
high attenuation of contrast marked fecal residuals and residual fluid (arrowheads), as well 
as a polyp in the ascending colon. 
CO2 can be administered either manually, over a standard enema bag filled with 
approximately 3L of gas (via a gas cylinder) attached to a rectal catheter over a connecting 
tube, or automatically, using a dedicated insufflations device (Protocol colon insufflations 
system, EZ-Em Inc., Wesbury, NY, USA). This device electronically controls the flow rate of 
CO2, the total administered gas volume, and the intracolonic pressure (which is limited up 
to a maximum of 25 mmHg).[2,41,42] This generally will take 2-4L of gas, depending on the 
patient’s individual colonic anatomy.[2] 
After distention, the catheter is left in the rectum, and a single scout CT image is obtained 
with the patient in the supine position to verify adequate bowel distention (Figure 3). If 
adequate bowel distention is present, the CT examination is performed. Otherwise, 
additional gas is insufflated into the rectum, according to the scout image. Following the 
supine axial image acquisition, the patient is turned to the prone position. Several additional 
puffs of air are then administered, or CO2 is continuously administered. After a second 
scout localizing image is obtained, the process is repeated over the same z-axis range. 
Supine and prone imaging doubles the radiation dose but is essential to allow optimal 
 
Virtual Colonoscopy: Indications, Techniques, Findings 
 
99 
bowel distention, redistribution of residual fluid, and differentiation of fecal material from 
polyps because visualization of mobility of a filling defect implies residual fecal material.[3] 
Before prone image acquisition, another scout scan is obtained with additional gaseous 
insufflation if needed.[2,3] 
 
 
Fig. 3. (A) Supine scout CT image and (B) 2D transverse CT colonographic image show 
adequate distension of colonic segments, allowing diagnostic examination.  
The i.v. administration of antispasmotic agents (buscopan, or glucagon) may improve 
colonic distention and reduce spasms. The general opinion is that IV spasmolytics should 
not be administered routinely, but can be used if patients experience pain, discomfort, or 
spasm.[2,43] 
Bowel distention may lead to perforation of the bowel in rare cases. In most of the reported 
cases, perforation occurred in symptomatic patients with acute inflammatory or stenotic 
colons.[2,30-32] 
4.3 Data acquisition 
CT scanning is ideally performed on a multi-detector computed tomography (MDCT) 
scanner in both the supine and the prone positions with a thin collimation. MDCT has 
several technical advantages over single-detector CT, including faster imaging times, 
reduced exposure to radiation and acquisition of multiple thin sections with nearly isotropic 
voxels.[2,3,7,11,22,23,43-46] Moreover, motion artifacts from respiration and peristalsis are 
decreased or eliminated with MDCT.[3] 
Thin sections are a prerequisite for high-quality multiplanar reformations (MPR) and 3D 
reconstructions. Near-isotropic imaging is already provided on a 4-row MDCT scanner with 
a detector configuration of 4 mm x 1 mm (minimal slice thickness of 1.25 mm), which allows 
scanning of abdomen during a 30-s breath-hold. With a 16-row or 64-row MDCT scanner, 
and a detector configuration of 16 mm x 0.75 mm or 64 mm x 0.6 mm, scanning is completed 
in 11-12 s or 6-7 s. Such datasets can be reconstructed as 1 mm sections overlapped every 0.7 
mm.[2] 
One of the major limitations of CT colonography is the relatively high radiation exposure, 
and thus, increasing attention has been focused on low-dose protocols. Because a thin 
collimation is necessary for CT colonography, dose reduction is widely achieved by 
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reducing the miliampere-seconds level. Generally useful exposure settings are 120kVp and 
50-100mAs in the prone and in supine positions.[2] Use of automated dose modulation 
techniques that adapt mAs values to patient anatomy should always be used, if these 
techniques are available on the CT scanner.[2,47] 
4.4 Data analysis 
Image processing and interpretation is performed on a commercially available computer 
workstation equipped with dedicated CT colonography software. In addition to 2D axial 
and MPR in a cine mode, such systems provide an interactive, manual, mouse-driven, 
automated or semi-automated, virtual “fly-trough” of the surface- or volume-rendered 3D 
intraluminal images.[2] 
There are two primary techniques for data interpretation: a primary 2D or a primary 3D 
approach (Figure 4). The combined use of both, 2D and 3D visualization techniques has 
been shown to be superior to the evaluation of single 3D or 2D views, with regard to 
sensitivity and specificity.[2,48,49] 
 
 
Fig. 4. (A) 2D sagittal CT colonographic image and (B) 3D CT colonographic image show a 
normal smooth colonic  wall. 
With a primary 2D technique, the entire colon is evaluated by using the transverse source 
images. This is accomplished at a specialized workstation, and the colon is “tracked” from 
the rectum to the cecum by using the supine images. This is facilitated by cine scrolling of 
images through the entire colon. If an abnormality is detected; coronal, sagittal, and 
endoluminal reformatted images are used to help determine whether the abnormality is a 
polyp, fold, or fecal matter.[3] Primary 2D evaluation provides information about the 
attenuation of findings during the search process and is more time-efficient.[2,48,50] 
Primary 3D evaluation is based on 3D virtual endoscopy in an antegrade and retrograde 
fashion. Primary 3D evaluation was shown to be sensitive for polyp detection because both, 
the conspicuity, especially of small and medium-sized polyps, and the duration of 
visualization, are increased.[2,38] The primary 3D evaluation is time-consuming because it 
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must be performed in antegrade and retrograde fashion for the perception of lesions behind 
haustral folds. Collapsed segments must be evaluated alternatively, by 2D planar images.[2] 
There are several limitations of the primary 3D evaluation. First, there are blind spots in the 
colon when 3D endoluminal views are used.[3,51] Several workstations currently have the 
capacity to display these blind areas to the reviewer after the 3D navigation is performed, 
which should allow a more complete visualization of the colon when a primary 3D 
interpretation technique is used. These are virtual dissection, panaromic, unfolded cube 
projection, and translucency rendering.[2,3,51] A second limitation of 3D endoluminal fly-
through imaging is that the centerline cannot be generated when segments of the colon are 
not well distended. Third, in over-distended segments the centerline may jump to an 
adjacent distended loop.[3] 
In addition to polyp size, segmental location, morphologic type (pedunculated, sessile, or 
flat), and diagnostic confidence score are recorded for each polyp.[52] For a number of 
reasons, the presence of diminutive lesions should not be mentioned. Tiny polyps are not 
clinically relevant, yet mentioning them can cause undue anxiety in patients and referring 
physicians.[38,52-54] Most diminutive “lesions” detected at CT colonography cannot be 
found at subsequent CC, representing either false-positive CT colonography findings or 
false-negative CC findings.[52] 
There are three criteria to use with 2D and 3D imaging that help distinguish residual fecal 
material from polyps. First, the presence of internal gas or areas of high attenuation suggest 
that a lesion is residual fecal material, since colorectal polyps are homogeneous in 
attenuation.[3,55,56] The second criterion is morphology. Morphologically, polyps and small 
cancers have rounded or lobulated smooth borders. Residual fecal material may have a 
similar morphology. However, if a lesion shows geometric or irregularly angled borders, it 
almost always represents residual fecal material.[3,50] Mobility of a lesion is the third 
criterion. Stool tends to move to the dependent surface of the colonic mucosa when a patient 
is turned from the supine to the prone position.[3,56,57] Polyps maintain their position with 
respect to the bowel surface (ventral or dorsal) regardless of the patient’s position. However, 
caution is required since pedunculated polyps and sessile polyps in segments of the colon 
with a long mesentery appear to be mobile.[3,58] 
Computer-aided detection (CAD) systems are software programs that automatically 
highlight polyp “candidates” and thus support the radiologist by pointing out possible 
abnormalities that may otherwise have been missed. Based on morphologic and attenuation 
characteristics, the reader then decides whether the “candidate lesion” is a true- or a false-
positive finding. Recent CAD algorithms showed a promising performance, with a reported 
a CAD sensitivity of 89,3% for adenomas ≥10 mm.[2,59] 
5. Findings 
One of the most common findings detected with CT colonography is diverticular disease. 
On 2D CT colonography images (Figure 5A), diverticula appear as air-filled outpouchings of 
the colonic wall. On the 3D virtual endoscopic images (Figure 5B), the diverticular orifice 
can be recognized as a complete dark ring.[2,60] 
Polyps are the most common benign lesions of the colon. The risk of malignant 
transformation increases with the size of the polyp. On 2D plane images (Figure 6A and 6C), 
polyps have homogenous, soft tissue attenuation. On 3D virtual endoscopic images (Figure 
6B and 6D), polypoid lesions present as a sessile or stalked, round, oval, or lobulated 
 
 
Endoscopic Procedures in Colon and Rectum 
 
100 
reducing the miliampere-seconds level. Generally useful exposure settings are 120kVp and 
50-100mAs in the prone and in supine positions.[2] Use of automated dose modulation 
techniques that adapt mAs values to patient anatomy should always be used, if these 
techniques are available on the CT scanner.[2,47] 
4.4 Data analysis 
Image processing and interpretation is performed on a commercially available computer 
workstation equipped with dedicated CT colonography software. In addition to 2D axial 
and MPR in a cine mode, such systems provide an interactive, manual, mouse-driven, 
automated or semi-automated, virtual “fly-trough” of the surface- or volume-rendered 3D 
intraluminal images.[2] 
There are two primary techniques for data interpretation: a primary 2D or a primary 3D 
approach (Figure 4). The combined use of both, 2D and 3D visualization techniques has 
been shown to be superior to the evaluation of single 3D or 2D views, with regard to 
sensitivity and specificity.[2,48,49] 
 
 
Fig. 4. (A) 2D sagittal CT colonographic image and (B) 3D CT colonographic image show a 
normal smooth colonic  wall. 
With a primary 2D technique, the entire colon is evaluated by using the transverse source 
images. This is accomplished at a specialized workstation, and the colon is “tracked” from 
the rectum to the cecum by using the supine images. This is facilitated by cine scrolling of 
images through the entire colon. If an abnormality is detected; coronal, sagittal, and 
endoluminal reformatted images are used to help determine whether the abnormality is a 
polyp, fold, or fecal matter.[3] Primary 2D evaluation provides information about the 
attenuation of findings during the search process and is more time-efficient.[2,48,50] 
Primary 3D evaluation is based on 3D virtual endoscopy in an antegrade and retrograde 
fashion. Primary 3D evaluation was shown to be sensitive for polyp detection because both, 
the conspicuity, especially of small and medium-sized polyps, and the duration of 
visualization, are increased.[2,38] The primary 3D evaluation is time-consuming because it 
 
Virtual Colonoscopy: Indications, Techniques, Findings 
 
101 
must be performed in antegrade and retrograde fashion for the perception of lesions behind 
haustral folds. Collapsed segments must be evaluated alternatively, by 2D planar images.[2] 
There are several limitations of the primary 3D evaluation. First, there are blind spots in the 
colon when 3D endoluminal views are used.[3,51] Several workstations currently have the 
capacity to display these blind areas to the reviewer after the 3D navigation is performed, 
which should allow a more complete visualization of the colon when a primary 3D 
interpretation technique is used. These are virtual dissection, panaromic, unfolded cube 
projection, and translucency rendering.[2,3,51] A second limitation of 3D endoluminal fly-
through imaging is that the centerline cannot be generated when segments of the colon are 
not well distended. Third, in over-distended segments the centerline may jump to an 
adjacent distended loop.[3] 
In addition to polyp size, segmental location, morphologic type (pedunculated, sessile, or 
flat), and diagnostic confidence score are recorded for each polyp.[52] For a number of 
reasons, the presence of diminutive lesions should not be mentioned. Tiny polyps are not 
clinically relevant, yet mentioning them can cause undue anxiety in patients and referring 
physicians.[38,52-54] Most diminutive “lesions” detected at CT colonography cannot be 
found at subsequent CC, representing either false-positive CT colonography findings or 
false-negative CC findings.[52] 
There are three criteria to use with 2D and 3D imaging that help distinguish residual fecal 
material from polyps. First, the presence of internal gas or areas of high attenuation suggest 
that a lesion is residual fecal material, since colorectal polyps are homogeneous in 
attenuation.[3,55,56] The second criterion is morphology. Morphologically, polyps and small 
cancers have rounded or lobulated smooth borders. Residual fecal material may have a 
similar morphology. However, if a lesion shows geometric or irregularly angled borders, it 
almost always represents residual fecal material.[3,50] Mobility of a lesion is the third 
criterion. Stool tends to move to the dependent surface of the colonic mucosa when a patient 
is turned from the supine to the prone position.[3,56,57] Polyps maintain their position with 
respect to the bowel surface (ventral or dorsal) regardless of the patient’s position. However, 
caution is required since pedunculated polyps and sessile polyps in segments of the colon 
with a long mesentery appear to be mobile.[3,58] 
Computer-aided detection (CAD) systems are software programs that automatically 
highlight polyp “candidates” and thus support the radiologist by pointing out possible 
abnormalities that may otherwise have been missed. Based on morphologic and attenuation 
characteristics, the reader then decides whether the “candidate lesion” is a true- or a false-
positive finding. Recent CAD algorithms showed a promising performance, with a reported 
a CAD sensitivity of 89,3% for adenomas ≥10 mm.[2,59] 
5. Findings 
One of the most common findings detected with CT colonography is diverticular disease. 
On 2D CT colonography images (Figure 5A), diverticula appear as air-filled outpouchings of 
the colonic wall. On the 3D virtual endoscopic images (Figure 5B), the diverticular orifice 
can be recognized as a complete dark ring.[2,60] 
Polyps are the most common benign lesions of the colon. The risk of malignant 
transformation increases with the size of the polyp. On 2D plane images (Figure 6A and 6C), 
polyps have homogenous, soft tissue attenuation. On 3D virtual endoscopic images (Figure 
6B and 6D), polypoid lesions present as a sessile or stalked, round, oval, or lobulated 
 
 




Fig. 5. The appearance of diverticula on (A) the 2D axial CT colonographic image (arrow) 
and (B) the 3D CT colonographic image (arrowheads). 
 
 
Fig. 6. (A) The appearance of a stalked polyp of the assending colon on 2D axial CT 
colonographic image. (B) Translucency rendering view shows a homogenous red bulging 
revealing the polyp. (C) The appearance of stalked polyps on 2D coronal CT colonographic 
image (arrowheads). (D) 3D CT colonographic image shows stalked (arrows) and sessile 
(arrowheads) polyps. 
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intraluminal filling defect. Typically, the margin to the normal mucosa is displayed as an 
incomplete ring shadow.[2,61] Flat polyps are defined as lesions with a height less than 50% 
of the lesion width. In CT colonography, flat polyps appear as a fairly circumscribed area of 
mild wall thickening with homogenous soft tissue attenuation. Sometimes a mild nodularity 
is found on the surface by 3D endoluminal images.[2,62] 
Lipomas are the most common submucosal lesions in the colon (especially common on the 
ileocecal valve). On 2D plane images, lipomas are present as homogenous fatty lesions. On 
3D virtual endoscopic images, lipomas are present as a sessile or pedunculated polpoid 
intraluminal filling defect, most often with a smooth surface. In general, small lipomas need 
no further treatment; only large lipomas require endoscopic resection because they can lead 
to intusseption.[2,61] 
Colorectal cancer is the most common colonic primary tumour. Colorectal cancer(Figure 7) 
typically shows extensive focal polypoid, asymmetric, or circular wall thickening with short 
extension (<5cm), especially with shoulder formation.[2,60,63] Pericolonic lymph nodes and 
distant metastases are signs of progression of the disease and can be evaluated using 2D 







Fig. 7. (A) 2D axial CT colonographic image shows circular wall thickening in the rectum 
(arrowheads). (B) 3D CT colonographic image shows an irregular, circular, stenotic filling 
defect. 
6. Pitfalls 
CT colonography has a number of potential pitfalls. Some pitfalls, such as prominent and 
complex folds, diverticular fold thickening, and shifting of pedunculated polyps, present 
more of a problem at 2D evaluation. Other pitfalls, such as annular masses, submucosal or 
extrinsic lesions, and impacted diverticula, are more an issue at 3D evaluation. With a 
biphasic interpretive approach, most pitfalls are easily recognized because of the 
complementary nature of the 2D and 3D displays.[52] 
 




Fig. 5. The appearance of diverticula on (A) the 2D axial CT colonographic image (arrow) 
and (B) the 3D CT colonographic image (arrowheads). 
 
 
Fig. 6. (A) The appearance of a stalked polyp of the assending colon on 2D axial CT 
colonographic image. (B) Translucency rendering view shows a homogenous red bulging 
revealing the polyp. (C) The appearance of stalked polyps on 2D coronal CT colonographic 
image (arrowheads). (D) 3D CT colonographic image shows stalked (arrows) and sessile 
(arrowheads) polyps. 
 
Virtual Colonoscopy: Indications, Techniques, Findings 
 
103 
intraluminal filling defect. Typically, the margin to the normal mucosa is displayed as an 
incomplete ring shadow.[2,61] Flat polyps are defined as lesions with a height less than 50% 
of the lesion width. In CT colonography, flat polyps appear as a fairly circumscribed area of 
mild wall thickening with homogenous soft tissue attenuation. Sometimes a mild nodularity 
is found on the surface by 3D endoluminal images.[2,62] 
Lipomas are the most common submucosal lesions in the colon (especially common on the 
ileocecal valve). On 2D plane images, lipomas are present as homogenous fatty lesions. On 
3D virtual endoscopic images, lipomas are present as a sessile or pedunculated polpoid 
intraluminal filling defect, most often with a smooth surface. In general, small lipomas need 
no further treatment; only large lipomas require endoscopic resection because they can lead 
to intusseption.[2,61] 
Colorectal cancer is the most common colonic primary tumour. Colorectal cancer(Figure 7) 
typically shows extensive focal polypoid, asymmetric, or circular wall thickening with short 
extension (<5cm), especially with shoulder formation.[2,60,63] Pericolonic lymph nodes and 
distant metastases are signs of progression of the disease and can be evaluated using 2D 







Fig. 7. (A) 2D axial CT colonographic image shows circular wall thickening in the rectum 
(arrowheads). (B) 3D CT colonographic image shows an irregular, circular, stenotic filling 
defect. 
6. Pitfalls 
CT colonography has a number of potential pitfalls. Some pitfalls, such as prominent and 
complex folds, diverticular fold thickening, and shifting of pedunculated polyps, present 
more of a problem at 2D evaluation. Other pitfalls, such as annular masses, submucosal or 
extrinsic lesions, and impacted diverticula, are more an issue at 3D evaluation. With a 
biphasic interpretive approach, most pitfalls are easily recognized because of the 
complementary nature of the 2D and 3D displays.[52] 
 




CT colonography is highly sensitive for colorectal cancer, especially when both cathartic and 
tagging agents are combined in the bowel preparation. Given the relatively low prevalence 
of colorectal cancer, primary CT colonography may be more suitable than CC for initial 
investigation of suspected colorectal cancer. 
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1. Introduction  
Hemodynamically unstable lower gastrointestinal bleeding is a challenge for on-call teams, 
especially when symptom severity leaves no time to apply diagnostic techniques. While 
colonoscopy and gastroduodenoscopy performed before arteriography or scintigraphy are 
considered the usual diagnostic tools, capsule endoscopy provides new options in patients 
with stable digestive bleeding that is difficult to locate. Computed tomography (CT) 
angiography is beginning to replace arteriography and labeled red cell scintigraphy. 
Nonetheless, the primary objective is to locate the bleeding source, and, in cases where this 
must be located by surgery, intraoperative enteroscopy using a colonoscopy can be applied. 
In fact, intraoperative enteroscopy is considered effective from a diagnostic and therapeutic 
perspective in selected patients, for example, those with severe gastrointestinal bleeding of 
no apparent etiology and for whom other diagnostic techniques are ineffective or 
unavailable. This technique ensures that surgical resection is minimally invasive. 
2. Etiology of severe gastrointestinal bleeding 
Massive gastrointestinal bleeding is often associated with the upper digestive tract. 
Therefore, in suspected upper gastrointestinal bleeding, the first technique to be applied is 
esophagogastroduodenoscopy, which makes it possible to diagnose lesions as far as the 
angle of Treitz. If the patient does not present hematemesis and upper endoscopy findings 
are normal, the diagnosis is lower gastrointestinal bleeding. 
Colonoscopy is one of two tools used to assess lower gastrointestinal bleeding. Some studies 
have shown that it can identify the bleeding source in slightly more than 70% of patients. 
Colonoscopy can be performed as an emergency technique or as an elective technique, 
depending on hemodynamic status, and in many cases it enables us to diagnose and treat a 
lesion endoscopically. However, in the case of massive bleeding, the effectiveness of 
colonoscopy could be limited by its poor visibility. 
In fact, massive lower gastrointestinal bleeding with an unidentified source is one of the 
most severe problems faced by a Digestive Service or General Surgery Service. Bleeding of 
the small intestine is rare, accounting for 2-10% of all cases of gastrointestinal bleeding. The 
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most common causes of gastrointestinal bleeding are vascular malformations (especially 
angiodysplasia), tumors (including lymphoma), ulcers (caused by nonsteroidal anti-
inflammatory drugs, Crohn disease, and enteritis), Meckel diverticulum, diverticulum of the 
jejunum and ileum, aortoenteric fistula, hemobilia, and pancreatic bleeding (Table 1). 
Meckel diverticulum should always be taken into consideration in children and young 
adults. However, in adults and elderly people, the most frequent causes are vascular lesions 
followed by tumors, irrespective of the presentation of the bleeding.  
 
Upper gastrointestinal tract   Small bowel Large bowel 




Diverticular disease  
17-40% 
Gastritis/duodenitis  
 5-30% Jejunoileal diverticula   
Arteriovenous malformations  
2-30% 
Esophageal varices  
 6-21% Meckel diverticulum 
Colitis (ischemia, IBD, 
radiation)  
 9-21%  
Mallory-Weiss tear 
 3-15% Benign/malignant neoplasm 




Post-polypectomy bleeding      
3-6% 
Gastric cancer  
 2-3% Enteritis 
Anorectal conditions    
4-10%       
Dieulafoy lesion  




Aortoduodenal fistula  




Table 1. Causes of acute massive gastrointestinal bleeding.  
(IBD, inflammatory bowel disease) 
3. Radiologic evaluation of severe gastrointestinal bleeding 
In cases of massive lower gastrointestinal bleeding where it is not possible to diagnose the 
cause, other diagnostic methods should be applied to identify the bleeding source. The 
primary objective of traditional radiologic tests, including labeled red blood cell 
scintigraphy and angiography, is localization of the bleeding source so that therapeutic 
embolization of the feeding vessel can be performed. Novel imaging studies such as CT 
enterography and CT angiography not only allow localization of the source and diagnosis of 
the underlying etiology of gastrointestinal bleeding, but also facilitate luminal and 
extraluminal evaluation of the small bowel. 
Mesenteric arteriography is widely used to assess massive gastrointestinal bleeding, although 
it is also used to assess bleeding of obscure origin that cannot be identified by endoscopy. It 
is very effective for detecting arteriovenous malformations and tumors—these lesions 
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present a characteristic vascular pattern—and, in active bleeding, it identifies the bleeding 
source in 50% of patients. It has the added advantage that it can embolize the feeding artery 
and control bleeding, thus stabilizing the patient. This is particularly important in many 
high-risk surgical patients, since the technique is safe, morbidity and mortality are low, and 
ischemia and rebleeding are very uncommon. 
Helical CT with intravenous contrast or CT angiography is similar to arteriography, although 
it could produce false negatives due to the intermittent nature of bleeding. In cases of 
massive bleeding, diagnostic efficacy (extravasated contrast medium in the intestine during 
the arterial phase) reaches 88.5%, with a sensitivity of 90.9% and a specificity of 99%. The 
location of the source of extravasation on the CT angiogram corresponds exactly to the 
results of arteriography. Once the bleeding source is found, therapeutic angiography can be 
applied or alternative treatment can be selected depending on the findings.  
CT enterography and CT enteroclysis are dedicated examinations of the small bowel that allow 
the detection of vascular lesions and tumors. The technique optimizes luminal distension by 
administering larger volumes of neutral oral contrast via peroral (CT enterography) or 
nasojejunal intubation (CT enteroclysis), thereby allowing optimal visualization of mucosal 
and vascular detail. The evaluation of gastrointestinal bleeding usually involves multiphasic 
imaging (arterial, enteric, and delayed imaging, with or without precontrast images). 
Typical features of angiodysplasia on CT include the presence of a vascular tuft in the 
arterial phase and an early draining mesenteric vein. Active bleeding may also be identified 
on multiphasic imaging by the increasing accumulation of contrast in the small bowel 
lumen. CT enterography has the added advantage being able to identify small bowel 
strictures/obstruction prior to capsule endoscopy and provides important information on 
luminal and extraluminal findings that cannot be detected on capsule endoscopy.  
Lastly, we must remember other radiologic tests such as 99mTc red blood cell scintigraphy, a 
noninvasive examination that can detect bleeding with a loss lower than that observed with 
arteriography (0.1-0.4 ml/min). It can identify an indeterminate source in 20-40% of 
patients—this percentage rises to 68% when there is active bleeding—and is generally used 
to detect the source of intestinal bleeding and improve the management of patients with 
active bleeding, thus making it possible to choose the best therapeutic option, which is often 
arteriography. 99mTc red blood cell scintigraphy is the technique of choice in the diagnosis 
of Meckel diverticulum. An additional approach in this disease is technetium 99m 
pertechnetate scintigraphy (MeckelScan), which makes it possible to detect ectopic gastric 
mucosa with 64-100% sensitivity; however, its main disadvantage is the rapid isotope 
washout when there is active gastrointestinal bleeding. 
4. Endoscopic evaluation of severe gastrointestinal bleeding  
In the last few years, several advances have been made in endoscopy techniques applied for 
the diagnosis and treatment of diseases of the gastrointestinal tract. However, few of these 
advances are of benefit in diseases of the small bowel, because access with an endoscope 
remains difficult. Since the introduction of push endoscopy in 1971, only the proximal 
jejunum could be examined to about 50 cm from the ligament of Treitz. Examination of the 
small intestine has improved with more recent discoveries, including include capsule 
endoscopy, double-balloon enteroscopy, and spiral enteroscopy. Capsule endoscopy as a 
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diagnostic method has revealed a new challenge, namely, determination of the confirmatory 
and therapeutic approach to the lesions found.  
Gastroscopy and colonoscopy are both available in all hospitals. If these techniques do not 
confirm the diagnosis in patients with massive low gastrointestinal bleeding, we must 
determine the cause of the lesion and decide how to diagnose and treat it. Bleeding of the 
small intestine has been a complex diagnostic problem for many years, because this organ 
could not be explored using endoscopy and the cause of the bleeding was difficult to locate 
using more conventional techniques. Severe active intestinal bleeding can be diagnosed 
using radiological techniques (see above) and endoscopic techniques, including push 
enteroscopy, capsule endoscopy, balloon-assisted enteroscopy, spiral enteroscopy, and 
endoscopy-assisted laparoscopy-laparotomy (intraoperative enteroscopy). However, these 
techniques are only available in tertiary hospitals. Secondary hospitals do not usually have 
all of the techniques described and the distance to the nearest reference hospital must be 
taken into account. Consequently, it is necessary to act more effectively and invasively in 
extreme cases (eg, intraoperative enteroscopy). Below, we provide a brief summary of the 
different endoscopic techniques. 
Push enteroscopy. For several years, push enteroscopy has been the most widely used and 
effective diagnostic procedure for direct evaluation of the intestinal mucosa. One of its 
limitations is that only the proximal jejunum can be visualized, leaving most of the small 
intestine unexamined. The technique provides a diagnosis in a large percentage of patients 
with undiagnosed gastrointestinal bleeding (Figure 1) and enables us to treat it, especially in 









Fig. 1. Stromal tumor in the jejunum diagnosed using push enteroscopy. 
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Video capsule endoscopy. Visual capsule endoscopy is a noninvasive technique that has 
proven effective in the evaluation of patients with suspected bleeding of the small intestine. 
It enables us to visualize the whole small intestine. Several studies have proven the 
superiority of this technique over other conventional modalities, including barium x-ray. 
However, the real significance of specific findings and the false negatives caused by food 
and liquids, the lack of distension or propulsion, and the rapid passage through large 
segments are limitations that have yet to be resolved. The main disadvantage of the capsule 
is that it is an exclusively diagnostic technique, with limited capacity for identifying the 
lesion with accuracy and with no possibility of obtaining biopsies or carrying out 





Fig. 2. Capsule endoscopy image of bleeding with a clot in the small intestine. 
Balloon-assisted enteroscopy  
a. Double-balloon enteroscopy. Double-balloon enteroscopy represents a huge advance. In 
theory, the whole small intestine can be examined, biopsies taken, and treatment 
administered, or, if this is not possible, the lesion can be marked. This technique makes 
it possible to reach more distal sections of the small intestine, although it rarely 
manages to reach the distal ileum; therefore, enteroscopy requires the combination of 
the antegrade and retrograde approaches for an examination of the whole intestine. 
Double-balloon enteroscopy is considered a safe and well-tolerated technique for the 
diagnosis and treatment of diseases of the small intestine. 
b. Single-balloon enteroscopy. Single-balloon enteroscopy is the latest balloon-assisted 
endoscopic technique for the evaluation and management of small bowel disorders. It 
involves inserting a balloon catheter through the working channel of a colonoscope and 
moving the endoscope progressively along the small intestine by inflating and deflating 
the balloon. This technique has proven safe and effective, and in some cases (up to 25%) 
has made it possible to perform a complete enteroscopy. 
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Spiral enteroscopy. Spiral enteroscopy allows for advancement and withdrawal of the 
enteroscope through the small bowel by using clockwise and counterclockwise movements, 
respectively. The distal end of the overtube is positioned 25 cm from the tip of the 
enteroscope and locked into place. The system is then advanced to the ligament of Treitz 
with gentle rotation. The collar is subsequently unlocked, and the enteroscope is advanced 
past the ligament of Treitz. The overtube is then advanced using clockwise rotation until 
pleating of the small bowel no longer occurs over the enteroscope. The enteroscope is then 
unlocked and advanced to facilitate further advancement into the small bowel. In order to 
ease withdrawal of the enteroscope, the overtube is rotated in a counterclockwise direction. 
The insertion depth is 262±57 cm, and mean examination time is 33-35 minutes. This 
endoscopic modality also makes it possible to adopt a therapeutic approach, including 
biopsy, hemostasis, and polypectomy. Only minor complications (sore throat and minimal 
mucosal trauma) have been reported thus far and no perforations have been observed. Some 
studies have compared spiral enteroscopy with double-balloon enteroscopy and report that 
double-balloon enteroscopy has a better diagnostic yield. 
Intraoperative enteroscopy. Intraoperative enteroscopy by insertion of an endoscope through 1 
or more enterotomies has a high diagnostic yield, identifying lesions in 70-100% of patients. 
The technique is started once the surgeon has performed a laparotomy, in general to gain 
access to the small intestine. Once the small intestine is exposed, 2 or more enterotomies are 
made and the colonoscope is inserted with the surgeon’s help. Intraoperative enteroscopy 
makes it possible to examine the whole small intestine, always with the assistance of a 
surgeon. It is limited by its high morbidity (intestinal wall hematoma, mesenteric 
hemorrhage, prolonged ileus, intestinal ischemia, and perforation); therefore, this procedure 
is reserved for patients with persistent bleeding and high transfusional requirements in 
whom diagnosis cannot be established by other means (Figure 3). A variation of the 
technique involves oral insertion of the enteroscope during surgery, which makes it possible 
to see 93% of the ileum and establish a diagnosis in almost 60% of cases. Its drawback is the 
considerable operative morbidity in a relatively high proportion of cases (serosal tear or 
ruptured mesenteric vein).  
 
 
A.                                                                       B. 
Fig. 3. Jejunal aneurysm. A. Endoscopic image using intraoperative enteroscopy; B. 
Microscopic image showing caliber-persistent artery with mucosal rupture (x20) 
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5. Management of severe gastrointestinal bleeding 
Severe bleeding in the small intestine is extremely problematic for a hospital. First, patient 
instability limits the diagnostic methods at our disposal. Second, not all hospitals have the 
diagnostic and therapeutic methods described here. Only tertiary hospitals can apply all the 
techniques described. Our objective should be to improve therapeutic options using the 
tools generally available in the hospital. 
Consequently, when faced with a hemodynamically unstable patient who cannot be 
transferred, we must use all available diagnostic approaches, beginning with standard 
techniques (gastroscopy, colonoscopy, and helical CT) and moving on to other available 
methods such as intraoperative enteroscopy, which is indicated in acute intestinal bleeding 
of unknown origin, either when alternative techniques fail or when the patient’s condition 
makes it impossible to apply them. Although this technique is very effective, in a small 
percentage of patients it may be impossible to find the bleeding source, especially when this 
is vascular and small. Nevertheless, it is still considered the reference technique, enabling 
accurate location of the lesion and minimally invasive surgery, with a lower number of 
recurrences.   
It is very important to examine the whole small intestine, even once a lesion has been 
identified, as the presence of concomitant lesions could cause subsequent problems. 
Location of the lesion enables minimally invasive resection, with lower morbidity and 
mortality. In some cases with active bleeding, hemostasis can be restored using endoscopy. 
Once the patient is stable, the lesion can be resected. 
Our approach to severe bleeding in the small intestine is to perform 
esophagogastroduodenoscopy and colonoscopy in order to rule out lesions in the 
corresponding areas. If the patient is sufficiently stable, capsule endoscopy can be 
performed and, depending on the location of the lesion, push enteroscopy or balloon-
assisted enteroscopy can be used for therapy. If the lesion is not accessible for endoscopic 
treatment, a medical approach (embolization) or surgical approach should be adopted. If the 
patient presents massive bleeding or is hemodynamically unstable, CT angiography and/or 
arteriography are advised to locate and treat the cause of the bleeding. Intraoperative 
enteroscopy should be reserved for severe recurrent bleeding with high transfusion 
requirements, inaccessible lesions, or unavailability of balloon-assisted enteroscopy.  
6. Summary  
Total intraoperative enteroscopy is effective for the diagnosis of severe gastrointestinal 
bleeding of unknown origin. It enables more localized and efficacious surgery when other 
diagnostic techniques—arteriography, labeled red cell scintigraphy, and endoscopic 
capsule—cannot be performed. Furthermore, total intraoperative enteroscopy can be 
performed in selected cases at any hospital without the need for advanced technology. 
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1. Introduction 
In general, local excision (LE) is one of the many techniques available for rectal cancer 
treatment. When this technique is used on a selective group of tumors, the survival rates are 
similar to those of patients submitted to abdominal surgery resections. In patients with high 
surgical risk, the LE shows smaller morbidity and mortality, with also less anorectal, urinary 
and sexual function alterations [1-3].  
The most commonly used techniques for LE include the colonoscopy with polypectomy 
loops, conventional transanal excision (CTE), transanal endoscopic microsurgery (TEM) and 
the posterior access surgery [4-7]. 
For local rectal cancer surgical treatment, the TEM has been used since 1983 with positive 
results, low recurrence rates and less post-operation complications compared to 
conventional procedures. The posterior access surgery presents a high complication rate and 
offers no advantage for villous tumor ressection that may be excised by transanal access 
techniques [8,9].  
The pre-operative evaluation of candidates for a LE is of importance, since one must be 
certified that possible cure will be achieved by one of the proposed local surgical techniques. 
The rectal touch, rectoscopy, endorectal ultrasound and nuclear magnetic resonance are 
useful on the diagnosis and to determine the tumor stage on the pre- and post-operative 
times [10-14].Selection criteria represent a relevant factor on the LE success. However, 
specific criteria for these tumors selection are still not universally accepted  [2,, 15-18].  Some 
parameters are indicated as requisites for determination of which tumors are theoretically 
adequate for transanal LE: smaller than 4 cm, mobile, restricted to only one quadrant, placed 
up to 10 cm of the anorectal line, well differentiated, with no lymphovascular or 
lymphonodal invasion, and endoscopic, tomographic and nuclear magnetic resonance 
evaluations that demonstrate that lesions are T1, T2 with no metastatic lesions [19]. 
The results of local treatment of rectal cancer are of difficult interpretation because the 
literature brings retrospective analysis of heterogeneous groups of patients, with different 
surgical indications and adjuvant therapies, while it lacks prospective homogeneous studies 
[1,20]. 
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In our environment, the endoscopic transanal or surgical procedures for rectal tumors up to 
15 cm of the anorectal line depend on the surgeon and/or endoscopist experience, on the 
equipment available and on the type of lesion. We use the CTE performed with anal 
retractors and basic surgical instruments for treatment of rectal lesions on the distal 1/3. The 
colonoscopy with polypectomy loops has allowed the resections of higher lesions, located 
on middle and superior rectum, on an appropriate manner.  
The challenge comes when there is a benign, but of large volume and extension lesion, with 
or without carcinoma focuses, or on non invasive malignant neoplasms, located on middle 
or superior rectum, with no possibility for an endoscopic  excision by colonoscopy and that 
can not be reached by CTE.  In these circumstances, there is an indication for a transanal 
endoscopic surgery. In the absence of economic viability for the material acquisition, and 
surgical experience with complex methods like the TEM used by Buess [21,22] as also for the 
videoendoscopic transanal microsurgery (VETM) used by Swanstron [23]  or the 
videoendoscopic transanal microsurgery without inflations  [17,24-26] we have idealized, 
researched and executed a more simple technique, so called Transanal Endoscopic 
Operation (TEO).  
In the present study, the main objective is to present the TEO as a method for local transanal 
excision of selected rectal lesions, and to present our clinical and surgical experience with 
this new method, comparing the results with those obtained with the well established 
endoscopic techniques available in the literature.  
2. Casuistic and methods 
We have designed a cylindrical rectoscope with 4 cm in diameter, with a 1 cm wide flap in 
one of the extremities, equidistantly perforated. In this flap, we attached a small (2 cm long) 
rectangular piece, of round contours, with a hole on the extremity and an aluminum screw 
on the base, used to fix it to the rectoscope flap (Fig. 1). This small piece is mobile and it is 
positioned in the way that its perforated extremity locates on the rectoscope lumen; in this 
position, the base screw is pressed and is used to hold the fiberlight cable, which will lighten 
the operative field (Fig. 2). The flap holes are used to fix the rectoscope with surgical thread 
to the anal border. In this way, with the rectoscope fixed to the anal border and the light 
correctly positioned, there is no need for an assistant surgeon for this task. 
 
 
Fig. 1. Proctoscope presentation. Perforated flap and rectangular piece, of round contours, 
and the proctoscope guide 
 





Fig. 2. Positioned proctoscope, together with the fixed fiberlight cable. 
The equipment extremity which will be introduced has a beveled aspect and round borders 
(Fig 3). This format is very important for the essence of the procedure: since there is no 
inflations, this mechanical disposition allows the surgeon to position the rectoscope on the 
way that the longest part of this extremity holds the contra-lateral mucosa when the surgeon 
identifies the lesion, which will be now located on the center of the operative field.  
 
 
Fig. 3. Distal proctoscope end, showing the beveled aspect and round borders. 
It is also part of the equipment a guide which will be positioned inside the rectoscope on the 
moment of its anal insertion (Fig. 1-4). It is composed of an aluminum cable with a round 
tip, being its caliber obviously smaller than the rectoscope´s one. On the tip of the guide 
there are two longitudinal ridges for air passage, avoiding the vacuum formation and the 
rectal mucosa aspiration during its removal from the rectoscope after its introduction. 
Initially, only one 12 cm long rectoscope was built. After our experience with the equipment, 
another one, 20 cm long was built, once higher rectal lesions were also able to be removed 
with this method. Also, a smaller rectoscope (7 cm long) was built, which was ideal for 
excision of tumors located up to 5-6 cm from the anal border. Independently of the length, 
the rectoscopes contain all components described in this text. 
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Fig. 4. Surgical proctoscopes (12 and 20 cm long) and respective guides. 
Acrylic was chosen as the main equipment material, with small components in aluminum, 
for the following reasons: both these materials are easy to acquire, are of low costs, are easily 
manipulated by the staff who build the equipment in our facility and also because they are 
easy to be cleaned, disinfected and sterilized. More recently, a stainless steel rectoscope was 
built, more resistant and not transparent like the acrylic ones, with the advantage that the 
surgical field was lighter during its use (Fig. 5). 
 
 
Fig. 5. Stainless steel rectoscopes 
The accessories used for the TEO, together with the surgical rectoscope include a light 
source with a fiberlight cable (most of the times we used the light source from a 
videolaparoscopy equipment), an electrocautery with long pens and, when possible, also 
with thin tips to facilitate the lesion visualization, and forceps for holding and aspiration, 
used simultaneously. Other important components are: polypectomy loops, forceps for 
holding and presenting lesions (graspers), some of them from the videolaparoscopy 
equipment, long needle holders (conventional or from the videolaparoscopy equipment), 
long and thin aspiration tubes, syringes and suture threads.  
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2.1 Technical steps of the Transanal Endoscopic Operation (TEO) 
Patients were prepared as for any other colorectal surgery: in the hospital, they receive clear 
liquid diet two days before the surgery, intestinal clearance with 10 % glycerin (retrograde 
preparation) or the oral use of osmotic laxatives (10 % manitol or sodium phosphate; 
anterograde preparation). Also, they are submitted to antibiotic therapy, beginning with i.v. 
metronidazole and ceftriaxona at the hospital and oral ciprofloxacin up to 7 days after 
surgery. All patients were regionally anaesthetized either by peridural (epidural) or spinal 
anesthesia, associated with i.v. sedation.  
Operatory position was dependent on the rectal lesion location; posterior tumors were 
accessed through the litotomy position and anterior tumors were accessed though the 
“Jacknife” position. 
After positioning the patient, antisepsis is done with topic PVP-I, surgical sheaths are 
placed, surgical tables and adequate surgical instruments are positioned, equipments such 
as light source, electrocautery and vacuum are checked and the anal dilation is carefully and 
manually performed, with topic lubrificant, until we get permeability for two fingers 
(usually the index and the middle fingers). The anus and anal canal are lubrified again with 
xylocaine 2% jelly before the rectoscope introduction. Two or three Allis forceps holding out 
the sphincters muscles might help the guide and the rectoscope penetration.  
With gentle movements, the complete equipment, guide and body, is completely introduced 
up to the flap (Fig. 6). The guide is removed and the light source is connected to its place 
next to the flap. With an adequate view of the rectal lumen, the endoscope is positioned the 
way that the best exposition and presentation of the lesion are achieved (Fig. 7). In this 
situation, the equipment is fixed with cotton thread to the anal border.  
 
 
Fig. 6. Final aspect of the proctoscope and guide, after the correct introduction. 
During the complete surgical procedure, saline irrigation and the electrocautery and 
vacuum are essential elements for the final result success. Observing the security limits 
(borders), adequate hemostasy and the resection deepness are also essential for a successful 
procedure.  
After the lesion removal, which must be correctly oriented for the pathologist observation 
and diagnosis, a revision of the wound is performed. The last procedures of the TEO are 
saline and PVP-I irrigation, hemostasy and suture, before the rectoscope removal.  
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Vesical catheterization was performed only when there was post-operatory urinary 
retention and only for patient relief. Patients were kept in the hospital until they could 
accept normal oral diet and present signs of normal intestinal function, usually for 24 to 48 





Fig. 7. Proctoscope surgically positioned and the correct presentation of the operatory field. 
2.2 Evaluation of patients submitted to the Transanal Endoscopic Operation (TEO) 
Eighty one patients submitted to the TEO, from August 2003 to February 2011 were 
included in the present study, being 36 patients from the Hospital São Paulo and 45 patients 
from the School of Medicine Hospital and Clinics, both in Ribeirão Preto City. The basic 
equipment and the surgeon was the same in all procedures. 
A protocol with personal data, clinical history, previous history, physical, proctological and 
other exams, the indications for the TEO, performed procedures and clinical outcome was 
studied based on patients´ hospital records. In this protocol, data on surgical time, lesion 
anal distance, hospitalization time, intra-and post-operatory complications, follow up time, 
recurrence rates and posterior resections data were also studied.  
Data obtained in this study was compared to data obtained by 39 different authors who 
used different techniques of TEO for transanal excision of rectal lesions. The metanalysis 
was used for the comparisons, a quantitative method whereby all data from all available 
studies of a determined subject are combined. Confidence intervals for proportions were 
obtained using the exact confidence interval for a proportion method [27]. Parameters 
analyzed by this method included the recurrence, complications and posterior resection 
rates. Recurrence rates were studied as total recurrence rate, adenoma recurrence rate and 
adenocarcinoma recurrence rate. For posterior resections, after the transanal excisions, the 
colorectal resection rates, so called rescue surgery, were quantified for all patients submitted 
to surgery and for patients with some kind of recurrence. Also, the rate for a new resection 
of local recurrence was evaluated.  
Other data: lesion distance from the anorectal border, lesion size (on the widest diameter, in 
cm), operation time (in minutes), hospitalization time (in days), were described in scatter 
plot graphs, according to author and technique.  
 




3.1 Rectoscope idealized and built specifically for TEO 
We consider successful the theoretical idea of building rectoscopes of 4 cm in diameter, with 
a fenestrated distal extremity and the proximal extremity with fixation and illumination 
supports. Because of the professional collaboration and support from our facility staff, 
associated with the financial support from the School of Medicine of  Ribeirão  Preto, there 
was no difficulty in projecting and building the ideal equipment for the TEO. In the time 
frame of 3 months, the ideal equipment was built and ready to use.  
3.2 The Transanal Endoscopic Operation (TEO) 
Eighty three patients were selected to be submitted to the TEO, with the described 
proctoscope. In two of these patients the TEO was not performed: one because of anal 
stenosis and the other because the lesion was more than 15 cm from the anal border, in an 
angulated area. The TEO, following the technical steps described previously, was 
successfully performed on the other 81 patients. 
3.3 Evaluation of the patients submitted to the TEO 
The table 1 shows the literature review of techniques used for local excision of rectal lesions, 
used for comparisons with the proposed TEO. Four studies were excluded from this 
analysis because there were not enough data for a comparative analysis. In this way, 35 
different studies, being 26 of TEM, 4 of two or more techniques, 3 of VETM and 2 of CTE 
were compared. Because not all authors have cited all parameters compared in the present 
study, the scatter plots that illustrate the comparisons do not always present 35 points.  
 
Number Used  techniques Author(s)/year 
1 CTE Budhoo & Hancok, 2000 
2 CTE Aguilar, 2000 
3 CTE-TEM- posterior access Balani, 2000 
4 CTE- posterior access Graham, 1999 
5 CTE-TEM Morschell, 1998 
6 TEM Mentges, 1996 
7 TEM Mentges, 1996 
8 TEM Mentges, 1997 
9 CTE-TEM Stipa, 2005 
10 TEM Salm, 1994 
11 TEM Said, 1992
12 TEM Steele, 1996 
13 TEM Lezoche, 1996 
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Number Used  techniques Author(s)/year 
14 TEM Winde, 1998 
15 TEM Heintz, 1998 
16 TEM Doornebosch, 1998 
17 TEM Yamasaki, 1999 
18 TEM Ikeda, 2000 
19 TEM Lev-Chelouche, 2000 
20 TEM Arribas del Amo, 2000 
21 TEM Demartines, 2000 
22 TEM Ziprin, 2002 
23 TEM Farmer, 2002 
24 TEM Lloyd, 2002 
25 TEM Marks, 2003 
26 TEM Cocilovo, 2003 
27 TEM Lee, 2003
28 TEM Neary, 2003 
29 TEM Kattri, 2004 
30 TEM Stipa, 2004 
31 TEM Meng, 2004 
32 TEM Palma, 2004 
33 TEM Endreseth, 2005 
34 TEM Duek, 2005 
35 TEM Rokke, 2005 
36 VETM  I Swanstrom, 1997 
37 VETM II Nakagoe, 2003 
38 VETM II Araki, 2003 
39 EMR Hurlstone, 2005 
40 TEO Rocha, 2004 
CTE: Conventional  transanal excision 
TEM: Transanal endoscopic microsurgery 
VETM: Video endoscopic transanal microsurgery 
EMR: Endoscopic mucosal ressection 
TEO: Transanal endoscopic operation 
Table 1. Relation between most commonly used techniques and respective authors. 
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3.4 Recurrence rates evaluation (average proportions) 
Adenoma recurrence rates 
From 11 references compared, only one is out of the confidence interval for the TEO, 
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Adenocarcinoma recurrence rates 
The TEO showed two adenocarcinoma recurrence and among 17 compared references, 6 























































CTE Ac. Post TEM Endosc 3
CTE Ac Post 4
TEM 7


















Transanal Endoscopic Operation - A New Proposal 
 
127 
Total recurrence rates 
Twenty-five references were selected for this comparison with TEO. Seven of them 
presented smaller total recurrence rates, out of the TEO confidence interval while 3 
presented higher rates. Most of them (15) are on the confidence intervals expected for the 
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Graph 3. Total recurrence rates. 
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Graph 3. Total recurrence rates. 
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3.5 Complication rates evaluation (average proportions) 
Only four in 28 references used for the analysis were out of the TEO confidence interval. 
Twenty-four of them present similar average proportions, and confidence intervals of the 









































































































Graph 4. Complication rates. 
 CTE/Post ac /TEM/Endosc 
 
Transanal Endoscopic Operation - A New Proposal 
 
129 
3.6 Posterior colorectal resections rate evaluation (average proportions) 
Colorectal resection rates in all patients  
With the exception of one reference which is over the maximum confidence interval for the 
TEO, the other 13 evaluated show similar average proportions in the TEO confidence 































































Graph 5.  Colorectal resection rates in all patients. 
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Graph 5.  Colorectal resection rates in all patients. 
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Recurrence colorectal resections rates 
In this analysis, the average proportion of all cases is of 0.5. From the 12 evaluated 
references, only one showed a smaller rate than the minimum confidence interval for the 


























































Graph 6. Recurrence colorectal resections rates. 
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New resection of local recurrence rates  
Only six references were available for this comparison. Half of them showed average 
proportions smaller than the TEO and only one showed a high value, larger than the 







































Graph 7. New resection of local recurrence rates. 
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Graph 7. New resection of local recurrence rates. 
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3.7 Average distance from the anal border evaluation  
This data is presented on graph VIII. Seven references described these values, being the 


























































Graph 8. Average distance from the anal border evaluation. 
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3.8 Average lesion size evaluation (wider diameter) 
The average diameter of the excised lesions with TEO was 3.6 cm. Maximum size was 4.9 cm 

































































Graph 9. Average lesion size evaluation (wider diameter). 
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Graph 8. Average distance from the anal border evaluation. 
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3.9 Surgical time evaluation 
Eleven references were compared and the maximum average described was 175 minutes 


















































































Graph 10. Surgical time evaluation. 
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3.10 Average hospitalization time 
The smaller average presented in seven references was the TEO data of 2.4 days. The higher 

































































Graph 11. Average hospitalization time. 
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3.10 Average hospitalization time 
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3.11 Follow up average time 
The longest follow up period was 10 years. From the 26 references, 11 presented follow up 




















































































































































Graph 12. Follow up average time. 
4. Discussion 
Local excision of rectal tumors is a well established procedure as a surgical method. It is a 
less invasive procedure that, according to its indication criteria, brings benefits in terms of 
rectal and canal anal functional preservation, morbid-mortality and costs [1,2]. 
Literature estimates reveal that 40 to 50 % of the primary rectal cancer will be presented 
without lymphonodal commitment (T1, T2, T3 - No) as soon as diagnosed [27,28] and that 
15% of the patients considered cured show tumors limited to the rectal wall (T1 - T3 - No) 
[29].  Every year, more than 7000 patients with rectal cancer are potentially cured by local 
excision as the only therapeutic method [30]. 
Proctological exam (clinical and rectoscopy), the USER and MRI are important on the 
selection of patients to be submitted to transanal excision [3,7,13,14]. 
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Classic and reasonable indications for rectal tumors local resection include T1, T2 mobile 
tumors, with adequate histological aspects (well or moderately differentiated, with no 
angiolymphatic invasion) [16-18]. 
Some references comparing transanal excision and radical resections demonstrated that low 
risk T1 lesions present similar survival and recurrence rates, with local excision, showing 
smaller hospitalization and surgical time, less analgesia and blood loss and less early and 
late morbidities. Data on T2 lesions are controversial [31-34]. Benign lesions are also 
included, especially the villous or tubulo-villous adenomas which resection was not possible 
by means of colonoscopy or conventional transanal excision. 
We believe that, in diagnosing a rectal neoplasm lesion within or close to the transanal 
resection criteria, the complete resection is the logical conduct, which will allow a better 
histopathological evaluation than the regular biopsy. 
It is not the tumor size or form but how deep it invades the wall and its malignant 
histological characteristics that will guide the final decision of a local excision. On the 
possibility of a complete lesion removal by local excision, this should be the first option. The 
decision for a large surgery depends on a good relation between the surgeon and the 
pathologist [35]. 
For the inferior or middle third rectal mobile tumors, technically accessible by the local 
excision, we suggest the excision to be done as “total biopsy”, considering this method as 
the best one for their treatment. The “total biopsy” may constitute the definitive treatment 
for patients carefully selected.  
On the presence of factors suggestive of bad prognosis, such as a deep lesion throughout the 
intestinal wall, incomplete surgical excision, presence of undifferentiated cells, venous or 
lymphatic invasion, and mucinous tumors, more aggressive and radical surgeries are 
indicated [36]. The final therapeutic decision must not be done before the complete 
examination of the tissue [9]. 
The advantage of having a tissue sample for the histopathological exam has been a stimulus 
for a complete local excision in selected patients. If we are sure that the cancer is not 
invasive, all efforts must be done in order to preserve the sphincter function.  
In this way, the local excision of the complete lesion is the logical procedure, much better 
than just the biopsy because it allows: 1- the whole sample histopathological evaluation, 2- a 
chance for cure with a minimal invasive procedure, 3- on the necessity of a radical surgery, 
there was no prejudice for the patient, 4- the histopathological evaluation of this “total 
biopsy” will guide the further therapeutic proposal. 
There are several procedures for local excision of rectal tumors. The conventional transanal 
excision (CTE), performed with anal retractors, is acceptable for lesions on the distal third of 
the rectum up to 4 cm in diameter. Posterior access, by means of transsacral or 
transsphincteric excisions do not offer advantages compared to the transanal techniques and 
have been less commonly used in the last decades [9]. 
Minimally invasive methods for rectal tumor resection with the use of rectoscopes are well 
accepted, widely used and improved in terms of technique in the last two decades. The 
transanal endoscopic microsurgery (TEM) idealized and preconized by Buess [37,38], is used 
in different countries: Germany, Italy, United Kingdom, Japan, Israel, Spain, Swiss, 
Australia, China, USA and others. Since its introduction into the clinical practice, some 
innovations were added to the technique, in order to improve the final performance of the 
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procedure. Among the TEM innovations are some different types (modalities) of the 
endoscopic access, mainly aimed in order to reduce the equipment costs. 
The first modification of the original TEM was proposed by Swanstron  [23] where the 
authors propose the use of the videolaparoscopy equipment; this technique is known as 
video-endoscopic Transanal Microsurgery (VETM). In sequence, Japanese surgeons have 
modified the VETM performing it without gas inflation. These two main modifications of 
the original technique reduced the equipment price in approximately US$ 50000.00 [24-26, 
39]. 
Despite that the literature on the local excision of rectal tumors indicates high survival rates 
and good results about the local control of the disease, selection criteria for patient are 
restrict. Only about 3 to 8% of invasive rectal tumors are qualified for this kind of treatment, 
based on those criteria [36,40]. 
From all available techniques for local excision of rectal lesions, the endoscopic procedures 
(TEM and others) are the most internationally used. Nevertheless, these techniques demand 
experience and, in consequence, must be performed in reference centers where a larger 
number of patients are available, facing that the surgeon training is mandatory and the 
small frequency of the indications is a reality [41-44]. Because of the necessity of having 
specific instruments and also the particular technical aspects, this method demands good 
training for the obtention of satisfactory results [45-47]. It was described that in 11 tumors 
located up to 4 cm of the anorectal line, a surgical conversion was necessary because of 
technical difficulties [48]. Due to two important disadvantages: first the high costs, taking 
into account the limitation of the equipment use and second, technical difficulties to perform 
the technique with ability and efficiency, the procedure has not achieved wide acceptance 
and popularity [23,49].  
In Brazil, very few surgeons use the TEM technique proposed by Buess. 
Due to the explained circumstances and facing the reality of a growing consecutive series of 
the distal third rectal neoplasm, with most of them committing old patients, with relevant 
comorbidities and high surgical and anesthetic risks, we started thinking of a less invasive 
alternative procedure than the radical abdominal resections, which would be more efficient 
than the conventional transanal excision and less complicated than the posterior accesses. 
In this way, we proposed the TEO: we idealized and built a surgical proctoscope of low 
costs, associated to conventional surgical instruments, a fiberlight source, polipectomy loops 
and videolaparoscopic forceps, without the necessity of inflation or video cameras. The 
equipment built in our precision tool facility (Oficina de Precisão da Faculdade de Medicina 
de Ribeirão Preto – Hospital das Clinicas) showed very good results. From the 83 proposed 
surgeries, in only two it was not possible to conclude the procedure, one due to a rectal 
stenosis and the other due to the distance of the lesion from the anal border (15 cm), with an 
accentuated rectal-sigmoidal angle. 
On the opposite way from the other transanal endoscopic techniques, mainly the TEM, 
which are inefficient for the excision of the inferior third rectal tumors because it is not 
possible to keep the equipment on the rectal lumen under inflation [50], on the TEO, with 
the 7 cm rectoscope, these lesions were easily excised.  
With the increasing surgeon experience, it was possible to modify the rectoscope making it 
easier to handle and the surgical steps efficient and fast. These modifications included the 
use of the stainless steel as the main component, the 0.5 cm enlargement in the rectoscope 
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diameter and the reduction of the electrocautery and vacuum tubes tips. This idealized 
proctoscope showed to be a very useful tool, with low cost, easy to handle and that allowed 
the obtaining of reliable results, similar to those already described for other transanal 
endoscopic techniques.  
On the casuistic of the present study, six cases previously submitted to one or two 
endoscopic excision by means of colonoscopy (two superficial adenocarcinoma three 
villous-adenomas) were successfully submitted to the TEO. Another patient with villous-
adenoma and high grade dysplasia, previously submitted to an CTE and presenting a 
recurrent lesion was also successfully submitted to the TEO. Eight patients were submitted 
to the TEO twice, or for the complete excision of the tumor or to the excision of residual or 
recurrent lesion suspect tissue. 
The comparative results presented by the several local excision techniques are difficult to 
interpret since most of literature descriptions are based on retrospective analysis and on 
heterogeneous groups. Also, there is no randomized prospective studies and there is a lot of 
variation concerning the adjuvant therapy indication [1,2,16,17,20]. 
Another relevant aspect for literature data comparison is the biological characterization of 
the tumor, i.e., interaction tumor-host, which might be inferred by the morphology, 
histology, size, localization and invasive stage. This is essential for the therapeutic results 
comparison in patients with similar disease stages [51]. 
The lack of homogeneity in the literature is due to the difficulty in having a large number of 
patients for the study and also due to the necessity of classifying them according to the 
tumor stage (Tis, T1, T2, T3). Some authors use radiotherapy and others don’t; while some 
authors exclude from the recurrence statistics those patients operated by local excision and, 
after diagnosing that the resection borders still had tumor, were right after submitted to a 
radical resection. 
Despite recognizing the difficulties to find reports with the necessary severity for closer 
comparisons with the reality, 35 reviews were compared aiming the objectives of the present 
study.  
We consider our recurrence rate very favorable since, to the moment only two recurrence 
were observed for the curative adenocarcinomas excised with TEO. For the adenomas, the 
average observed in our study is compatible with the literature revised, except one (Graphs 
I and II). If we group both rates on the total recurrence rate, the results are also similar to the 
literature (Graph III). These observations indicate that we should keep the surgery 
indication criteria, and continue to improve the technique and to observe the patients for a 
longer period of time.  
The post-operatory complications were observed in total since the literature available does 
not discriminate in mild or severe complications. Our complications rate is acceptable 
(Graph IV) and compatible with most of the literature revised. In two cases there was a 
severe complication (pneumoretroperitoneum) on the 5th and 3rd post-operatory day. The 
first patient was operated on for a distal rectum opening on a patient with invasive,  
advanced  and obstructed neoplasm and in this particular case a re-intervention was 
necessary, with a loop sigmoidostomy.  The other case was treated conservatively and had 
good response There was one pneumoperitoneum after a second TEO for a recurrent villous 
adenoma, when the peritoneal  fold was opened, treated clinically, the patient had a good 
response. Other complications such as pain, evacuation bleeding, urinary difficulties, were 
treated clinically. 
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The average proportions of the intestinal resections after local excisions are small and 
equivalent to the literature (Graph V). The observations of the intestinal resections after 
neoplasm lesions recurrence were ten times larger but also comparable to the literature 
(Graph VI). 
In our study, two patients were re-operated (intestinal resections) after the TEO: one with a 
resting villous-adenoma 15 cm above the anorectal border, not reached with the surgical 
rectoscope, and the other one with an adenocarcinoma on the rectal mid third, with 
angiolymphatic invasion and compromised border, who was submitted to a total 
proctocolectomy. Nevertheless, the folowing histopathological exam did not show the 
presence of neoplasm on the tissue.  
The results of a second local excision due to a residual lesion or recurrence demonstrated 
that performing another local excision or an intestinal resection it is still controversial since 
half of the revised literature has shown average proportions inferior to the TEO (Graph VII). 
In the present study we performed four TEO re-operations being the indication based on the 
fibrosis and suspect granulation on the lesion border but in both cases, the histopathological 
analysis did not show resting neoplasm.  
For some variables of interest, the correlation between or results and the literature were 
analyzed (Graphs VII to XII). These variables were the distance of the lesion from the anal 
border, lesion size represented by its maximum diameter, operation time ant hospitalization 
time.  
The evaluation of the anal border distance of the lesions allows us to infer that the local 
excision is safely performed on the mid and inferior thirds of the rectum. In the literature, 
there are reports of TEM excisions of 15 to 18 cm lesions. In the present study we reached 
tumors up to 12 cm. Only one case of a lesion located 15 cm from the anal border was not 
reached due to a rectal-sigmoidal angulation. 
The lesion size analysis, expressed in cm in its maximum diameter, showed very good 
results since, in our study, lesions up to 7 cm were excised. Other authors refer the excision 
of 8-9 cm lesions but this situation is related to those giant villous-adenomas, in which the 
endoscopic resections might be done in more than one surgical time. 
The analysis of Graph X indicates that TEO shows a very short operative time, which is 
probably due to the fact that the equipment is simple and easy to use and that the procedure 
itself is also simply performed.  
In terms of hospitalization time, despite the fact that TEO has shown the smallest time, other 
authors also show very similar results. Some reports do not present this pattern because 
they described complicated cases, when long hospitalization was needed, and others 
because the follow up protocol demanded a longer hospitalization time.  
The variable follow up after surgery, expressed in years (Graph XI) reflects the importance 
and the stability of the local excision surgeries. In several reports, the follow up time has 
been studied between 10 and 15 years. In our experience, the follow up time is in between 2 
months and  8 years. 
In this way, the challenge of idealizing, projecting and using a surgical endoscopic 
instrument of low costs, and adequate for its main purposes, i. e. appropriate for use in 
transanal endoscopic surgeries, was fully achieved.  
The results of the TEO showed and discussed in the present study, compared to the 
international literature, demonstrated that the TEO is an adequate and feasible procedure 
for the local excision of rectal tumors.  
 




1. The proctoscope specially designed and built for the TEO has shown appropriate, 
efficient and of low costs; 
2. The TEO was easily performed on lesions of the mid and inferior third rectal tumors; 
3. The results obtained with TEO were favorable and similar to those obtained with other 
available techniques for endoscopic transanal resection that are of high costs and of less 
availability. 
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Diagnosis and Endoscopic  
Treatments of Rectal Varices 
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Japan 
1. Introduction 
Esophagogastric varices are considered to be the most common complication in patients 
with portal hypertension, while ectopic varices, that is, those outside of the esophagogastric 
region, are less common. Rectal varices represent portal systemic collaterals that are 
manifested as discrete dilated submucosal veins and constitute a pathway for portal venous 
flow between the superior rectal veins of the inferior mesenteric system and the middle 
inferior rectal veins of the iliac system. Rectal varices are an infrequent but potentially 
serious cause of hematochezia. Massive bleeding from rectal varices occurs rarely, with a 
frequency ranging from 0.5% to 3.6% (1-3). In this chapter, we describe the diagnostic 
modalities and endoscopic treatments for rectal varices in patients with portal hypertension.  
2. Diagnosis of rectal varices 
Endoscopy is the principal method for diagnosis of rectal varices. Endoscopic 
ultrasonography (EUS) can detect the presence and number of rectal varices better than 
endoscopy (4). Recently,  color Doppler ultrasonography has allowed us to detect fine small 
blood flow (5). Sato et al. have  reported the usefulness of percutaneous color Doppler 
ultrasonography (CDUS) for the hemodynamic  evaluation of rectal varices (6).  
Although endoscopic injection sclerotherapy (EIS) (7) and endoscopic band ligation (EBL) (8) 
for esophageal varices are well-established therapies, there is no standard treatment for rectal 
varices. In this article, we also review the therapeutic effects and complications of EIS versus 
EBL on rectal varices in patients with portal hypertension. Several diagnostic procedures have 
been performed to evaluate rectal varices, including endoscopy, magnetic resonance (MR) 
angiography, EUS. Endoscopy is the principal method for diagnosis of rectal varices and MR 
angiography is useful for evaluating the overall portosystemic collateral circulation. On the 
other hand, conventional EUS (7.5 or 12 MHz) reveals rectal varices as rounded, oval, or 
longitudinal echo-free structures in the submucosa and also shows perirectal veins outside the 
rectal wall (4,9,10). With endoscopic color Doppler ultrasonography (ECDUS), color flow 
images in blood vessels can be obtained, and ECDUS allows for more detailed observation of 
the hemodynamics of rectal varices than EUS (11). CDUS is a simpler, more non-invasive 
method than ECDUS and it enables us to detect slight blood flow and to evaluate the portal 
venous system. Nelson et al. concluded that CDUS was valuable for accurate determination of 
the direction of portal flow and patency of the vessel (12). Sato et al. have reported the 
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usefulness of CDUS for the hemodynamic evaluation of rectal varices and compared velocities 
of rectal varices with CDUS and colonoscopic findings, and they concluded that CDUS was a 
useful noninvasive tool in the evaluation of portal hemodynamics, including the observation 
of blood flow in rectal varices (6).  
2.1 Diagnosis of rectal varices via endoscopy 
Endoscopy is the principal method for the diagnosis of rectal varices; it is a useful modality 
for diagnosing and observing rectal varices of a certain size and extent, and has a very 
sensitive predictive value for variceal hemorrhage. The endoscopic findings for rectal 
varices were evaluated according to the grading system outlined in‘The General Rules for 
Recording Endoscopic Findings of Esophago-gastric Varices ’prepared by the Japanese 
Research Committee on Portal Hypertension (13).  
The form (F) of the varices was classified as small and straight (F1), enlarged and tortuous 
(F2), large and coil-shaped (F3), or no varices after treatment (F0). The fundamental color of 
the varices was classified as either white (Cw) or blue (Cb). The red color sign (RC) referred 
to dilated, small vessels or telangiectasia on the variceal surface. RC shows a high risk of 
variceal bleeding based on endoscopic findings (Table 1). The following images show: blue 
color and red color-positive coil-shaped rectal varices (Fig.1-a); blue color and red color-
positive enlarged tortuous rectal varices (Fig.1-b), and a white plug on the rectal variceal 
surface in a patient with a case of rectal variceal bleeding (Fig.1-c).  
 
Form (F)  
F1: small, straight  
F2: enlarged tortuous  
F3: coil-shaped 
F0: no varices after treatment 
Fundamental color of the varices (C)  
Cw: white  
Cb: blue 
Red color sign (RC): dilated, small vessels or telangiectasia on the variceal surface  
RC0: no RC sign 
RC1: only a few RC signs 
RC2: several RC signs 










Table 1. The General Rules for Recording Endoscopic Findings of Esophago-gastric Varices 
prepared by the Japanese Research Committee on Portal Hypertension 
 




Fig. 1a. Endoscopy showing blue color and red color-positive coil-shaped rectal varices. 
 
 
Fig. 1b. Endoscopy showing blue color and red color-positive enlarged tortuous rectal 
varices. 
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Fig. 1c. Endoscopy show a white plug on the rectal variceal surface in a patient with a case 
of rectal variceal bleeding. 
Hemorrhoids are vascular cushions resulting from arteriolar venous communications in the 
hemorrhoidal plexus, with no direct communication with any of the major branches of the 
portal venous system being demonstrated. Fast-Fourier transform analysis of blood flow in 
the intramural rectal varices showed a continuous wave with a pulsatile wave in some 
patients. This phenomenon explains the coexistence of rectal varices and hemorrhoids, 
whereby blood from the hemorrhoids flows into the rectal varices at the anal site, causing a 
pulsatile blood flow wave from the hemorrhoids (arteriolar venous communication).  
2.2 Diagnosis of rectal varices via endoscopic ultrasonography (EUS) and endoscopic 
color Doppler ultrasonography (ECDUS) 
EUS has become a useful modality for hemodynamic diagnosis of esophagogastric varices 
(14,15). The usefulness of EUS (4,9,10) in the hemodynamic diagnosis of rectal varices has 
been described, and Dhiman et al. found rectal varices via endoscopy in 43% of patients and 
via EUS in 75% of patients with portal hypertension (10). Sato et al. demonstrated that 
intramural rectal varices, peri-rectal collateral veins, and the communicating veins between 
intramural rectal varices and peri-rectal collateral veins could be observed clearly via an 
ultrasonic microprobe (16). ECDUS is better equipped than conventional EUS to visualize in 
detail the hemodynamics of esophagogastric varices (17,18). With ECDUS, color flow images 
in blood vessels can be obtained, and ECDUS allows for more detailed observation of the 
hemodynamics of rectal varices than EUS (11). ECDUS is useful for detecting rectal varices 
through color flow images, and it is a necessary tool for effective and safe EIS by calculating 
the velocity of blood flow in rectal varices (Fig.2).  
 











Fig. 2. Color flow images of rectal varices and inflowing vessel with endoscopic color 
Doppler ultrasonography 
2.3 Diagnosis of rectal varices via percutaneous color Doppler ultrasonography 
(CDUS) 
Recently, color Doppler ultrasonography has become widely accepted for the assessment of 
the hemodynamics of abdominal vascular systems, but few color Doppler findings of 
gastrointestinal varices have been reported. Komatsuda et al. reported the usefulness of 
CDUS for the diagnosis of gastric and duodenal varices (19), and Sato et al. concluded that 
CDUS was useful for evaluating the hemodynamics of gastric varices (20). CDUS cannot be 
performed successfully without a suitable acoustic window. Impediments such as bowel 
gas, body habitus, and cirrhosis limit the value of sonography for assessing the portal 
venous system. In addition, with color Doppler sonography, it is difficult to observe the 
collateral veins situated far from the probe due to the limitations of Doppler sensitivity. The 
rectal wall was detected at the back area of the vagina in females or prostate in males by 
sonography and rectal varices could be observed through the bladder filled with urine via 
color Doppler ultrasonography (Fig.3).  
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Fig. 3. Color flow images of rectal varices with color Doppler ultrasonography. 
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Sato et al. compared the velocities of rectal varices with CDUS and colonoscopic findings (6). 
The majority of the 44 cases underwent colonoscopy after diagnosis with color Doppler. In 
this study, the mean velocity of the F2 type rectal varices was significantly higher than that 
of the F1 type, and the mean velocity of the RC-positive varices was significantly higher 
than that of RC-negative varices with color Doppler ultrasonography. These results suggest 
that the measurement of velocity in rectal varices via color Doppler ultrasonography is 
useful in diagnosing the grade of rectal varices. CDUS is a useful noninvasive tool in the 
evaluation of portal hemodynamics, including the observation of blood flow in rectal 
varices.  
3. Endoscopic treatments of rectal varices 
Rectal varices are considered to occur infrequently, however, several articles have reported 
that they occur with high frequency in patients with hepatic abnormalities (21-23). Hosking 
et al. reported that 44 % of 100 consecutive cirrhotic patients had anorectal varices (21). 
Other studies found that the prevalence of anorectal varices was 78% in 72 portal 
hypertensive patients (22) and 43% in 103 cirrhotic patients (23). Although EIS and EBL for 
esophageal varices are well-established therapies, there is no standard treatment for rectal 
varices.  
Various medical treatments have been used to control bleeding from rectal varices, but 
none of these is currently considered to be a standard method. Surgical approaches 
include portosystemic shunting, ligation, and under-running suturing (21). Some 
investigators have reported that interventional radiologic techniques such as transjugular 
intrahepatic portosystemic shunts were successfully employed for rectal variceal bleeding 
(24-26). Several cases of successful treatment of rectal varices with endoscopic treatments 
have been reported. Wang et al. first reported the usefulness of EIS in treating rectal 
varices and found it to be effective for controlling bleeding (27). EBL was introduced as a 
new method for treating esophageal varices, and it is reportedly both easier to perform 
and safer than EIS. Several cases of successful treatment of rectal varices using EBL have 
been reported (28-30).  
3.1 EIS for rectal varices 
We performed EIS in 21 of the 30 patients, who were successfully treated without 
complications. EIS was performed using 5% ethanolamine oleate with iopamidol (5%EOI), 
which was injected intermittently under fluoroscopy. The procedure was performed using a 
flexible GI endoscope (GIF XQ200; Olympus Optical Co., Ltd., Tokyo, Japan) by a free-hand 
method, using a 25-gauge injection needle. EIS was repeated every week until the 
disappearance of all rectal varices and RC signs were confirmed by endoscopy. Fluoroscopic 
observation with infusion of 5%EOI was performed to determine the extent of the varices, 
taking care that 5%EOI did not flow into the systemic circulation. We decided the amount of 
5%EOI on depiction of passageways (superior rectal vein) of rectal varices. After EIS, 
colonoscopy revealed shrinkage of the rectal varices in all 21 patients, with no complications 
reported. 
It is necessary to evaluate the hemodynamics of the rectal varices before EIS to avoid severe 
complications such as pulmonary embolism, and the sclerosant should be injected slowly 
under fluoroscopy (Fig.4).  
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Fig. 4. Fluoroscopic observation with infusion of 5%EOI was performed.  
3.2 EBL for rectal varices 
EBL was introduced as a new method for treating esophageal varices, and it is reportedly 
both easier to perform and safer than EIS. Several cases of successful treatment of rectal 
varices using EBL have been reported. Levine et al. treated rectal varices initially with EIS, 
and 1 week later, EBL was performed on the remaining rectal varices (28). These 
investigators described EBL as a safe and effective therapy for rectal varices (30).  
EBL was performed in 9 patients on our ward; it was performed weekly using a pneumo-
activated EBL device (Sumitomo Bakelite, Tokyo, Japan), and bands were placed on the 
varices. An overtube was not used during EBL (Fig.5). After EBL, colonoscopy revealed 
ulcers and improvement of the varices in the rectum of all 9 patients. Eight of the 9 patients 
experienced no operative complications. However, colonoscopy revealed bleeding from 
ulcers after EBL in 1 case, in whom endoscopic clipping was performed on the oozing 
ulcers.  
 




Fig. 5. EBL was performed weekly using a pneumo-activated EBL device.  
3.3 Comparison EIS and EBL for rectal varices 
We have used EIS or EBL to treat rectal varices. In our ward, we retrospectively evaluated 
the therapeutic effects and rates of recurrence of rectal varices after EIS or EBL. We 
performed EIS in 21 of the 30 patients, who were successfully treated without complications. 
The overall recurrence rate for rectal varices over the 1-year follow-up period after 
treatments was 10 of 24 (41.7%). The patients with recurrence included 5 of the 15 patients 
(33.3%) receiving EIS and 5 of the 9 (55.6％) who received EBL. The recurrence rate was not 
significantly different between the EIS group and EBL groups, although recurrence tended 
to be more frequent with EBL.  
EBL may be suitable as an initial treatment for rectal varices, but it appears that the varices 
can easily recur after EBL (31,32). The recurrence rate for bleeding in the EBL group was 
significantly higher than in the EIS group in our result. All four patients with recurrence of 
bleeding had been treated using EBL.  
EIS appears to be superior to EBL with regard to long-term effectiveness and complications 
following endoscopic treatment of rectal varices in patients with portal hypertension. More 
investigations are necessary in larger numbers of patients before evidence-based treatment 
recommendations can be made.  
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Hemorrhage from rectal varices should be kept in mind in patients with portal hypertension 
presenting with lower gastrointestinal bleeding. It is difficult to determine the best 
treatment strategy for rectal varices because of inaccessibility, initial difficulty in diagnosis 
and subsequent difficulty in treatment.  
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